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SUMMARY
The triterpenoid compound glycyrrhizin (GL) is widely used in Japan for the 
treatment of viral hepatitis. GL, carbenoxolone sodium (CBX), and cicloxolone sodium 
(CCX) exhibit broad range antiviral activity both in vivo and in vitro (Galt et al.., 1992; 
Pompei et al., 1979). Both in vitro and in vivo anti-HIV activity has also been reported 
for GL (Hatori et al., 1989; Mori et al., 1989, and 1990; Ito et al., 1986 and 1988).
This thesis investigates the effect of triterpenoid compounds on replication of 
two retrovirus in tissue cultures; Feline leukaemia virus type A (FeLV-A) and Feline 
immunodeficiency virus (FIV). Both of these viruses cause AIDS-like 
immunodeficiency diseases in cats. The anti-retrovirus activity of the triterpenoid 
compounds is contrasted with the effect of the drugs on the replication of bovine 
herpesvirus type 1 (BHV-1) in MDBK cells.
Tri terpenoid compounds are lipophilic and effect the host cell membrane 
functions. In order to determine drug concentrations in which cytotoxic effect of the drug 
could be uncoupled from the antiviral activity, cyotoxicity tests were performed. The 
effect of the drugs on cell culture growth and percentage cell viability were determined by 
trypan blue dye exclusion. The highest drug concentrations tolerated were; for FeA and 
CrFK cells lOOpM CCX, or lOO i^M CBX and for MDBK cells 300|liM CCX (used for 
BHV-1 studies). Drug removal experiments have shown that the effect of the drugs was 
reversible and that two days treatment with 100pM CCX, or lOOpM CBX had no effect 
on the subsequent growth of FeA or CrFK cell cultures. The IC50 concentrations 
(concentration of the drug inhibiting cellular growth by 50%) determined for both CrFK
and FeA cells after 24h or 48h drug treatments were > 300jiM and 150pM respectively. 
Based on the data obtained from cytotoxicity tests, it was concluded that CrFK and FeA 
cells could be placed within the grouping of CCX-resistant cell lines classified by Galt et 
al., (1990).
In order, to investigate the intracellular location of CCX molecules, an attempt 
was made to generate an anti-CCX antibody in immunise rabbits. Despite detection of an 
apparent anti-CCX antibody in an ELISA test, experiments designed to demonstrate the 
specific antibody tagging of CCX molecules in drug treated cells by immuno­
fluorescence were unsuccessful.
Previous studies have shown that CCX treatment impaired the glycosylation of
HSV, VSV, and SFV glycoproteins (Dargan and Subak-Sharpe 1986 and 1986a; Galt et
al., 1990), suggesting that the Golgi apparatus might be a target for triterpenoid
compounds. A trans-Golgi specific monoclonal antibody (directed against the p58
protein) was employed to investigate the effect of CCX on the MDBK and CrFK cells
Golgi apparatus. While perinuclear (Golgi) immunofluorescence was observed in drug-
free cultures, little or no such staining was detected in cells treated with CCX,
s
suggesting that the drug perturb the Golgi apparatus.
It was further postulated that up-regulation of Na+/K+ATPase activity (a known 
effect of triterpenoid compounds) might play a role in the effect of CCX on the Golgi 
apparatus. To test this hypothesis, ouabain (a specific inhibitor of Na+/K+ATPase 
activity) was used in Golgi immunofluorescence labelling experiments. The effect of 
CCX on the Golgi apparatus of MDBK cells was impaired when cells were pre-treated
with ouabain, confirming that the CCX-induced perturbation of the trans-Golgi 
compartment was associated with the up-regulation of Na+/K+ATPase activity. A model 
that can explain the effect of the triterpenoid compounds on Golgi apparatus has been 
given.
CBX and GL exhibit mild virucidal activity against FeLV-A, FIV, and BHV-1. 
300JJ.M CCX treatment of virus particles in suspensions resulted in a 4 fold reduction in 
FeLV-A, and 10 fold reduction of FIV infectivity. Treatment of BHV-1 particles with 
1500pM GL resulted in a 4.2 fold reduction infectivity.
FeLV-A infectious virus yield, drug-dose-response experiments in which 
infected FeA cells were treated with increasing concentrations of CCX, CBX, or GL 
resulted in extracellular reductions of 155, 101, and 128 fold, when treated with 150pM 
CCX, 150pM CBX, or 2500jiM GL respectively. The kinetics of the dose-response 
curves obtained for each drug were triphasic; an initial ~ 10 fold reduction in infectivity 
when cells were treated with 25(iM CCX, 25pM CBX, or 500pM GL, followed by a 
near plateau in the curve up to lOOpM CCX, lOOjiM CBX or 2000pM GL, and a sharp 
decrease in the curve at 150pM CCX, 150pM CBX, or 2500pM GL. The results suggest 
that the antiviral activity of triterpenoid compounds may operate by inhibiting two 
different target functions; the first, a function that enhances but is not essential for virus 
infectivity and which is sensitive to low drug concentrations, and the second, a function 
which is probably essential for virus replication and which is only sensitive to high 
concentrations of the drugs. However, at high drug concentrations the window between 
cytotoxicity and antiviral activity is very narrow. Fractionation of FeLV-A drug-dose-
response samples into cell released (CR ) and cell associated (CA) virus components,
revealed that CR infectivity generally decreased more rapidly than infectivity in the CA
£<*■
component. This finding cannot be accountedAby virucidal activity alone, suggesting 
that the drugs might impair the release of FeLV-A particles from infected FeA cells. 
CCX treatment of FeLV-A infected FeA cells appeared to have little or no effect on the 
synthesis of virus proteins. However, investigations of the polypeptide composition of 
the virus particles produced in the presence of CCX revealed that the surface 
glycoprotein (gp70) was present in slightly reduced amounts. Whether, or not, this 
affected the infectivity of progeny virions is not known.
The fact that infectious FIV yields are generally low (103 to 104 p.f.u./ml) has 
precluded high MOI drug-dose-response experiments. Nevertheless, the potency of the 
anti-FIV activity of triterpenoid compounds was estimated by determination of ED50 
concentrations (75pM CCX, and IOOjiM CBX).
SDS PAGE analysis of the protein extract from FTV-infected CrFK cells grown 
in the presence of lOOpM CCX revealed that cleavage of the precursor gag p55 protein 
into its products p24 and p i7 was diminished, suggesting impairment of post-release 
maturation of FIV particles. However, it is not known, whether the impairment of p55 
cleavage was due to CCX molecules embedded in the plasma membrane of the infected 
cells^in the virus envelope, or tbe result of some action of the drug on the viral
id
protease activity. 35S-methionine/cysteine labelling experiments reveal^infected cell 
proteins of 160K, 120K, and 41K molecular weights, these are thought to represent the 
FIV precursor gpl60 which is cleaved to yield the gpl20 surface and gp41
transmembrane proteins. The gp 160 precursor protein is not normally detected in FIV 
infected cell extracts and this suggest impairment, though not abolition , of the 
cleavage. l4C-glucosamine labelled gpl20 was not detected in the protein extract from 
FIV infected cell cultures grown in the presence of 100|iM CCX, although a band of 
120K was present in extracts from parallel cultures labelled with 35S- 
methionine/cysteine. If these proteins are the same, this suggests that glycosylation of 
the gpl20 was inhibited. The results can be interpreted as suggesting that CCX- 
treatment impairs transport of glycoproteins through the Golgi to the cell plasma 
membrane, and consequently limits the number of virus particles that can be 
assembled. In addition, presence of CCX molecules at the site of virus budding might 
impair the release of progeny virions from the cells, and presence of CCX in the 
envelope might impair the maturation of the virions.
Treatment of BHV-1-infected MDBK cells with 300jiM CCX resulted in 4.73 x 
105 and 6.95 x 104 fold reductions for CR and CA fractions respectively. Infectivity in 
the CR fraction decreased at a faster rate than the CA infectivity, however, virucidal 
activity could only account for a ~ 4 fold decrease in infectivity suggesting that other 
factors are involved. Electron microscopy investigation of control and drug-treated 
BHV-1-infected MDBK cell cultures indicated that CCX impaired assembly, maturation 
and release of BHV-1 virus particles, however, CCX did not impair the percent^of 
BHV-1 particles that was enveloped. Treatment with CCX also resulted in a reduction 
of protein synthesis per se in MI and BHV-1-infected MDBK cells. Thus, inhibition of 
protein synthesis must, in part, play a role in the anti-BHV-1 activity of CCX and may
account for some of the reduction in the number of virus particles assembled. SDS 
PAGE investigation of BHV-1 infected cell extracts showed that BHV-1 protein 
synthesis was impaired although not all proteins were affected to the same extent.
The antiviral mechanism of the drugs has been described in relation to the model 
proposed for the effect of the drugs on the Golgi apparatus.
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1. CHAPTER ONE
INTRODUCTION
i
1.1. ANTIVIRAL COMPOUNDS.
Two strategies have been employed to control virus infection: vaccination and 
antiviral chemotherapy. Vaccination for the control of smallpox virus began in 18th 
century, and in recent years resulted in world-wide eradication of smallpox virus. Vaccines 
for polio, measles, and rubella are the principal method for the control of infections by 
these viruses. Vaccines, however, may be of limited use for the control of viruses which 
exhibit a latent phase in their life cycle (herpesviruses and HIV), and here antiviral 
chemotherapy is used to control the infection. However, in contrast to development of 
antibacterial agents, the development of antiviral compounds faces greater obstacles, as 
viruses use much of the cellular machinary in their replication .
Some viruses, such as herpesviruses have replication mechanisms which are unique 
to these viruses and are not found in the host cell. Some of the steps in this pathway have 
been successfully targeted by specifically designed antiviral compounds. Unfortunately, 
there are few antiviral agents which offer high selectivity. In addition, most of the antiviral 
compounds are only effective against actively replicating viruses, and at present no antiviral 
compound is being used successfully in inhibition of latent viruses.
Some of the antiviral compounds, which are used clinically or exhibit a promising 
future in antiviral chemotherapy are discussed below.
1.1.1. ANTIHERPES COMPOUNDS.
ACYCLOVIR (ACVVVALCICLOVIR.
Acyclovir [9-(2-hydroxyethoxymethyl) guanine] (Zovirax™) (Figure 1) is a
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nucleoside analogue of guanosine and has selective antiviral activity against herpesviruses. 
ACV is activated upon phosphorylation by the viral specific thymidine kinase to yield 
ACV-monophosphate. Further phosphorylation to ACV-diphosphate (ACV-DP) and ACV- 
triphosphate (ACV-TP) is carried out by cellular kinases (Fyfe et al., 1978). ACV-TP is 
both a competitive inhibitor of dGTP and a substrate for viral DNA polymerase. ACV-TP 
becomes incorporated into the growing viral DNA chain but, because ACV-triphosphate 
lacks the 3’ hydroxyl group, the viral DNA polymerase can not add the next dNTP and the 
whole process is terminated (Furman et al., 1984).
The antiviral activity of ACV-triphosphate is selective for herpes-infected cells and_, 
although a small amount of ACV-TP has been found in extracts from uninfected Vero cells, 
the rate of conversion of ACV to ACV-TP is 30-120 times faster in HSV-1-infected Vero 
cells (Fyfe et al., 1978). ACV is not effective against those herpesviruses which lack a 
thymidine kinase gene (TK) (e.g. CMV). ACV-resistance can be conferred by mutations in 
two different loci- the sequences encoding the TK gene or those encoding the DNA POL 
gene (Burns et a l, 1982; Coen and Schaffer, 1980).
Acyclovir is widely used both topically and systemically for the treatment of herpes 
simplex virus infections. The ED50 value for HSV can be as low as 0.1 pM (Collins et al., 
1983) buqfor HCMV, the ED50 can be as high as 200|liM (Balfour et al., 1988). VZV and 
EBV exhibit intermediate sensitivity to ACV with ED50’s (between 1.3 to 20.6|iM and 0.3 
to 25pM respectively) depending upon the viral strain and the cell line used (Balfour et al., 
1988; Biron and Elion, 1980). Due to the poor oral bioavailability of ACV (about 20%) 
(De Miranda and Blum, 1993)., much higher oral or intravenous doses of ACV have been
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administered to obtain clinically beneficial results against infections caused by less 
sensitive herpesviruses (e.g. EBV)
Several prodrug derivatives of acyclovir have been investigated to identify 
compounds with increased oral bioavailability. One such drug is valciclovir (the L-valyl 
ester of acyclovir), the oral bioavailability of which is about 3-5 times higher than that of 
oral acyclovir (Blum et al., 1994). The antiviral activity of valciclovir is entirely due to its 
rapid and complete conversion to acyclovir in vivo (Beutner, 1995).
PENCICLOVIR/FAMCICLOVIR.
Penciclovir [9-(4-hydroxy-3-hydroxymethylbut-l-yl) guanine] (Figure 1) is also
aistiv iVaA
derivative of guanosine and consequently has a similar (but not identical) mode of action (Eamshaw et
A
al., 1992). Penciclovir is active against HSV, VZV, and EBV (Boyd et al., 1987 and 1988; 
Bacon et al, 1995). Penciclovir-TP is 10 to 20 times more stable than ACV-TP (Earnshaw 
et al., 1992) thus, PCV, like valciclovir might be administered less frequently than ACV in 
treatment of herpesvirus infections. Indeed famciclovir ( the prodrug of penciclovir) has 
already been licensed for use in patients suffering from herpesvirus infections (Carrington, 
1994) Famciclovir is converted to penciclovir giving an absolute oral bioavailability of about 
77% which is better than that reported following the conversion for acyclovir 
following conversion from valaciclovir^ pu-e- et" j
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GANCICLOVIR.
Ganciclovir {[9-(l,3-dihydroxy-2-propoxymethyl-gua.nine]; DHPG, (Figure 1) like 
ACV, is selectively phosphorylated to ganciclovir-monophosphate by HSV-TK. 
Ganciclovir-TP is a potent inhibitor of HSV DNA polymerase. Oral ganciclovir (GCV)
m o r t
treatment is more than 50 fold^effective than oral ACV in the treatment of systemic or local 
HSV-1 or HSV-2 intravaginal infection in mice (Smee et al., 1983).
prolonged ganciclovir therapy is 
associated with bone marrow suppression resulting in severe neutropenia (Fan-Havard et 
al., 1989).That is why GCV is not used in therapeutics against HSV-infections in humans. 
Ganciclovir, however, is important as a potent inhibitor of human cytomegalovirus 
(HCMV). The mechanism of GCV anti-HCMV activity is essentially the same as its anti- 
HSV activity (Mar et al., 1985). HCMV does not code a vims-specific
thymidine kinase but,the HCMV UL97 gene product has been found to be responsible for 
the phosphorylation of GCV in HCMV infected cells (Sullivan et al., 1992 and Littler et 
al., 1992). Ganciclovir has marginal oral bioavailability in man and is administered 
systemically. GCV is employed for the treatment of HCMV-induced retinitis, particularly in 
immunocompromised patients ( a  TPS patients or allograft recepient on immunosuppressive drug
(Fan-Havard et al., 1989). GCV- 
resistant mutants (usually mutated in the UL97 gene) have been isolated from patients. 
(Stanat et a l , 1991; Sullivan et al., 1992). However, GCV-resistant virus with mutations 
in the POL gene have been isolated from the AD 169 lab strain of HCMV. (Sullivan et al., 
1993).
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HPMPC ( CIDOFOVIR)
HPMPC belongs to the group of phosphonylmethoxyalkyl derivative of purines and
pyrimidines (Figure 1). These compounds have broad-range antiviral activity against DNA 
Ou\ol r«.tr<5viras«.s
viruses^(DeClercq et al., 1986). (S)-HPMPC is the most active of these compounds with 
an ED50 of about 0.1pg/ml for HCMV and a therapeutic index of 1500 (Snoek et al., 
1988). HPMPC is converted to HPMPC-diphosphate (the active form of the compound) by 
cellular enzymes in both infected and uninfected cells (Bronson et al., 1990). HPMPC-DP 
is a competitive inhibitor of viral DNA polymerase and has a higher affinity for HCMV 
DNA POL than for cellular DNA polymerase (Ho et al, 1992). HPMPC-DP has a half life 
in excess of 48h with activity against GCV-resistant and GCV-sensitive HCMV (Bronson 
et al., 1991; Stanat et al., 1991). In a study involving 21 asymptomatic HTV-1 infected 
patients, receiving HPMPC intravenously (0.5 or 1.5mg/kg body weight twice weekly)^ 
HCMV was cleared from the urine. None of the patients in the study had adverse side- 
effects resulting from drug treatment. However, patients receiving 5mg/Kg body 
weight twice weekly developed renal dysfunction (Polis et al., 1995).
IDOXURIDINE (IDU).
IDU was the first antiviral agent to be licensed for use in the treatment of HSV- 
induced keratitis (Figure l).The drug was applied topically but proved too toxic for 
systemic use.
Cellular or virus specific thymidine kinase enzymes are capable of phosphorylating 
IDU to IDU-monophosphate (Littler et al., 1986) however, the affinity of IDU for vims
6
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TK is slightly better than that the cellular TK. Therefore, phosphorylation of IDU is more 
efficient in virus-infected cells, conferring a small measure of antiviral selectivity. HSV 
TK' mutants are less susceptible to IDU than the wild type virus (Field et al., 1981). 
Following phosphorylation in vivo and incorporation into DNA molecules, IDU inhibits 
both viral and cellular synthesis. However, IDU also has been reported to inhibit several 
cellular and viral regulatory enzymes (thymidine kinase, thymidylate kinase, and DNA 
polymerase) (Prusoff and Lin , 1988).
5-TRIFLUOROMETHYL-2’-DEOXYURIDINE (TFT) (TRIFLURIDINE).
TFT has also been used topically for the treatment of HSV keratitis (Figure 1). Like 
IDU, TFT is too toxic for systemic use. Cellular enzymes are largely responsible for 
conversion of TFT to TFT-TP. TFT-TP is a substrate for, and inhibitor of both viral and 
cellular DNA polymerases (Prusoff et al., 1984).
ADENINE ARABINOSIDE (Ara-A) (VIDARABINE).
Adenine arabinoside was the first compound licensed for systemic use in the 
treatment of herpesvirus infections (Whitely et al., 1977) (Figure 1). In vivo, Ara-A is 
deaminated by cellular enzyme adenosine deaminase to 9-(3-D
arabinofuranosylhypoxanthine (AraHx) which has less activity than Ara A. Inhibitors of 
adenosine deaminase [such as erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA)] can 
therefore, increase the antiviral activity of Ara-A in vivo. Ara-A is poorly soluble in water 
and therefore needs to be administered intravenously with a large volume of liquid.
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Cellular adenosine and deoxycytidine kinase converts A ra-A  to Ara-A- 
monophosphate (Ara-A-MP) which is more soluble than Ara-A and is not deaminated by 
adenosine deaminase. Ara-A-MP is further converted to Ara-A-TP (the active form) by 
cellular enzymes. Ara-A-TP competes with dATP as substrate for both cellular and viral 
polymerases. Thus, Ara-A-TP inhibits viral DNA polymerase and/or becomes incorporated 
into the growing DNA chain, making DNA elongation less likely to occur (Reid et a l,
1988). HSV-DNA polymerase, however, is 15 fold more sensitive to Ara-A-TP inhibition 
than cellular DNA polymerase (Ostrander and Cheng, 1980).
Ara-A has been shown to be effective against HSV-1, HSV-2, (including TK' HSV 
mutants), VZV, and HCMV. Ara-A has been used mainly for the treatment of HSV- 
encephalitis. Ara-A-resistant HSV mutants with mutation in the POL gene have been 
isolated both in vitro and in vivo (Coen et a l, 1982).
( S / - HP MP C
FIGURE 1. Structure of anti-herpes con^mnds.
1.1.2. ANTI-INFLUENZA AGENTS.
AMANTADINE AND RIMANTADINE.
Amantadine (1-aminoadamantane hydrochloride) and its derivative rimantadine 
(ot-methyl-l-admantane methylamine hydrochloride) (Figure 2) inhibit influenza A vims 
replication in humans (Davis et al., 1964). The drugs are effective both as prophylactic and 
therapeutic agents (Dolin et al., 1982 and Douglas et al., 1990).
Although the US FDA approved the use of oral amantadine in the prevention and 
treatment of influenza vims infections in 1966, the use of these dmgs in the developed 
world has generally been very limited. Rimantadine, however, has been used extensively in 
Russia (Zlydnikov et al., 1981), and has recently been licensed for use in France (Hay et 
al., 1992).
Amantadine exerts different antiviral actions depending on the concentration of the 
drug used. At high concentrations ( > 0. ImM),influenza vims infection of cells is inhibited 
by elevation of endosomal pH (Daniels et a l, 1985). Like many enveloped RNA vimses, 
influenza virus enters cells by receptor mediated endocytosis (Wallbank et al., 1966 and
i
Heljnus et al., 1982). The low pH of the endosomes prompts fusion of the viral envelope 
with the endosomal membrane, allowing release of the virus core and initiation of infection. 
Influenza virus mutants which are resistant to high concentrations of amantadine, have 
hemagglutinin (HA) proteins which fuse with cellular membranes at a higher pH than those 
of the wild type virus (Daniels et al., 1985). The replication of a number of enveloped RNA 
viruses, dependent upon receptor mediated endocytosis, are inhibited by amantadine at 
high concentrations (Wallbank et al., 1966; Helinus et al., 1982).
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At low amantadine concentrations ( < 5pM), there is a specific antiviral activity 
against influenza A virus which operates during both uncoating and particle assembly (Hay 
et al., (1985). The target of amantadine (at low concentrations) is the M2 protein, a 
component of the virus envelope (Zabedde and lamb, 1988). The influenza M2 protein 
functions as an ion channel allowing penetration of H+ into the virus particle. The 
decreased pH inside the particle results in the dissociation of the virus matrix protein and
the ribonucleoprotein complex which is needed to allow the latter to enter the nucleus and
1
initiate infection (Martin and Helinus, 1991). Amantadine and rimantadine block the M2 
ion channel and so inhibit virus particle dissociation (Burkinskaya et al., 1982 and 1982a; 
Martin and Helinus 1991a).
A
The M2 protein ion channel also has a role late in the infection cycle of influenza 
virus. The lumen of cisternae and vesicles of the trans-Golgi network is maintained at an 
acidic pH by the action of the proton pump. Following influenza virus infection, the M2 
ion channel counteracts the low pH by either permitting the outflow of the H+ ions or the 
inflow of counterions. Amantadine induced blocking of the channel results in lowering of 
pH below that required to trigger the conversion of the native viral protein HA to the low 
pH form leading to conformational changes in the HA molecule and impairing release of 
the virus (Sugrue et al., 1990).
Amantadine-resistant mutants have been easily isolated both in vitro (Appleyard, 
1977) and in vivo (Oxford et al., 1970). Most amantadine or rimantadine resistant isolates 
of influenza virus have mutations in the M gene that result in a single amino acid 
substitution in the transmembrane domain of the M2 protein. Mutations in the HA gene 
have also been reported (Hay et al., 1985).
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Amantadine and rimantadine do not have any antiviral activity against influenza B 
vims (which constitutes 20% of the common influenza infections) and both drugs have 
been associated with some mild neurological disorders (Dolin et al., 1982). However the 
drugs have proved efficient in blocking the spread of influenza within isolated small 
communities (Douglas et al., 1990).
Rimantadine is a licensed therapy for Parkinson disease due to its similarity to L- 
dopamine.
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1.1.3. ANTISENSE ANTIVIRAL AGENTS.
Inhibition of viral gene expression by synthetic oligonucleotide analogues with 
sequences to bind to viral DNA or RNA is a highly specific way to inhibit viral replication.
Antisense oligonucleotide/RNA duplexes can impair viral protein synthesis by the 
enzymatic hydrolysis of the RNA part of oilgonucleotide/RNA duplex by RNase H. An 
example of the latter group are compounds called ribozymes (Pieken et a l,  1991). 
Ribozymes targeted against HIV-1 gag transcripts reduced p24 protein level in tissue 
culture (Sarver et a l, 1989). Han. et al) (1991) have also shown that transgenic mice 
containing genes which express antisense oligonucleotides against Molony murine 
leukaemia virus (M-muLV) were resistant to development of leukaemia symptoms 
following viral infection.
Synthetic oligonucleotides can also specifically interact with mRNA, resulting in 
inhibition of mRNA transport or impairment of mRNA splicing process (Bischofberger and 
Wagner, 1992). HIV regulatory proteins (Tat, Rev, and Nef) are essential for virus 
infectivity, therefore, they provide important targets for antisense oligonucleotides against 
their mRNA’s.
A problem arising from targeting viral mRNA s is the overabundance of the targets* 
fhe intracellular concentration of the antisense oligonucleotides required to hybridise with 
the target RNA s has to be more than the intracellular concentration of the target RNA s. 
Furthermore, the concentration of the antisense compounds should be kept at steady 
levels during the therapy as target viral RNA s are continuously being transcribed.
Another mechanism for targeting viral genes is by synthesising oligonucleotides 
targeted against viral dsDNA (genomic). The advantage of these compounds over the
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antisense oligonucleotides against mRNA’s, is that there are fewer targets for them 
to bind, Furthermore, these oligonucleotides can target latent and episomal viral DNA. 
Binding of these compounds to viral dsDNA forms a triple helix molecule, leading to 
inhibition of viral replication (Maher et al., 1989). These compound directly target dsDNA 
viruses.
Eventhough, antisense oligonucleotides offer a very selective range of antiviral 
compounds with a high therapeutic ratio in vitro, several problems in Wvohavelimited their 
use in therapeutic treatments. These molecules have a very low cellular permeability and 
are susceptible to degradation by cellular enzymes, furthermore it has been shown that 
sequences of oligonucleotides which are not expected to bind to any targets have biological 
activity. This non-specific binding can be against viral or cellular targets.
More work is needed in the area of improving permeability and stability of these 
compounds in vivo, before they can efficiently be used as antiviral agents in therapeutics.
1.1.4. PROTEIN-PROTEIN INTERACTION AS ANTIVIRAL 
MECHANISM.
Interaction of viral protein subunits is important for virus replication, therefore any
agent which can selectively disrupt this interaction is a potential antiviral agent.
Short synthetic peptides have been shown to selectively disrupt viral protein-protein
interactions. Peptides can theoretically inhibit viral protein-protein interaction by competing
for the binding site on one of the subunits, bind to the interface between the two subunits,
A»A<^
or bind to a site which will induce conformational changes in the peptides.
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Short peptides have been synthesized to identify antiviral targets in different classes 
ofviruses[eg. HSV (Digard et al., 1995; Marsden et al., 1994)]. Short peptides of 15-19 
amino acids corresponding to the connection domain of HIV-1 reverse transcriptase have 
been employed successfully to inhibit dimmerization of HIV-1 RT, thus inhibiting reverse 
trancriptase activity (Divita et al., 1994). However, further modifications are needed to 
improve delivery and stability of these peptides in vivo, before they can be successfully 
employed in therapeutics.
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1.1.5. ANTI-HIV COMPOUNDS.
PROTEASE INHIBITORS.
The HIV protease is responsible for cleaving the HIV gag and gag-POL 
polyproteins into their smaller component proteins. Thus, protease activity is essential for 
the assembly and maturation of the infectious virus. The HIV protease is a member of the 
aspartic proteases. The protease functions as a dimer with two aspartate amino acids in its 
active centre (Miller et al., 1989). Pepstatin A, a specific inhibitor of aspartic proteases has 
been shown to inhibit retrovirus protease activity at high concentration (Katoh et al., 1987).
Many novel inhibitors of HIV protease have been synthesised and several are now 
in clinical trials [L-735,524 (Merck) (Wei et al., 1995).,and ABT-538 (Abbott) (Ho et al., 
1995)]. These compounds bind specifically to the active site of the protease resulting in 
drastic conformational changes in structure, and blocking proteolytic activity (Miller et al.,
1989).
RO 31 -8959 (saquinavir, Roche jwas among the first compounds designed to inhibit 
the HIV-1 protease (Roberts et al., 1990). In cell cultures chronically infected with HIV-1, 
Ro 31-8959 inhibited the cleavage of the p55 precursor protein into the p24 and pl7 
products. Antiviral activity was observed at very low concentrations (InM), while 
cytotoxic effects occurred only at much higher concentrations > 5|iM. Synergistic effects 
have been reported in HIV-infected peripheral blood mononuclear cells, when Ro 31-8959 
was used in combination with AZT, or ddC (Johnson et al., 1992).
Ro 31-8959 was well tolerated by AIDS patients and was responsible for raising
(o<
CD4 cell numbers (Vella, 1994). The compound has been licensed AIDS
A
in USA. Rapid degradation of protease inhibitors in human sera, low solubility, and poor
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oral bioavailability in vivo, have hindered the efficient use of this class of compounds in the 
treatment of AIDS (Crumpacker, 1992).
HIV-1 mutants resistant to protease inhibitors have been isolated from both in vitro 
and in vivo sources. HIV-1 mutants resistant to Ro 31-8959 exhibited amino acid 
substitutions at positions; 48 (glycine to valine), 90 (Leucine to methionine), and/or 54 
(isoleucine to valine) in the protease protein. The most common substitution was at amino 
acid 48. Virus mutants having all three RO 31-8959 resistance mutations in the protease 
gene were 50 fold less sensitive than the wild type virus (Eberle et al., 1995),.
Viruses resistant to a range of different protease inhibitors have been reported 
(Condra et al., 1995), and these exhibit a high degree of cross-resistance between the 
different inhibitors (Tisdal et al., 1995).
AZIDOTHYMIDINEIAZTU’-AZIDO-S’-DEOXYTHYMIDINE)/ 
ZIDOVUDINE/RETROVIR.
Azidothymidine was first synthesised, as an anti-cancer drug in 1964 by Horwitz et 
al., and was the first drug to be licensed for use in the treatment of AIDS patients (Figure 
3). AZT is converted to its active form (AZT-triphosphate) by cellular kinases (Furman et 
al., 1986). Thymidine kinase converts AZT to its monophosphate and diphosphate forms, 
while thymidylate kinase converts it to AZT-triphosphate (Furman et al., 1986). AZT- 
triphosphate is a very potent inhibitor of the HIV-1 reverse transcriptase enzyme, with an 
affinity 100-fold greater for HIV-RT than cellular polymerases (Furman et al., 1986). AZT- 
TP competes with dTTP as substrate for the HIV-RT. When AZT is incorporated into the 
viral growing DNA chain, it causes DNA chain termination. AZT-TP cannot form a
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normal 3 - to 5’-  phosphodiester bond with the hydroxyl group (5’-OH) of the next 
nucleotide, since it lacks the 3 'OH group on the ribose sugar (Furman et al., 1986; Mitsuya 
and Border, 1986 and 1987)
In the first clinical trials conducted by (Fischl et al., 1987), it was revealed that 
treatment with AZT resulted in a reduction in HIV p24 antigen, a moderate increase in the 
CD4 counts, and a significant reduction in the incidence of death among patients in the test 
group. This study also revealed some of the toxic-side effects of AZT treatment, including; 
headaches, nausea, insomnia, myalgia, and most importantly haematological disorders 
(anaemia, neutropenia). Following confirmation by other clinical trials, AZT became the 
drug of choice in combating AIDS. Recent results from the Concord studies have revealed 
that the administration of AZT early in HIV infection has no significant effect on the rate of 
survival of the patients or the progression of HIV disease. Although a transient clinical 
benefit was observed in the test group.
Prolonged treatment of AIDS patients with AZT is frequently associated with the 
emergence of , AZT-resistant mutants (Larder et al., 1989). A further study by Larder et 
al., (1989a), indicated that amino acid substitution in the HIV reverse transcriptase protein 
at positions; 67 (Asp to Asn), 70 (Lys to Arg), 215 (Thr to Phe or Tyr), and 219 (Lys to 
Gin) were responsible for the resistance to AZT. More recent study has identified an 
additional substitution at position 41 (Meth to Leu) which also confers resistance to AZT 
(Kellam et al., 1992).
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PIDEOXYCYTIDINE (ddC) AND DIDEOXYINOSINE (ddl).
2’, 3’-dideoxycytidine (Zalcitabine) and 2’, 3’- dideoxyinosine (Didanosine) (Figure 
3jare nucleoside analogues with a mode of action similar to that of AZT (Cooney et al., 
1986; Mitsuya and Broder, 1986). HIV isolates resistant to ddl and ddC have been isolated 
from patients after prolonged drug treatment (St.Clair et al., 1991). Ddl resistance was 
generated by a point mutation in the HIV RT gene resulting in a Leu to Val change at amino 
acid 74. Curiously, this same mutation resulted in increased sensitivity to AZT (St. Clair et 
al., 1991). Combinations of ddl or ddC with AZT have been administered for the treatment 
of AIDS patients (particularly those suffering from AZT-induced suppression of bone 
marrow activity). In vitro experiments using AZT and ddl in combination, resulted in 
synergistic antiviral activity but only additive cytotoxicity (Dornsife et al., 1991). The 
exact mechanism by which the synergistic effect is achieved is not known. However, when 
AZT and ddl are combined at the ratio of 1:1 the phosphorylation of ddl to the active 
triphosphate form was increased (Palmer and Cox, 1994). More recently, however, it was 
demonstrated that AZT and ddl could be mixed at ratios other than 1:1, and still exhibit 
synergistic antiviral activity (Palmer and Cox, 1995).
NEVIRAPINE.
5,11-dihydro-1 l-cyclopropyl-4-methyl-6H-dipyrido-[3,2-b2’,3’e][l,4]diazepin-6- 
one (Nevirapine) (BI-RG-587) (Figure3) is a dipyridodiazepinone and a non-nucleoside 
inhibitor of HIV-RT (Merluzzi et al., 1990) . Based on studies with HIV infected and 
uninfected human T-cells the Ki of nevirapine for HIV-RT was reported to be 200nM, with 
a therapeutic index of > 8000 (Merluzzi et al., 1990).
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The drug is a specific inhibitor of HIV-RT and operates by binding non- 
competitively (with respect to the primer, template, nucleotide, and RNA) to the tyrosine 
residues at amino acid position 181 and 188 of the p66 subunit of HIV-1 RT enzyme 
(Kohstaedt et al, 1992 and Shih et al., 1991). Nevirapine also partially inhibits the RNase 
activity of the RT (Merluzzi et al., 1990). Binding of nevirapine to RT is thought to result 
in conformational changes, which affect the polymerase activity more than the RNase 
activity. The activity of nevirapine is highly specific for HIV-1 RT and has no effect on 
SIV RT, or FeLV-A RT, nor does it affect the activities of human DNA polymerases a , p, 
y, or 5 (Merluzzi et al., 1990). The IC50 concentrations of nevirapine against different 
laboratory strains of HIV-1 ranged from 32 to 42 nM. However the compound has no 
activity against HIV-2 strains (Merluzzi et al., 1990).
At concentrations 8000-fold lower than the cytotoxicity dose, nevirapine inhibited 
HIV-1 induced syncytium formation and p24 antigen production by wild type virus in tissue 
culture experiments (Richman et al., 1991). Nevirapine is synergistic in combination with 
AZT, and also inhibits AZT-resistant HIV-1 mutants (Richman et al., 1991).
A clinical trial involving 21 HIV-infected patients, showed that, treatment with 
nevirapine at concentrations up to 400mg/day was well tolerated (Cheeseman et al., 1992). 
Results from phase I and II clinical trials of nevirapine monotherapy showed a reduction in 
serum p24 levels and an increase in the CD4 cell counts, after only 7 days treatment 
(Cheeseman et al., 1992). However, the p24 and CD4 values returned to their initial values 
shortly after discontinuation of the therapy. Nevirapine-resistant viruses can be isolated 
after a very short time (as early as a week after drug treatment) (Richman et al., 1994). The 
nevirapine resistant mutant most commonly isolated after nevirapine monotherapy has a
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ttyrosine to cysteine substitution at residue 181 in the RT protein (Richman et al., 1991a and 
1994).
TIBO.
Tetrahydroimidazol[4,5,l-jk][l,4]-benzo-diazopin-2(lH)thione (TIBO) (Figure3), is 
another non-nucleoside inhibitor of HIV-1 reverse transcriptase activity (Pauwels et al.,
oF
1990). The mechanism of the action TIBO is very much the same as nevirapine, indeed 
nevirapine is inactive against TIBO-resistant mutants (Richman et al., 1991a).
TIBO completely inhibited p24 production from HIV-1 infected peripheral blood 
lymphocytes at 0.7pM, whereas a cytotoxic effect was observed at 800|iM (Pauwels et al.,
1990). TIBO selectively inhibits the HIV-1 RT polymerase activity and has no effect on the 
RNase activity of the enzyme, and no activity against HTV-2 RT activity. Neither do the 
drugs inhibit human DNA polymerases a, (3, or y activities (Debyser et al., 1991; Frank et 
al., 1991). Treatment of HIV-infected cell cultures with TIBO resulted in rapid emergence 
of TIBO-resistant mutants [with a single base mutation at codon 181 (Tyr to Cys)] (Larder,
1992). This mutant was cross-resistant to nevirapine. Furthermore, acquisition by AZT- 
resistant isolates, of TIBO resistance mutation at position 181, resulted in a suppression of 
AZT resistance (Larder etal., 1992).
TAT INHIBITORS.
[7-chloro-5-(2-pyrryl)-3H-l 1,4-benzodiazepine-2(H)-one] (Ro 5-3335) and its 
derivative [7-chloro-N-methyl-5 (1 H-pyrrol-2-yl)3H-1,4-benzodiazepin-2-amine] (Ro 24- 
7429) are both potent inhibitors of TAT-mediated transcriptional activation in HIV-1 (Hsu
2 0
et al., 1991 and 1993). Ro 24-7429 toxicity in laboratory animals is less than that of Ro 5- 
3335.
While the mechanism of action of these compounds against HIV-TAT is not fully 
understood, it is possible that they impair TAT binding to TAR (the cis acting binding site 
for TAT).alternatively they might inhibit interaction of TAT with cellular factors (Hsu et 
al., 1993).
Ro 24-7429 is active against a broad range of HIV-1 laboratory strains, and is also 
active against HIV-2 Tat activity. The drug inhibited viral RNA and antigen production in 
both acutely and chronically infected cell cultures at noncytotoxic concentrations (IC50 at 
0.2-1 pM). Ro 24-7429 was also effective against clinical isolates resistant to AZT and 
nevirapine (Hsu et al., 1993). Following two years of repeated weekly passages of the virus 
in the cell culture in the presence of the RO 24-7429, no resistant virus mutants have been 
isolated. Despite of these encouraging results, Ro 24-7429 proved to have low solubility in 
vivo, and the results from phase I and II clinical trials have indicated that RO 24-7429 is 
inefficient in vivo (Bowen et al., 1995)
1.1.5.1. ANTI-HUMAN IMMUNODEFICIENCY VIRUS COMPOUNDS DERIVED 
FROM NATURAL SOURCES.
Despite the immense effort expended in pursuing rational drug design programmes, 
there remains a need to investigate the vast reservoir of natural compounds for those that 
display antiviral activity. Hundreds of thousands of terrestrial and marine plant extracts 
have been tested for activity against HIV by both the US National Institute of Health (NIH), 
and pharmaceutical companies. Because plants or plant extracts are used in traditional
21
HOCH7 n
AZT
M
r
.CH,
' C H .
TIBO
HOCH, nC?
DDC
A
NEVIRAPINE
FIGURE 3 . Stucture of anti-HIV compounds.
medicine throughout the world to treat a variety of diseases, including viral infections, the 
World Health Organisation (WHO) has encouraged the scientific investigation of plant 
extracts for possible anti-HIV activity.
Although, many plant derived compounds are administered to AIDS patients in 
under-developed countries, there is either no scientific basis for their use, or if there is a 
genuine anti-HIV activity, the antiviral mechanism remains obscure. Some of the naturally 
occurring compounds which have shown anti-HIV activity are described below.
POLYSACCHARIDES.
Compounds such as dextran sulphate and heparin (Figure 4) block the adsorption of
HIV to the cell membrane (reviewed by Wright, 1995). Both of these compounds
completely protected MT-4 cells in culture against HIV-1 induced cytopathogenecity at
25|ig/ml, while no cytotoxicity was observed at 625pg/ml (Baba et al., 1988). The
compounds exhibited anti-HIV activity at concentrations that are thought to be safe in
humans (eg. heparin and dextran sulphate inhibit HIV replication at 1/10 and 1/100 of
concentration required for their anti-coagulant effect respectively). However, poor oral
e.
absorbance and low stability hay limited their use as an effective anti-HIV treatments 
(reviewed by Wright, 1995).
PSUEDOMONAS EXOTOXIN.
A novel approach has been taken in delivering toxic compounds to HIV-infected 
cells. A recombinant protein consisting of the CD4 molecule and the pseudomonas
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exotoxin-A, selectively destroys HIV infected cells by biding to the, HIV surface protein 
(gpl20), expressed on their plasma membrane (Chaudhury et al., 1988).
ALKALOIDS AND SUGAR ALKALOIDS.
Papaverine is an alkaloid present in the seeds of the opium poppy Papaver 
somniferum (Figure 4). This compound is already used clinically as a smooth muscle 
relaxant for the treatment of gastrointestinal colic. Turano et al., (1989) have shown that 
Papaverine impairs HIV replication in vitro; viral protein synthesis was markedly reduced 
although, not all proteins were equally affected (the synthesis of envelope proteins was 
most markedly inhibited). However, in clinical trials the serum level of HIV-core protein 
(p24) was not affected by papaverine treatment, although opportunistic infections were 
decreased and lymphocyte counts improved (Reviewed by Wright et al., 1995).
Sugar alkaloids, in which a nitrogen has replaced the oxygen atom on the sugar 
molecule generally exert an antiviral effect by inhibiting protein glycosylation. 
Castanospermine [from the seeds of the Australian Moreton Bay chestnut tree 
(castanospermum australe)] (Figure 4), inhibits a-glucosidase I, thereby preventing the 
trimming of glucose residues; an early event in glycoprotein processing (Elbein et al., 1984; 
Saul et al., 1985).
Deoxynojirimycin, a sugar alkaloid present in Bacillus and Streptomyces bacteria, 
and also in the berry of Morus (mulberry) (Reviewed by Wright et al., 1995) inhibits both 
glucosidase I and II activities (Furmann et al., 1985). Both castanospermine and 
deoxyjirimycin have been shown in in vitro experiments to impair syncytium formation and 
virus replication in HIV-infected cells at concentrations of > lpM  (Gruters, et al., 1987;
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Tyms et al., 1987; Walker et al., 1987). The effect of castanospermin on HIV induced 
syncytium formation is probably due to the inhibition of processing of the HIV glycoprotein 
precursor gpl60. HIV-infected T-cells treated with castanospermine exhibited reverse 
transcriptase activity and produced capsid protein (p24) at the same levels as control cells, 
although, infectious virus yields were reduced (Walker et al., 1987). In vitro experiments 
have shown that, while the anti- HIV-1 and HIV-2 activitiesof castanospermine and AZT 
was synergistic, cytotoxicity was unaffected (Johnson et al., 1989). Although, both 
castanospermine and deoxyjirimycin are well tolerated in tissue culture, little, or no 
information regarding the toxicity in vivo has been available.
FLAVONOIDS AND TANNINS.
While, flavanoids such as quercetin, quercetagetin, baicalein (Figure 4) and 
myricetin all have anti-RT activity, the use of these compounds as anti-HIV dmgs is 
excluded by the finding that they are also potent inhibitors of mammalian DNA 
polymerases (reviewed by Wright, 1995)
AROMATIC POLYCYCLIC DIONS.
Hypericin and psuedohypericin are aromatic polcyclic dions (Figure 4), isolated 
from plants of the Hypercium family. Both compounds have anti-retrovirus activity; 
inhibiting the replication of Friend leukaemia virus (FV), and radiation leukaemia vims 
(RadLV), both in vitro and in vivo (Meruelo et al., 1988). Treatment of FV-infected 
BALB/c strain mice with a single dose of eithei^the compounds, prevented virus-induced
2 4
death. The in vitro studies suggest that the mode of antiviral action is likely to be through 
interference with the assembly, maturation or release of the vims (Meruelo Et al., 1988).
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1.1.6. COMPOUNDS WITH BROAD-RANGE ANTIVIRAL ACTIVITY.
PMEA (ADEFOVIR).
9-(2-phosphonylmethoxyethyl) adenine (PMEA) (Figure 2) and its derivative, 9-(2- 
phosphonylmethoxyethyl)-2,6-diaaminopurine (PMEDAP) are potent and selective 
antiviral agents having broad-range antiviral activity (De Clercq, 1991). The viruses 
inhibited include; adenovirus (Baba et al., 1987), herpesviruses [HSV-1, HSV-2, VZV, 
CMV, EBV, BHV-1, EHV-1, TK' HSV-1, and TK* VZV] (De Clercq et al., 1986), HIV-1 
(Balzarini et al., 1991), FIV (Egbernic et al., 1990), and Friend leukaemia virus (Naesens et 
al., 1993).
PMEA blocked FIV replication (ED50 0.6pM) in infected feline thymocytes, and 
suppressed virus replication in FIV-infected cats. However^at very high doses of the drug, 
toxic side effects, such as megaloblastic anaemia occurred (Egbernic et al., 1990). PMEA 
is converted to its diphosphorylated form (PMEA-DP), by cellular 5-phosphoribosyl-l- 
pyrophosphate (PRPP) synthetase (Balzarini et al., (1991). The affinity of PMEA-DP for 
HIV-l-RT is higher than that for cellular DNA polymerase (Ki/Km values of 0.01 and 0.6 
respectively). PMEA-DP competes with dATP for HIV RT. PMEA-DP is an inhibitor of 
RT and, after incorporation into viral DNA, results in DNA chain termination (Balzarini et 
al., 1991). The oral bioavailabiltiy of PMEA is low (12%) (Cundy et al., 1995). However, 
in vivo, PMEA-DP has an intracellular half life of 16-18h (Balazarini et al., 1991). Thus, in 
contrast to AZT, PMEA required less frequent administration to be effective against HIV. 
PMEDAP, however, proved to have good oral bioavailability in mice (Naesens et al.,
1993). A study by Valenkamp et al., (1995) comparing PMEA and PMEDAP in the
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treatment of FIV infected cats, revealed that the latter inhibited FIV replication (both in 
vivo and in vitro) more efficiently and was less toxic.
PMEA and PMEDAP have both anti-herpes and anti-retrovirus activity, and this 
could be beneficial in the treatment of AIDS patients in wh° , herpesviruses vims 
infections are very common.
RIBAVIRIN (VIRAZOLE).
Ribavirin (l-p-D-ribofuranosyl-l,2,4-triazole-3-caboxamide) (Figure 2) is a 
synthetic nucleoside analogue, first synthesised in 1972, and shown to have antiviral 
activity against a wide range of DNA and RNA viruses in vitro (Sidwell et al., 1972).
The precise antiviral mechanism of the drug is still not clear. Ribavirin is 
phosphorylated by cellular enzymes to ribavirin-TP. Ribavirin-MP inhibits inosine 
monophosphate dehydrogenase (IMD), which is responsible for the synthesis of GMP from 
IMP, resulting in a decreased pool of GTP, inhibiting both DNA and RNA synthesis 
(Streeter et al., 1973). Ribavirin-TP, however, interferes with the capping and elongation 
of m-RNA’s. The antiviral activity of ribavirin-TP against influenza vims is thought to be 
due to inhibition of the mRNA capping enzyme, guanyltransferase (Wray et al., 1985).
The multi-site antiviral action of ribavirin might explain , the failure to isolate ribavirin- 
resistant mutants (Gilbert et al., 1986).
In 1986, the US Food and Drug Administration (FDA) approved the use of ribavirin 
aerosol for the treatment of respiratory syncytial virus (RSV) infection in infants.
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FOSCARNET.
Trisodium phosphonoformic acid (Foscarnet) (Figure2) is a pyrophosphate 
analogue. Foscarnet inhibits the replication of a diverse range of DNA and RNA viruses by 
directly blocking the pyrophosphate binding site on the POL protein leading to inhibition of 
polymerase activity (Chrisp and Clissold, 1991). Since the mechanism of antiviral activity 
of foscarnet is different than that of ACV or GCV, it is currently used for treatment of 
ACV-resistant and GCV-resistant herpesvirus infections (Field et al., 1994). Foscarnet 
has also been licensed for the treatment of retinitis caused by HCMV in AIDS patients 
(Field et a l,  1994). HCMV isolates resistant to foscarnet and having point mutations in 
the DNA polymerase gene have been reported (Sullivan and Coen, 1991).
In a recent study, in which AIDS patients were treated with foscarnet for one week, 
a reduction in serum p24 level was found in all of the patients (Fletcher et al., 1994). 
Inhibition of HIV reverse transcriptase by foscarnet was probably responsible for the 
finding. After long-term treatment of AIDS patients with foscarnet, the emergence of HIV 
foscarnet-resistant isolates was rare (Tachedijian et al., 1994), but was associated with 
point mutations in the RT gene. (Mellorser al., 1995).
Unfortunately, foscarnet is accumulated in bone tissue, Although d does not 
suppress bone marrow activity, it has been associated with renal failure (Chrisp
andClissold, 1991).
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1.1.7. TRITERPENOIDS.
The aqueous extract of licorice root (Glycyrrhizia Radix), has been widely used in 
traditional Chinese medicine for its anti-inflammatory properties. Knowledge of the 
medicinal properties of licorice root has a long history, and the work of Hippocrates 
published in the 5th century BC recorded its use as a therapeutic agent (Fujisawa, 1993). 
Glycyrrhizin (GL), a saponin present in the aqueous extract of licorice root, was first 
isolated in 1909 and a derivative, carbenoxolone sodium (CBX), became the first 
compound used for the treatment of gastric ulcer in the 1960 s. GL consists of one 
molecule of the triterpene, glycyrrhetinic acid (also known as enoxolone) and two 
molecules of glucuronic acid (Arai, 1981). The enoxolone portion of the compound is 
thought to constitute the active part of the molecule. A family of related compounds based 
on enoxolone have been produced. The structural formulae of glycyrrhizin (GL), 
enoxolone (EX), and the two synthetic derivative investigated in this thesis; carbenoxolone 
sodium (CBX) and cicloxolone sodium (CCX), are shown in Figure 5. Triterpenoid 
compounds are highly lipophilic > bind strongly to cellular membranes (Johnston et al., 
1974), and at high drug concentrations (>50|iM CCX) can cause the plasma membrane5to 
become leaky (Dargan and Subak-Sharpe, 1986; Reardon and Audus, 1993). Triterpenoid 
compounds are also known to disturb the normal flow of monovalent cations across plasma 
membrane (Baron and Green, 1986).
Pompei et al., ( 1979, 1980 and 1981) have investigated the antiviral activity of GL 
against a range of DNA and RNA viruses, and have found that at GL concentrations well 
tolerated by cell cultures (2mM and 4mM) the growth of vaccinia, HSV, Newcastle disease 
virus (NDV), and vesicular stomatitis virus (VSV) was inhibited. In addition, GL inhibited
29
the replication of influenza (A and B) and NDV in embryonated eggs (Pompei et al., 
1983). Baba and Shigeta (1987) have reported that GL has anti-VZV activity. GL induced 
inhibition of VZV replication in HEF cells operated at an early stage in the virus replication 
cycle (penetration or uncoating). These authors also reported that GL in combination with 
other compounds (acyclovir, adenine arabinoside, bromovinyldeoxyuridine or 
phosphonoformate) resulted in additive or slightly synergistic antiviral activity in in vitro 
experiments
The US food and drug administration (FDA) has approved GL for human use. 
Taken in sufficient quantity, triterpenoid compounds, can induce a mineral-corticoid effect 
(increased serum sodium level and decreased serum potassium level) (Tomkins and 
Edmond, 1975; Epsteine et al., 1977) (this may also be induced by the consumption of 
confectionery licorice). The basis for the mineral corticoid activity is thought to result from 
the effect of triterpenoid compounds on the cellular Na+/K+ATPase (the sodium pump). 
Baron and Green (1986) have shown that CBX stimulates Na+/K+ATPase activity in intact 
human leukocyte*5 Using ouabain, a specific inhibitor of Na+/K+ATPase 
Gary et al., (1979) have shown that the increase in enzyme activity was not due to the 
synthesis of new enzyme molecules or unmasking of presynthesized molecules, but to a 
direct stimulation of the operation of pre-existing sodium pumps. The sodium pump 
hydrolyses ATP to exchange 2 intracellular Na+ ions for 3 extracellular K+ ions. The 
Na+/K +ATPase enzyme consists of two separate proteins which function as a  and p 
heterodimers. The catalytic activity of the sodium pump is associated with the a  subunit. 
The a  subunit of the sodium pump is regulated through the action of protein kinase C 
(PKC) (Ling et al., 1984; Bertorrelo et al., 1991; Middelton et al., 1993). Na+/K+ATPase
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activity is inhibited by PKC-mediated phosphorylation of the a  subunit of the pump. Other 
cell-response factors, such as neurotransmitters and hormones, which trigger PKC activity 
also inhibit Na+/K+ATPase activity (Bertorello et al., 1991).
Ito et al (1987) have demonstrated that GL inhibits the activity of the PKC. 
Consequently, it seems probable that the observed triterpenoid-induced increase in 
Na+/K+ATPase activity is due to impaired regulation of the sodium pump via decreased 
phosphorylation of the a-subunit of the enzyme by PKC. Although, this seems a likely 
explanation, it should be noted that, the Na+/K+ATPase present in some cell types does not 
respond to PKC (Middelton et al., 1993) (this may explain the differential tolerance of 
various cell lines for triterpenoid drugs). Furthermore, it may also be relevant to note that 
PKC is a ubiquitous enzyme that exists in several different soluble and membrane-bound 
isoforms, some of which are involved in secretion, exocytosis, modulation of ion 
conductance, regulation of receptor interaction with components of the signal transduction 
apparatus, gene expression, and cell proliferation (Nishizuka, 1986 and 1988). Thus it is 
possible that the triterpenoid compounds interfere with several different cellular 
biochemical systems.
Prolonged triterpenoid treatment, especially in patients of advanced years, may 
induce psuedoaldosteronism (increased serum Na+ level) and hypokalaemia (decreased 
serum K+ level) (Stewart et al., 1987). These unwanted side- effects can usually be 
controlled by treatment with diuretics and are reversible upon removal of the drug 
(Molhuysen et al., 1950; Conn et al., 1968). In order to alleviate the in vivo mineral- 
corticoid effect of GL, an intravenous preparation of GL, consisting of GL (0.2%), Cysteine 
(0.1%), and glycine (2 %) in physiological saline, sold under the name of Stronger Neo-
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Minophagen C (SNMC) is routinely used in Japan to treat chronic viral hepatitis and/or
allergic skin diseases (Fugisawa et al., 1980; Suzuki et al., 1983). The glycine present in
SNMC is said to eliminate the mineral-corticoid effect of GL, while the cysteine is thought
to have detoxicative and anti-allergic properties.
The triterpenoid compounds can be cytotoxic in tissue culture, but the magnitude of
the cytotoxic effect depends upon the type of the cell line used. Based on their tolerance for
CCX, Galt et al., (1990) have classified ~ 20 cell lines, into three different group; resistant
A
r i s(CCX ), intermediate in sensitivity (CCX ), and sensitive (CCX ). The cell lines classified
as CCX-resistant included: bovine MDBK, canine MDCK, rabbit RK, and human; Hela, 
Hep2, Chang liver, Detroit 532, and Flow 2002 cells. The intermediate class contained; 
rabbit epithelium, rabbit keratocytes, hamster BHK 21, human MRC-5, and human flow 
4004 cells. The CCX-sensitive class included; rat cells (Re 99, Re a, and Hood cells), 
primary chicken embryo fibroblast, humanFG293, and frog XTC-2 cells. The cell type may 
determine tolerance to CCX; of 10 fibroblastic cell lines two belonged to the resistant class, 
three were placed in the intermediate group, and the rest belonged to the sensitive class, 
while 7 of 11 epithelial cell lines examined were classified as resistant (Galt et al., 1990). 
CCX-resistant cell lines have facilitated the study of the antiviral activity of the drug- 
because the cytotoxic and the antiviral effects can be uncoupled.
A randomised double-blind placebo controlled trial of 133 chronic active hepatitis 
patients (diagnosed by histological techniques) treated intravenously with 80 mg of GL 
(SNMC) per person/day for one month, showed that there was a significant improvement in 
serum transaminase levels in the test group compared to those of the placebo group (Suzuki 
et al., 1983). Several clinical trials in Germany (between 1988-1991) have shown that
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treatment of patients, diagnosed as having a history of chronic active hepatitis B and C 
with SNMC [usually three 60 ml (80 mg of GL) injections/week ] for a period of 6 months 
to 3 years, resulted in significant improvement in liver transaminase enzymes (AST, and 
ALT) in more than 80% of the patients. Importantly, no side effects were reported, nor 
were relapses observed after withdrawal of treatment (Wildhirt, 1993). The mechanism by 
which GL exerts its anti-hepatitis B activity is not clear. It may be due to the induction of 
interferon by the drug (Abe et al., 1982) or may be due to a direct effect of the drug on virus 
replication.
Takahara et al., (1994) have shown that glycyrrhizin suppresses the secretion of the 
hepatitis B surface antigen (HBsAg) in PLC/PRF/5 cells in culture, resulting in the 
accumulation of the HBsAg protein in cytoplasmic vacuoles located at, or near the 
proximity of the Golgi apparatus. GL suppressed the intracellular transport of HBsAg at a 
stage after O-linked glycosylation but before sialation of the protein; probably in a trans- 
Golgi compartment.
GL also inhibited replication of hepatitis A virus (HAV) in PLC/PRF/5 cells; this 
was not due to virucidal activity against HAV, since GL had no effect on the adsorption of 
(3H) uridine-labelled HAV to the cells (Crance et al., 1995). The same group of workers, 
also showed that a combination of GL and interferon a  resulted in a synergistic antiviral 
effect against HAV.
Treatment of infants exhibiting abnormal liver function caused by congenital CMV 
infection, with SNMC (60 mg of GL) (50ml/day for a period of one week), resulted in 
recovery of normal liver function, indicating possible anti-CMV activity for GL (Numazaki
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et a l ,  1994). Indeed, Galt et al.,( 1990) have demonstrated in vitro anti-HCMV activity for 
CCX.
The anti-HIV activity of GL (SNMC) has been demonstrated both in vitro and in 
vivo. GL completely inhibited the HIV-induced fusion of MT-4 cells and HIV antigen 
expression, at 0.3 and 0.6mM respectively. The GL ID50 for HIV in MOLT 4 cells was 
determined to be 0.15mM (Ito et al., 1987). Studies of the mode of anti-HTV activity of GL 
revealed that, GL did not impair HIV-1 reverse transcriptase activity in in vitro assays, 
even at concentrations up to 12 mM (Ito et al., 1987). The observation that treatment of 
HIV-1 infected cell cultures with a combination of GL and AZT resulted in additive 
antiviral activity, implies that the antiviral targets of these two compounds are different, 
and that the target for GL is not RT (Ito et al., 1987). Further studies by Ito et al., (1988) 
have shown that GL inhibits protein kinase C (PKC), a ubiquitous enzyme responsible for 
phosphorylation of the CD4 protein on the cell surface. The CD4 protein is recognised as 
the specific receptor for HIV on susceptible lymphocyte cells. The authors suggested that 
at least part of the anti-HIV mechanism of GL operates at the level of virus adsorption 
(through the inhibition of CD4 phosphorylation). The effect of GL on virus binding can 
only account, however, for a relatively small contribution to the overall antiviral effect of 
GL, indicating that other antiviral mechanisms are also in operation. In contrast to the 
findings of Ito et al., (1988), Ohtsuki et al., (1988) could find no evidence that GL inhibited 
PKC, or protein kinase A activity but did report that low doses of GL selectively inhibited 
the activity of protein kinase P in a dose-dependent manner. As PKC exists in up to eleven 
different isotypes, it is possible that these conflicting reports may be due to the use of 
different lines by each group of investigators.
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Several groups have investigated the treatment of AIDS patients with GL and have 
reported some clinical benefit. Hattori et al., (1989) reported that AIDS patients (with T4 
lymphocyte count of < 100/pl of serum) treated with intravenous SNMC (at 400-1600mg of 
GL/day), for a month), had a reduced level of serum HIV p24 antigen. However, a 
sustained increase in the number of T4 cells was not achieved. An increase in T8 cell 
number was observed and was thought to be due to the immunostimulatory effect of GL 
(Kimura et al., 1992). GL stimulates interferon y production in mice (Abe et al., 1982), and 
enhances both antibody production and cellular immune responses such as; lymphocyte 
proliferation, interleukin 2 synthesis, and natural killer activity (Kakumu, 1993). Treatment 
of nine haemophiliac, patients diagnosed as HIV-positive (asymptomatic carriers), with 
intravenous SNMC (200-800mg GL /day for more than 8 weeks), resulted in an increase in 
T4 cell numbers in all cases, and an increase in the CD4/CD8 cell ratio for 6 out of 9 cases 
(Mori et al., 1989). As expected, treatment of 3 control patients (HTV-negative 
haemophiliacs) with GL did not alter the number of T4 lymphocytes (Mori et al., 1989). 
The authors, therefore suggested that treatment of HIV-positive individuals with large doses 
of GL early in HIV-1 infection, might delay or prevent the infection from developing into 
full blown AIDS (Mori et al., 1990).
The two derivatives of GL; CBX and CCX have been shown in clinical trials to be 
effective against orofacial and genital HSV infection (Poswillo and Roberts, 1981; Csonka 
and Tyrrell, 1984; Partridge et al., 1984).
Triterpenoid compounds exhibit broad range antiviral activity. It is thought that 
antiviral activity of the compounds does not stem from impairment of any specific vims 
gene or virus gene product, but rather that the drugs inhibit vims replication by disturbing
35
cell membrane functions which are essential for virus replication (Dargan et al., 1992). 
Based on sensitivity to CCX, DNA and RNA viruses from eight different families were 
placed into three classes (Galt et al., 1990). The first class, CCX-sensitive 1 (CCXS-1) 
(100-100,000 fold loss of infectivity in the virus yield) was composed of; HSV-1, HSV-2, 
EHV-1, BHV-1, VSV, and FLU A. Based on their ED50 values, VZV and HCMV were 
also included in this group. The dose-response curves of this class were characterised by a 
continuous CCX-dose-dependent decrease in virus yield. The second class (CCXs-2)
consisted of; Ad-5, Reo-3, polio-1, and the bunyaviruses (Germiston , and Bunyamwera). 
The dose-response curves of this class were characterised by bi-phasic kinetics; with 
increasing concentration of CCX, there was an initial drop in the virus yield (10-fold to 
100-fold reduction in infectious virus yield), after which the curve reached a plateau. The 
third class (CCXs-3), contained only one virus, the togavirus (SFV). The overall yield of 
infectious SFV was not affected by treatment with up to 300|iM CCX, although the release 
of the virus from infected cells was impaired. The sensitivity of different viruses to CCX 
did not correlate with virus genome type (DNA or RNA; single-stranded or double­
stranded; segmented or non-segmented RNA genome). Neither was there any indication 
that enveloped viruses were more CCX sensitive than non-enveloped viruses (Galt et al., 
1990).
The plateau reached in the dose-response curves of the CCXs-2 group viruses was
not due to the emergence of drug-resistant viruses, but was thought to be either due to the 
partial impairment of a process essential for virus infectivity or to inhibition of a cell or 
virus specific function which modifies, but is not essential for virus infectivity (Dargan et
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al., 1992). That a virus specific component can contribute to the overall antiviral effect of 
the drug was shown by the finding that, the difference in the CCX-sensitivity of HSV-1 and 
HSV-2 mapped to genes encoding glycoproteins; UL22 (gH) and UL44 (gC). Differential 
sensitivity of both viruses to monensin mapped to the same genome locations and suggest 
that monensin and CCX share the same antiviral target - the Golgi apparatus. (Dargan and 
Subak-Sharpe, 1991). Repeated attempts to isolate HSV-1, HSV-2, and VSV variants 
resistant to CCX were unsuccessful (Dargan and Subak-Sharpe, unpublished results). The 
proposed mode of antiviral action of the drug, suggests that, drug-resistant mutants would 
be unlikely to emerge.
The overall antiviral activity of CCX is composed of three effects. The particular 
combination of these effects and their magnitude was found to vary between the 
different viruses tested. The first effect arises from poor quality (low infectivity) progeny 
virus produced in the presence of the drug. Dargan and Subak-Sharpe (1985) showed that 
the particle/p.f.u. ratio of HSV increased by 100-fold to 1000-fold in CCX-treated infected 
cell cultures. EM studies revealed that, although DNA-containing HSV-nucleocapsids 
were produced in the presence of CCX, their maturation into fully infectious virion was 
inhibited (Dargan et al., 1988). The effect of CCX on progeny particle quality (infectivity) 
might be explained by the effect of the drug on virus protein synthesis and post- 
translational processing, and/or by the incorporation of the drug molecule into the virion 
envelope. CCX treatment resulted in the assembly of HSV particles with a protein 
composition different from that of control HSV particles. Both the amounts of individual 
proteins and their apparent molecular weights were altered. CCX and CBX treatments 
affected not only the total amount of HSV proteins produced in drug-treated cells, but also
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in particular cases,their post-translational processing (Dargan et al., 1986). Both CCX 
and CBX impaired sulphation, glycosylation and phosphorylation of HSV proteins 
(although only a small number of HSV phosphoproteins were affected) (Dargan and Subak- 
Sharp, 1986).
The second effect induced by CCX treatment is a reduction in the numbers of virus 
particles assembled in drug-treated cell cultures. CCX treatment results in a decrease in 
protein synthesis per se and thus must be a contributing factor in limiting the number of 
virus particles produced. While, CCX treatment impaired the synthesis of the VSV 
secondary mRNA transcripts, the mechanism by which this was achieved is not understood. 
It could involve inhibition of the transcription complex, mobilisation of the cellular stress 
response, activation of RNases, or modification of cellular transcription factors (Dargan et 
al., 1992).
Drug-induced impairment of the intracellular transport of virus proteins could also 
contribute to the reduction in the number of progeny virus particles assembled. In HSV 
infected BHK cells treated with CCX the relative amounts of particular proteins increased 
in the nucleus, while decreasing in the cytoplasm, indicating an effect on the 
nuclear/cytoplasmic transport of these proteins (Dargan and Subak-Sharpe, 1986). 
Furthermore, treatment of VSV-infected cells with CCX resulted in the accumulation of the 
virus glycoprotein (G) and matrix protein (M) within the cell (Dargan et al., 1992a). 
Treatment of VSV-infected cells with the glycosylation inhibitor monensin, also resulted in 
accumulation of G and M, implicating involvement of the Golgi apparatus. Thus 
impairment of the assembly of VSV in infected CCX-treated cells is partly due to the 
inhibition of the transport of the G glycoprotein through the Golgi apparatus to the plasma
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membrane, and partly due to a reduction in the amount of virus proteins made in the 
infected cells (Dargan et al., 1992).
The third effect of triterpenoid compounds is due to virucidal activity. The 
hydrophilic nature of the triterpenoid compounds and their affinity for cellular membrane, 
is thought to result in insertion of drug molecules into the virion envelope and/or plasma 
membranes. Presence of the drug molecules at either of these sites could inhibit virus 
infection at its earliest stage - virus adsorption or penetration (Dargan et al., 1992b). 
Pompei et al., (1980) have reported a reduction in HSV-1 infectivity of 100,000-fold, when 
particles were treated with 8mM GL. The virucidal effect of CCX against HSV-1, HSV-2, 
and VSV was quite modest at about 10-fold (Dargan et al., 1985 and 1992), but this 
represents the greatest virucidal activity found for CCX. Only a 2-fold reduction in Ad-5 
infectivity resulted from CCX virucidal activity, and no CCX virucidal activity was 
detected against Reo-3 (Dargan et al., 1992). As Ad-5 is a non-enveloped virus, virucidal 
activity against this virus is presumably due to non-specific binding of CCX to the surface 
proteins of the virus particle.
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1.2. RETROVIRUSES.
The retrovirus class of RNA viruses, have received much recent attention due to the 
threatening HIV epidemic, and the emergence of AIDS as a major threat to human health 
world-wide. Retroviruses cause a variety of infections, ranging in severity from benign 
(endogenous retroviruses) to lethal infections (HIV and HTLV-1).
Based on the pathogenecity and type of the infection in vivo, retrovimses have been 
classified into three groups (Teich, 1982, 1985). (1) Oncovirinae: the viruses belonging to 
this group can induce tumours upon infection. There are two types of oncoviruses: those 
exogenous oncoviruses carrying cellular one genes derived from host cell DNA, which 
when expressed can result in rapid induction of cancer (eg. Rous sarcoma virus and Murine 
leukaemia virus); and those which lack the cellular oncogene, but nevertheless express a 
viral protein that can induce cancer in the host (eg human T-cell leukaemia virus). (2) 
Lentivirinae: The infection of these exogenous non-oncogenic viruses is characterised by 
emergence of a s l o w l y  d e v e l o p i n g  d i s e a s e .  The viruses in this group mainly infect ungulate 
mammals, eg. caprine arthritis encephalitis virus (CAEV) (goat), visna maedi virus (W ) 
(sheep), equine infectious anaemia vims (EIAV) (horses). The immunodeficiency viruses: 
human immunodeficiency virus (HIV), simian immunodeficiency vims (SIV), feline 
immunodeficiency virus (FIV), and bovine immunodeficiency vims (BIV) are also included 
in this group. (3) Spumavirinae: These are vimses also known as foamy vimses, they are 
generally not associated with any known disease, however, they may cause persistent 
infection in their host (eg simian foamy virus 5).
Retroviruses are enveloped viruses ranging in size from 100 to 120nm. The 
retrovirus genome is composed of two subunits of single stranded RNA (of identical
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sequence), and ranging in size from 7Kb to 10Kb. All retrovirus genomes are capped at the 
5’ end and polyadenylated at the 3’ end. Other small RNA molecules are associated with 
the genome, mainly tRNA and small ribosomal RNA s. The t-RNA serves as primer for 
the synthesis of provirus DNA by viral reverse transcriptase. The retrovirus genome is 
flanked by two long terminal repeats (LTR s). The LTR s contain many non-coding 
sequences (from 5’ end these are; R, U5, primary binding site (PB), leader, polyurine tract, 
U3, R, and polyadenylation site).
The first large open reading frame (ORF), adjacent to the 5’ LTR, codes for the 
GAG gene. This gene is translated from full-length RNA, and yields a precursor 
polyprotein that is cleaved to yield three proteins; matrix (MA), capsid (CA), and 
nucleocapsid protein (NC). The NC protein is associated with the RNA genome of the 
mature virus particle. A known DNA binding sequence (CYS-X2-CYS-X4-HIS-X4-CYS) is 
well conserved among retrovirus nucleocapsid proteins. The MA is a myristoylated 
membrane associated protein, located between the capsid and the envelope component of 
the virion. The CA protein is hydrophobic and forms the core structure of the virion.
The second largest ORF in retrovirus genome is pol. The pol ORF generally 
overlaps that of the gag ORF, but is transcribed from a different reading frame. The pol 
ORF codes for three proteins; protease (PR), reverse transcriptase/ribonuclease (RT), and 
integrase/endonuclease (IN). The protease gene is located at the 5’ end of the pol ORF and 
is cleaved from the pol gene polyprotein by an autocatalytic process. The RT consists of a 
heterodimer of a 66K polypeptide and a 51K polypeptide. The reverse transcriptase of 
retroviruses specify both RNA-dependent DNA polymerase, and ribonuclease H activities. 
The reverse transcriptase activities of most retroviruses requires the presence of Mg
41
(with the exception of mammalian C-type viruses which prefer Mn2+). The RT region of
$
the pol ORF is one of the most conserved region^of the retrovirus genome. The integrase 
gene is located at the carboxy-terminal of the pol ORF and its protein product is 
responsible for the specific integration of the provirus DNA into the cellular genome. 
Integration of provirus into cellular DNA sequences occurs at random sites within the host 
genome. However, on the virus side the integration is specific, occurring at the specific 
virus sequence.
The third large ORF in retrovirus genome is known as env. The env ORF is the 
least conserved of all retrovirus genomic sequences. This region encodes for both a 
surface and a transmembrane protein, which are usually held together in a complex by 
disulphide bonds, and/or non-covalent interactions. In all retroviruses, the surface protein is 
heavily glycosylated, and is responsible for the specific binding of the virion to the host cell 
membrane during virus adsorption. The surface protein is the main target for neutralising 
antibodies in the infected host. The transmembrane protein has 3 distinct domains; 1. the 
external domain, which is responsible for attachment to the surface protein, 2. the 
hydrophobic membrane domain which is responsible for the fusion of the vims envelope 
with the cell membrane (facilitating virus penetration), and 3. the cytoplasmic domain.
In addition to the three large ORF’s , some retroviruses contain additional short 
ORF’s which are important for virus replication. In lentivimses, and particularly HIV, at 
least six additional genes have been identified, these are: vif, vpu, vpr, tat, rev and nef 
(Figure 6).
The HIV-1 tat gene encodes a 86 amino acid protein which is the product of a 
doubly spliced m-RNA coded for by two ORF’s, the first 5’ to env and the second
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overlapping the transmembrane protein (gp41), but in a different reading frame. The tat 
protein is mainly localised in the nucleus of infected cells (Sheridan et al., 1993). Tat 
operates as a trans-activator (Siegel et al., 1986), and has a positive regulatory function 
(Arya et al., 1987). It is thought that tat increases the rate of transcription initiation, the 
efficiency of transcript elongation and the stability of the transcription initiation complex 
(Laspia et al., 1989; reviewed by Cullen, 1990; and Feinberg et al., 1991). The cis-acting 
sequence that responds to tat (TAR) is a 59 nucleotide stem loop structure located at the 5’ 
end of all HIV-1 transcripts (Muesing et al., 1987). The tat protein operates by 
specifically binding to TAR element and increasing the efficiency of the RNA polymerase- 
II mediated transcript elongation process (Marciniak et a l, 1991). At least two functional 
domains of the tat protein have been identified; the first is a highly conserved motif, 
containing seven cystein^residues, which may mediate protein-protein interactions in vivo 
(Frankel and Pabo., 1988), and the second, rich in lycine and argenine residues, is located at 
the C-terminal, and is required for the nuclear localisation of the tat protein.
The 116 amino acid protein product of the HIV-1 rev gene arises from a doubly 
spliced mRNA that overlaps the tat exon (reviewed by Green and Cullen, 1990). The rev 
protein is located in the nucleus (Cullen et a l, 1988), particularly in the nucleolus, of the 
HIV-infected cells. The rev protein functions as a negative regulator of its own synthesis 
and also mediates the establishment of an equilibrium between virus structural and 
regulatory protein synthesis. Rev is required for the cytoplasmic transport of unspliced and 
singly spliced HIV-1 mRNA species. Rev does not have any effect on the splicing pattern 
of HIV-mRNAs (Emerman et al., 1989). In the absence of rev, high levels of unspliced 
transcripts can be detected in the nucleus. Rev has no effect on the cellular location of
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spliced or unspliced cellular RNA’s. A highly structured 234 nucleotide cis-acting element 
[ rev response element (RRE)], which is important for modulating the level of free rev 
protein in the nucleus is located within the env gene (Hadzopoulos-cladaras et al., 1989). 
The binding of rev protein to RRE is essential for the nuclear transport of unspliced and 
singly spliced mRNA’s to the cytoplasm, by directly facilitating their interaction with a 
component of the cellular RNA transport pathway (Malim et al., 1988).
The HIV-1 nef gene overlaps the 3’ LTR and encodes a 27Kd protein, which is 
translated from a multiply spliced mRNA transcript (Harris et al., 1992). Nef-minus 
mutants replicate at 2 to 10 fold higher titre than the wild type virus (Luciw et al., 1987), 
demonstrating the negative regulatory role of this protein. Additional functions attributed to 
nef include; involvement in signal transduction pathways (Guy et al., 1987), and regulation 
of CD4 receptor expression (Guy et al., 1987; Garcia and Miller, 1991), Other workers, 
however, (Cheng-Mayer et al., 1989; Bachalerie et al., 1990; Harris et al., 1992) have 
failed to detect any of these additional functions attributed to nef.
The HIV-1 vif gene encodes a 23 Kd protein (Kan et al., 1986; Lee et al., 1986), 
which plays a role in virus infectivity (Strebel et al., 1987). Vif-minus mutants, produced 
wild type level viral mRNA, proteins, and virus particles, but the cell-free virions produced 
were not infectious (Fisher et al., 1987).
The HIV-1 vpr gene encodes a 78 amino acid membrane-associated protein (Wong 
et al., 1987; Sato et al., 1990), which appears to act as a weak transcriptional activator.
The HIV-1 vpu gene encodes an 81 amino acid protein, which is thought to play a 
role in virus maturation (Strebel et al., 1988). Infection with vpu minus mutants results in 
impairment of the release of the vims and accumulation of virion proteins (Strebel et al.,
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1989; Terwilliger et al., 1989; Klimkait et a l 1990). Interestingly the HIV-1 vpu gene is 
absent in closely related viruses; HIV-2 and SIV. In contrast, HIV-2 and SIV contain a 
gene known as vpx, which is not present in HIV-1. The vpx gene encodes a 14 Kd protein, 
which is abundant in cells infected with HIV-2 or SIV (Henderson et al., 1988). It has been 
suggested that vpx might have role in cell tropism of the virus (Guyader et al., 1989).
REPLICATION OF RETROVIRUSES .
Retroviruses can be classified as simple or complex types, based on their genomic 
organisation and regulation of their genome expression in the infected cell (Cullen et al., 
1993). There are several criteria that distinguishes complex retroviruses (HIV or FTV) from 
simple retroviruses (FeLV-A or MLV); complex retroviruses encode multiply-spliced 
mRNA’s, that give rise to proteins with regulatory functions (eg tat and rev)
ATTACHMENT AND VIRUS ENTRY.
Retrovirus infection initiates with the binding of virus surface glycoprotein to a 
specific receptor on the cell surface. A hypervariable region (V3.3) in the HIV-1 surface 
protein is required for efficient virus entry (Clements et al., 1991). The virus then enters 
the host cell by the mechanism of membrane fusion (Marsh and Helenius, 1989). In the 
case of HIV-1 this process is mediated by the amino-terminus domain of the 
transmembrane protein (gp41) (Kowalski et al., 1987; Freed et al., 1990). With the 
exception of ectropic murine leukaemia virus (MLV-E), retrovirus entry into the host cell is 
a pH-independent process (McClure et al., 1988 and 1990)
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IJNCOATING.
During the entry of the virus into the cell, virus envelope is lost, the capsid structure 
disintegrates, and the functional RNA genome is released into the cytoplasm of the 
infected cell. Little is known of the precise details of retrovirus uncoating.
REVERSE TRANSCRIPTION.
During reverse transcription the virus RT transcribes the single-stranded virus RNA 
genome into a double-stranded DNA sequence (known as the provirus). The RNase H 
activity of RT specifically degrades the RNA template from the RNA-DNA hybrid to 
permit synthesis of the double stranded provirus DNA. During the process of reverse 
transcription the RT enzyme switches several times from one strand to another strand at 
random, a mechanism which increases the frequency of genetic recombination events (Hu 
andTemin, 1990).
INTEGRATION OF THE PROVIRUS.
Following synthesis and migration of the provirus to the nucleus, the next step in 
retroviral replication is integration of the provirus into the host cell genome. Based on the 
studies on the retrovirus; murine leukaemia virus. The integrase protein and the two 
inverted LTR’s at the end of the provirus DNA are required for the process of integration 
(Colicelli and Goff, 1985). In general, integration of the provirus, is an essential step in 
productive retrovirus replication, however, avian spleen necrosis virus integrase-minus 
mutants were able to produce infectious virus in infected cells (Panganiban et al., 1983). In 
general unintegrated provirus DNA can be detected in the cytoplasm of retrovims-infected
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cells, including HIV-1 infected cells. Stevenson et al., (1990) have reported that HIV 
antigens were present in the supernatant of lymphocyte cell cultures, which have been 
infected with HIV-1 strains deficient in integrase; however, no infectious virus was isolated 
from these cultures. These results indicate that unintegrated provirus DNA can serve as the 
template for HIV-1 core and envelope protein production. Accumulation of unintegrated 
provirus DNA in vivo in HIV-1 infected cells may play a role in the cytopathic effect of 
the virus.
TRANSCRIPTION AND TRANSLATION OF THE VIRAL PROTEINS.
Transcription of the provirus is carried out by cellular RNA polymerase II. In 
simple and complex type retroviruses, expression of provirus DNA is controlled by host 
cell transcription factors. However, in complex type retroviruses, such as HIV-1, the vims 
LTR sequences contain several cis-acting recognition sites for host cell transcription factors 
which allows a more sophisticated control of viral gene expression. In all retroviruses, 
transcription results in an unspliced (gag and pol), or singly spliced (env) mRNA. 
However, the genomes of complex type retroviruses, such as HIV or FIV, encode shorter 
multiply-spliced mRNA that regulate virus gene expression. (Cullen et al., 1991). 
Expression of multiply-spliced viral mRNA’s occurs early (Kim et al., 1989), whereas 
unspliced or singly-spliced mRNA’s which encode viral structural proteins are expressed 
later in the vims replication cycle (Feinberg et al., 1986; Felber et al., 1990). In contrast in 
simple type retroviruses the availability of cellular transcription factors is responsible for 
the control of provirus expression and the pattern of mRNA processing.
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VIRION ASSEMBLY AND RELEASE
The assembly of retrovirus particles and their release from infected cells is thought 
to be similar for both the complex and simple type retroviruses (Cullen et al., 1993). Virus 
assembly takes place at a location adjacent to the plasma membrane of the infected cell. In 
the case of HIV-1, the myristoylated N-terminal of both the gag and gag-pol polyproteins 
plays an important role in the assembly of the virion (Gottlinger et al., 1989). The 
interaction between the zinc-finger motif of the HIV-1 nucleocapsid protein (Aldovini and 
Young, 1990) and a signal, in the leader sequence, of genomic RNA is important for the 
packaging of two subunits of genomic RNA within the budding virion. All retroviruses 
bud through the plasma membrane, which is abundant in viral glycoproteins. Thus the viral 
envelope acquired during the budding process exhibits glycoprotein spikes projected on the 
surface. Either, during or soon after, release of the virus from the cell surface, the gag and 
gag-pol precursor proteins are cleaved by the action of the virus protease to render the 
virion infectious (Skala et al., 1989; Kohl et al., 1988)
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1.2.1. FELINE 1MMUNODEFFICIENCY VIRUS (FIV).
FIV is a T-lymphotropic lentivirus originally isolated from a group of cats with an 
immunodeficiency -like syndrome (Pederson et al., 1987). FIV has proved to be a 
valuable animal model for human lentivirus infection, and has facilitated understanding of 
the pathogenesis of HIV-induced AIDS. Furthermore FTV provides an interesting and 
potentially useful model for the development of lentivirus antiviral and vaccine strategies. 
It is thought that FIV infection of cats has a long history (Sodora et al., 1994). The 
prevalence of FIV infection in domestic cats ranges from 1% (central Europe and USA) to 
30% (Japan and Australia). The rate of infection among male cats is two, or more, times 
higher than among female cats, and is usually acquired after the first year (Bendinelli et al., 
1995). Viruses similar to FIV may infect large cat wild life populations, including; 
cougars of Northern America, cheetahs of the Sergenti ecosystem (Olmsted et al., 1992), 
and lions (Brown et al., 1994). No disease is associated with the lion lentivirus (FIV-Ple) 
(Brown et al., 1994). Although the mode of FIV transmission among domestic cats has 
not yet been precisely defined, there is some evidence to suggest that biting is the 
predominant route of transmission (Bendinelli, et al., 1995). The presence of FIV in the 
saliva of experimentally and naturally infected cats supports this view (Matteucci et al.,
1993). Prenatal and postnatal routes of vertical transmission of FIV, have been reported. 
Foetal infection, in the uterus, leads to abnormalities in the foetus including; arrested foetal 
development, subnormal birth weight, and T-cell deficiency. Foster-nursing experiments 
indicate that kittens can be infected via the milk of an infected mother. Vertical 
transmission of FIV during the acute maternal infection is about 70% (Oneal et al., 1995). 
Transmission of FIV through sexual contact has never been clearly confirmed (Hosie, et al.,
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1990), while airborne transmission of FTV is very unlikely. Like HIV, FIV can be 
transmitted across mucosal surfaces by infected cells. Moench, et al., (1993), have reported 
that FTV-infected T-cells are capable of transmitting FIV infection through the mucosal 
surfaces of the vagina, rectum, or oral cavity. Neutralising maternal antibodies from 
naturally infected, or vaccinated, cats protect kittens from FIV infection (Pu et al., 1995).
FIV infection in vivo initiates most likely in lymphoid tissue. One week after 
infection, FIV DNA and/or RNA can be detected in bone marrow , thymus , and lymph 
nodes. The salivary gland was the only nonlymphoid tissue in which FIV was detected 
(Matteucci et al., 1993). In the later stage of infection (3 weeks post-infection), most of the 
nonlymphoid tissues examined, were positive for the presence FIV. The presence of anti- 
FIV antibodies in the serum of experimentally infected cats could be detected within 2 to 6 
weeks post-infection. Most of the antibodies produced early in the infection, are directed 
toward the virus glycoproteins and/or the major core proteins ( Lombardi et al., 1993). The 
presence of neutralising antibodies can be detected 5 to 6 weeks post-infection and the titres 
usually remain high throughout life, reaching a plateau after 10 to 11 months post-infection 
(Tozzini et al., 1992). Sera isolated in the field from different cats, neutralised different 
FIV isolates indicating that FIV, like HIV, has antigenic epitopes capable of inducing 
broad-range neutralising antibodies (Tozzini et al., 1992). One such epitope maps to the 
V3 region of the FIV surface protein (Lombardi et al., 1993).
Different isolates of FIV differed in their ability to infect different cell lines in in 
vitro experiments, having the same surface phenotype (Phillips et al., 1990). Differences in 
virus env proteins are thought to account for these differences in cell tropism. It has been
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shown that virus cell tropism can be affected by the passage history of the virus, possibly 
due to the different host cell membrane proteins acquired by the virus during the 
budding process, however, the mechanism by which this operates is unclear (Orentas et 
al., 1993). Appearance of FIV cytopathic effect in different cell lines may depend on the 
FIV isolate/host cell system used (Tokunaga et al., 1992). Dow et al., (1992) have reported 
th a t, among neuronal cells susceptible to FIV infection, astrocytes were the most sensitive 
(producing syncytium and cell death), whereas microglial cells yielded infectious vims in 
the absence of any CPE, while endothelial cells gave no apparent CPE, and little vims 
yield.
The Clinical manifestations of in vivo FIV infection are very similar to that of HIV 
infection of humans. FIV infections in cats can be divided in 5 different phases based on 
the appearance and severity of the clinical symptom; (1) Acute phase, which is a transient 
stage following the primary infection and is accompanied by a range of clinical symptoms 
(Lymphoadenopathy, acute diarrhoea, conjunctivitis, dermatitis, gingivitis, and mild upper 
respiratory infections ( Beebe et al., 1994; Torten et al., 1991); (2) Asymptomatic phase, 
which is characterised by the presence of an occult and clinically inapparant infection over 
a long period of time, during which haematological and immunological abnormalities due 
to the infection of FIV are detectable (Ackley et al., 1990; Matteucci et al., 1993). During 
this period virus can be isolated from the plasma and saliva of the asymptomatic cats with 
the same frequency as the diseased cats (Matteucci et al., 1993); (3) persistent generalised 
lymphoadenopathy, which is characterised by the persistent activation and enlargement of 
the lymph nodes. During this period, some clinical symptoms appear such as, etiologically 
unknown recurrent fevers, anorexia, weight loss and apparent changes in sleeping patterns
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(reviewed by Bendinelli et al., 1995); (4) ARC (AIDS-related-complexes), a range of 
chronic secondary upper-respiratory and oral infections caused by other micro-organisms 
appears in infected cats during this period. Other symptoms such as neurological 
abnormalities, alopecia, and neoplasia may also occur (Reviewed by Bendinelli et al., 
1995); (5) FAIDS (feline immunodeficiency syndrome), this period is marked by the 
appearance of a variety of opportunistic infections, neoplasia, severe anaemia, leukopenia, 
and neurological disorders, most cats die within a year of the diagnosis of FAIDS 
(Bendinelli et al., 1995).
MORPHOLOGY AND GENOMIC STRUCTURE OF THE VIRION.
The mature FIV particle consists of a capsid, surrounded by an outer envelope 
membrane derived from the host cell plasma membrane. The particle is 100 to 125nm in 
diameter and has spikes containing viral glycoproteins on the surface of the vims envelope 
(Pederson, et al. 1987).
The vims genome consists of two copies of positive-stranded polyadenylated RNA. 
Like other lentiviruses, FIV has a complex genomic structure. The genome encodes three 
large open reading frames corresponding to GAG, POL and ENV, flanked by two LTRs 
(variously reported to be 355 to 361 base pair long) which are bordered by two base pair 
inverted repeats (Talbott, et al. 1989; Maki, et al., 1992) (Figure 6). In addition, the 
genome contains at least four short open reading frames (Olmsted, et al. 1989), three of 
which (Vif, ORF A, and Rev ) have been shown to encode protein products(Miyazawa, et 
al. 1994).
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The FIV LTR element contains three regions; the U3 region (216 base pairs), the R 
region (65 base pairs), and the U5 region (65-68 base pairs) (Olmsted, et a l  1989; Talbott, 
et al., 1989). FIV LTRs appear to be strong basal promoters, at least in some cell types 
(Miyazawa, et al., 1992 and Sparger, et al., 1992). The regulatory cis- acting sequences 
detected in FIV LTRs include a consensus polyadenylation signal in the R region, two 
TATA like sequences, a CCATT sequence, and several transcription factor binding sites 
(AP-1, Ap-4, ATF-1, EBP-20, and NF-kB) in the U region ( Kawaguchi, et al., 1991 and 
1992, Sparger, et al., 1992, and Miyazawa, et a l, 1994). The AP-1 and Ap-4 binding sites 
are important for basal promoter activity in non-lymphoid feline cell lines (Kawaguchi, et 
al., 1992, and Sparger, et al., 1992), however the presence of an AP-1 binding site is not 
required for FIV replication in feline T lymphocytes (Miyazawa, et al., 1993). The 
presence of a stem-loop structure, reminiscent of the HIV-1 TAR element has been reported 
in the R region of the FIV LTR, but at the present time there is no evidence for protein 
binding to this structure (Miyzawa, et al., 1991; Morikawa, et al., 1991). The presence of a 
negative regulatory element (NRE) similar to that present in HIV (Siekevitz, et al., 1987), 
has been located within the first 62 bases of the LTR of the Petaluma strain of FIV 
(Sparger, et al., 1992). However, a NRE sequence was not detected in another strain of FTV 
(FIV TM1 (Kawaguchi, et a l, 1992).
Six different classes of viral specific m-RNA were identified in FIV infected cells;
9.2 Kb, 5.2 Kb, 4.4Kb, (doublet), 1.7 Kb, and 1.4 kb (Tomonaga, et a l, 1993). The 9.2 Kb,
5.2 Kb, and 4.4 Kb (doublet mRNAs) are not expressed in the cytoplasm of cells 
transfected with rev minus mutants (Tomonaga, et a l,  1993). The region between the POL 
and ENV genes contains at least three splice acceptor and two splice donor sites. The 9.2
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kb mRNA is considered to be the primary transcript for the GAG-POL precursor 
polyprotein, the Vif and env mRNAs (5.2 and 4.4 kb respectively) are formed by a single 
splicing event, and the Rev mRNA arises from multiple splicing of the primary transcript 
(Tomonaga, et al., 1993a). The mRNA for the ORF A (putative tat gene) seems to contain 
the entire env and rev genes(4.4kb) or two rev-coding exons (1.7kb) (Miyazawa et, al.,
1994). The FIV virus core structure is derived from the GAG-POL polyprotein precursor. 
The GAG gene of FIV encodes a 450 amino acid precursor polyprotein of about 50k (Maki, 
et al., 1992), which is post-translationally cleaved to yield three protein products; the 
matrix (p i5), the capsid (p24), and the nucleocapsid (plO) proteins (Egberink, et al., 1990a; 
Steinman, et al., 1990). Serological cross reactivity observed to the FIV capsid (CA) 
protein among FIV, CAEV, and visna virus, indicates the presence of a conserved region 
within this protein (Olmsted, et a., 1989; Egberink , et al., 1990). The FIV matrix protein is 
myristoylated and starts with a Met-Gly-Asn-Gly sequence (Elder, et al., 1993), which is 
identical to the myristoylation signal of the HIV matrix protein (Talbot, et al., 1989). 
Interestingly the matrix proteins of other non-primate lentiviruses (ELAV and visna virus) 
are not myristoylated (Miyazawa, et al., 1994). The FIV nucleocapsid protein (plO) 
contains two sequences of Cys-(X)2-Cys (X)4-His-(X)4-Cys (Maki, et al., 1992), which are 
characteristic of retroviral nucleic acid binding proteins (Gorelic, et al., 1988).
The FIV POL gene which encodes the polymerase gene products (bases 1868-5239) 
is the second largest ORF and overlaps the GAG gene by 109 base pairs (Talbott et al., 
1989, and Olmsted et al., 1889). The POL gene is in a -1 reading frame with respect to the 
GAG gene and a GAG-POL polyprotein is synthesised by ribosomal frame shifting as in the 
case of primate lentiviruses (Olmsted et al., 1989; Morikawa and Bishop, 1991; Miyazawa
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et al., 1994). The overlapping region contains the GGGAAAC sequence required for 
ribosomal frame shifting. The GAG-POL polyprotein is cleaved to generate the protease 
(p i3), reverse transcriptase (p61), integrase (pi4), dUTPase (p i4). FIV reverse 
transcriptase is very similar to that of HIV (more than 45% homology in genome sequence) 
(Talbott, et al., 1989). FIV RT is a Mg2+ dependent enzyme with dual enzymatic functions, 
having both DNA polymerase and RNase H activities (Cronn ,et al., 1992). dUTPase is 
not encoded by primate lentiviruses, but is specified by ELAV, visna virus and CAEV 
(Miyazawa et al., 1994). The FIV dUTPase (p i4) protects against misincorporation of 
deoxyuridine into viral DNA, thus increasing the fidelity of genome replication ( Elder et 
al., 1992; Lerner et al., 1995). While dUTPase activity is not essential for FTV replication, 
it may be required for the replication of FIV in non-dividing cells such as non-dividing 
macrophages, or resting T lymphocytes (Miyazawa, et al., 1994). Indeed, dUTPase activity 
is required for the replication of EIVA in non-dividing equine macrophages (Threadgill et 
a l  1993).
The env gene is encoded by the third largest ORF in the FIV genome (bases 6250- 
8850), and overlaps the 3’ end of open reading frame C. The env gene encodes a precursor 
glycoprotein (gpl60)which is trimmed soon after synthesis, before the protein is transported 
from the endoplasmic reticulum yielding a glycoprotein of 130K Mwt (gpl30). Gp 130 is 
further cleaved during passage through the Golgi apparatus into the mature gp 95 (surface 
protein), and gp41 (transmembrane) glycoproteins (Stephens et al., 1991). The env gene 
nucleic acid sequence is the least conserved sequence among FIV isolates. The FIV env 
gene exhibits 9 variable and hypervariable regions (VI-V9); of which VI and V2 are 
located in the leader sequence of the env gene; four (V3-V6) are located in the sequences
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coding for surface protein; and 3 (V7-V9) are located in the transmembrane protein env 
regions (Pancino et al., 1993 and 1993a). The sequence variability observed in the V3 and 
V4 regions of FIV surface protein is analogous to that found for the V3 loop of the HIV-1 
gpl20 surface protein (Pancino, et al., 1993). Lombardi, et al. (1993) have mapped a 
linear epitope for the binding of B-cells to the third variable region (V3) of the FTV (gp95) 
surface protein. The presence of a neutralising domain in the hypervariable region of HIV-1 
and HIV-2 envelope glycoproteins is well established (Wolf, et al., 1993). The FIV surface 
protein V3 region also contains at least 4 binding sites for neutralising antibodies. Two of 
the FIV epitopes for neutralising antibodies are positioned towards the amino-terminal and 
two towards the carboxy terminal of the V3 region (Lombardi, et al., 1995). The two 
surface glycoprotein epitopes, which mapped to the V3 carboxy terminal are detectable on 
the surface of mature FIV particle and in the cytoplasm of FIV infected cells, but are not 
detectable when the protein is expressed on the surface of the plasma membrane of infected 
cells. Lombardi et al. (1995) demonstrated that the epitopes involved in binding 
neutralising antibodies are discontinuous.
Greene, et al.( 1993) have reported that, in response to pressure from the host 
immune system, the FIV env gene has a 3X1 O'3 nucleotide substitution rate. FIV isolates 
are grouped in at least 3 distinct subtypes depending upon the nucleotide sequence of the 
env gene (Sordora et al., 1994). Different world-wide isolates of FTV have been classified 
into four major subtypes A, B, C, and D, based on phylogenic analysis of the V3 and V5 
regions in the FIV env surface protein. Among the different subtypes, sequence divergence 
ranged from 18% to 26%. Within each subtype, the sequence divergence varied by 3% to
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15%. The env gene nucleotide sequence from individual infected cats varied by as much as 
4% (Sodora, et al., 1994).
The FIV regulatory vif gene (virus infectivity factor) overlaps the 3’ end of pol 
gene and is similar in size and location to the vif genes of primate lentiviruses (Talbott et 
al., 1989, and Philips et al., 1990). The FTV vif gene product is hydrophilic and basic 
(Maki et al., 1992). FIV vif-minus mutants transfected into CrFK cells produced wild type 
level of reverse transcriptase, but infection was only possible by cocultivation with FTV- 
infected cells, and not with cell-free virus (Tomonaga et al., 1992). Indeed, virus isolated 
from the vif-minus transfected cells failed to infect feline CD4 positive T cells (Tomonaga, 
et al., 1992). Furthermore, Shacklett, and Luciw, (1994) have shown that transfection of 
CrFK cells with FIV proviruses containing deletion in different regions of the vif gene 
yielded very little cell-free virus or p24 gag viral protein. Therefore it is concluded that the 
vif gene is important for FIV infectivity in CrFK cells in vivo.
The FIV Rev gene consists of two exons; the first (ORF B) located at an intergenic 
region (at the 3’ end of the Pol gene through the L region of the env gene and utilises the 
first 81 amino acids of the env precursor) (Kiyomasu et al., 1991; Philips et al., 1990; 
Tomonaga et al., 1993). The second exon (ORF H) is located immediately downstream 
from the env gene and overlaps the LTR (Kiyomasu, et al., 1991; Philips, et al., 1992). The 
FIV Rev response element (RRE) is located at the 3’ end of the env ORF and partially 
overlaps the 5’ end of LTR (Philips, et al., 1992), while those of the primate lentiviruses 
are located entirely within the env gene ( Rosen, et al., 1988; Malim, et al., 1989). In the 
absence of rev, no unspliced or singly spliced FIV mRNA is expressed, and virus
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production is inhibited (Kiyomasu, et al., 1991; Tomonaga, et al., 1993), thus Rev seems 
to be essential for FIV replication.
The putative FIV TAT gene (ORF A) is located between the vif and the rev genes 
and is similar in size and location to the first exon of primate lentivirus tat genes. 
However, ORF A is not essential for FTV replication in feline T lymphoblastoid cell lines, 
and some strains of FTV do not have detectable tat activity (Miyazawa, et al., 1993; 
Tomonaga, et al., 1993). Nevertheless, ORF A-minus mutants replicate poorly in primary 
peripheral blood lymphocytes (Tomonaga, et al., 1993a), suggesting that ORF A may have 
a role in FIV replication in vivo.
FIV cell tropism in infected cats is analogous to that of HIV in humans, in that the 
main target is the T lymphocyte. However, FIV also infects monocytes, macrophages, 
microglial cells, and astrocytes, as does HIV (Dow, et al., 1992; Brunner and Pederson, 
1989). Early in infection, and before the onset of the clinical manifestations of the disease, 
between 25% to 75% of infected cells are T-lymphocytes, with a small percentage of 
macrophages (2%-10%) also infected. Beebe, et al., (1994) have reported that in the later 
stages of infection (after the appearance of the clinical signs) the percentage of 
macrophages which are infected increased dramatically (40%-90%), and have suggested 
that, as FIV infection is less cytopathic in macrophages than T-lymphocytes, the shift from 
T-cell infection to macrophages late in the FTV infection could be important for viral 
persistence. Although, the CD4+ lymphocytes decline is observed in FIV-infected cats 
(Hofmann-Fezer et al., 1992), it has been demonstrated that there is no correlation between 
the presence of CD4 molecules on the cell surface and the ability of the cell to harbour FIV
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(Brown, et al., 1991). Recently Hosie et al., (1993) have isolated a monoclonal anti- 
ideotype antibody (designated vpgl5), which can block FIV infection of susceptible cat 
cells, by binding to a specific receptor on the cell surface, thus blocking virus adsorption. 
This antibody identified a 24-kd protein on the surface of susceptible cells. This protein has 
been identified as the feline homologue of human CD9 (Willet, et al., 1994).
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1.2.2. FELINE LEUKAEMIA VIRUS (FELV).
Feline leukaemia virus is a class C-retroviruses, which has been associated with 
immunodeficient diseases, malignancy, and degenerative diseases of haematopoetic origin 
(Essex, 1975). Indeed, feline leukaemia viruses were first isolated from a group of cats 
with lymphosarcoma (Jarret et al., 1964).
FeLV particles are about lOOnm in diameter and are composed of an icosahedral 
capsid surrounded by envelope derived from the plasma membrane of the infected cells. 
The viral genome consists of two positive sense linear, single- stranded RNA molecules in 
the form of a dimer. The genomic RNA is capped at the 5’ end and polyadenylated at the 
3’ end. The FeLV genome consists of ~ 8 Kb of nucleotide sequences encoding the three 
retrovirus large open reading frames; gag, pol, and env (Figure 6 ).
The FeLV gag gene encodes a 501 amino acid non-glycosylated precursor 
polyprotein (Pr65gag), which is posttranscriptionally cleaved by the virus encoded aspartyl 
protease to yield ; P I5 (matrix protein), P27 (major capsid protein), P I2 (structural protein), 
and PlO (nucleocapsid protein) (Khan and Stephens, 1977).
The FeLV pol gene encodes a 1,709 amino acid precursor gag-pol polyprotein 
(Prl80gag po1), which is cleaved by virus protease during, or after virus budding to yield the 
protease (p i3), integrase (p47), and reverse transcriptase (p70) proteins (Rho and Gallo., 
1979; Donahue et al., 1988).
The FeLV env gene encodes a precursor polyprotein (Pr85), with a 33 amino acid 
leader sequence, followed by a 412 amino acid surface protein (gp70), and a 197 amino 
acid transmembrane protein (pl5E) (Neil et al., 1980; Donahue et al., 1988),
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In addition to the three major ORF’s the FeLV genome also encodes number of 
potential short, spliced, orfs, but as yet it is not clear whether any of these specify a 
functional protein (Donahue et al., 1988).
The LTRs of FeLV consist of 480-560 bp sequences which contain promoter and 
enhancer elements required for viral transcription, and also contain signals for 
polyadenylation.
FeLV isolates fall into one of three subgroups; A, B, or C, depending upon their 
behaviour in vims neutralisation and vims superinfection interference assays (Samara and 
Log, 1973). The behaviour of the vimses in such assays is due to differences in the viral 
envelope gylcoprotein (p70) antigen (Samara and Log, 1973).
All of the cats infected naturally with FeLV have the FeLV-A subgroup vims, either 
alone or in combination with one or other of the subgroup vimses. Thus, FeLV-B isolates 
are present along with FeLV-A in approximately 40% of naturally occurring infections, 
while the FeLV-C subgroup isolates are found in only 1 % (Jarret et al., 1978).
The FeLV subgroup viruses differ in host cell range; FeLV-A isolates are generally 
restricted to growth in feline cells, while FeLV-B and C isolates can grow in cells from a 
variety of species including; feline, human, and canine cells. The extended host cell range 
is due to differences in the outer surface glycoprotein (gp70) (Jarret et al., 1973). 
Although, FeLV (B and C) can grow in human cells in tissue culture, there seems to be 
little risk involved of FeLV transmission from cats to humans (Hardy et al., 1976).
In a study by Hardy et al., (1976) involving 2000 cats, 12% of the uninfected cats 
housed along with persistently infected cats became infected with FeLV. Cats persistently 
infected with FeLV shed virus in the saliva, urine and faeces (Hardy et al., 1973). The
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main route of transmission is probably via saliva, perhaps by biting or mutual grooming 
(Hardy et al., 1973).
While in natural infection, FeLV-A is transmitted horizontally, the B and C 
subgroup viruses can only be transmitted in the presence of FeLV-A (Jarret et al., 1978).
FeLV-B infections of cats is associated with leukaemia, while FeLV-C infections is 
associated with aplastic anaemia. Both FeLV-B and FeLV-C are derived by genetic 
recombination between FeLV-A and endogenous FeLV-like sequences (enFeLV) carried in 
the genome of domestic cats (Russel and Jarret, 1978; Stewart et al., 1986; Overbaugh et 
al., 1988). These endogenous FeLV-like sequences cannot be induced to produce 
infectious virus particles (Benveniste et al., 1975).
The enFeLV sequences (~ 4kbp long) are significantly shorter than the FeLV 
genome, having 3.3 to 3,6 kb deletions in the gag-pol region and ~ 0.7 to 1.0 kb deletion in 
the env gene. Both LTR’s are however, intact (Soe et al., 1983). EnFeLV sequences are 
present at multiple locations in feline genome and are arranged in a nontandem fashion. 
Although, the sites of integration of enFeLV sequences in the host DNA is identical in 
different tissues from the same animal, these sites vary between different individuals 
(Koshy etal., 1980).
Recombination between FeLV-A and enFeLV is mostly confined to the env gene; 
FeLV recombinants having exchanged up to 60% of the surface gp N-terminal sequence 
have been reported. This substitution probably accounts for the expanded host range of the 
recombinant isolates (Sheets et al., 1992).
Three forms of clinically distinct FeLV-associated lymphomas have been described. 
Firstly, a Thymic lymphoma characterised by a rapidly progressive tumour. Secondly,
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Alimentary lymphoma, with tumours in the gastrointestinal tract, and finally, multicentric 
lymphoma, in which many different tissues and lymphoid organs are involved (Cotter et al., 
1992).
Although, the mechanism by which FeLV induces tumors is not fully understood, 
transduction of a host proto-oncogene, and/or insertional mutagenesis of host gene might be 
involved (Levy et al., 1993).
By altering the regulation of the expression of the host genes the LTR’s play an 
important role in FeLV-related leukaemia. The LTR sequences from the proviruses 
isolated from cats with a thymic lymphosarcoma have repeated enhancer elements, not 
present in non-leukomogenic viruses (Fulton et al., 1990). Viruses with multiple enhancer 
elements can be generated after only a single passage in cats (Rhon and Overbaugh, 1995). 
It seems possible that the enhancer sequence might play a role in leuk^mogenesis, through 
insertional activation of cellular proto-oncogenes. Insertion of a FeLV provirus upstream 
of the natural promoter of a proto-oncogene resulted in deregulation of the promoter and 
overexpression of the gene product. Thus, FeLV viruses can activate transcription of 
cellular proto-oncogenes to a level sufficient for tumour induction (Rhon and Overbaugh, 
1995).
FeLV can cause a severe immunosuppression of cats (FeLV-FAIDS) The course of 
the disease depends on the age of the cat; younger cats ( < 8  weeks old) develop acute 
disease within 6  months of infection, while older cats remain asymptomatic for up to 2  
years, but thereafter advance to a full blown immunodeficiency disease reminiscent of 
human AIDS (Overbaugh et al., 1988a). Defective FeLV virus isolates associated with 
acute immunodeficiency have been isolated, and have been shown to consist of subgroup A
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viruses (clone 6 IE) mixed together with a family of immunodeficiency-disease- associated 
variants (possibly From subgroup B) (clone 61C). The latter, although replication 
defective, are propagated in the presence of FeLV-A (6 IE), which functions as a helper 
virus (Overbaugh et al., 1988a). An FeLV-FAIDS virus isolated from an infected cat and 
now regarded as the prototype of FeLV-FAIDS has a 6  amino acid deletion near the amino 
terminus of the gp 70 and a 6  amino acid insertion near the carboxy terminus, as well as 11 
scattered amino acid changes throughout the protein (Overbaugh et al., 1988a). The 
prototype FeLV-FAIDS virus (61C) also has point mutations at two locations within the 
LTR U3 region and a nucleotide deletion at the boundary between the U3 and the R region 
(Overbaugh et al., 1988a). The extensive destruction of cat T cells by 61E/61C isolates is 
associated with massive superinfection (Donahue etal., 1991).
Although, the majority of cats infected with FeLV develop vireaemiathey acquire 
immunity and eventually clear the infection. Cats which harbour latent FeLV-A may 
remain healthy for up to 3 years before becoming ill with FeLV-related diseases.
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1.3. BOVINE HERPESVIRUS TYPE 1 (BHV-1).
Bovine herpesvirus type-1, also known as infectious bovine rhinotracheitis virus 
has been associated with infectious bovine rhinotracheitis, infectious pustular 
vulvovaginitis, infectious blanosthitis , and abortion. Close contact is required for 
transmission of BHV-1 infection, which can result in subclinical, mild, or severe disease. 
Because BHV-1 infection is of economic importance, several of vaccines (mostly live 
attenuated) have been developed by different agencies to prevent the spread of viral 
infection.
BHV-1 is a typical a-herpesvirus having a double-stranded DNA genome packaged 
in an icosahedral capsid composed of 150 hexameric, and 12 pentameric capsomers. The 
nucleocapsid is embedded in a proteinaceous layer known as the tegument, which is in turn 
surrounded by a lipid envelope, derived from host cell nuclear membrane.
The genome of BHV-1 contains 137kb of linear double stranded DNA, organised 
as, long (UL; 105kb) and short (US; 1 lkb) segments of unique DNA sequence (Mayfield 
et al., 1983). US sequence is flanked by internal and terminal inverted repeat sequences of 
12kb. The repeated elements enable US sequences to invert orientation with respect to the 
L segment, giving two isomeric form of the BHV-1 genome (Mayfield et al., 1983).
As with other heipes viruses, the replication and assembly of BHV-1 occurs in the 
nucleus of the infected cell. The BHV-1 genome is sequentially transcribed in three waves 
in a cascading manner. These three class of genes are; immediate early (IE), early (E), and 
late (L). Expression of IE genes does not require the expression of other viral proteins. 
The expression of E genes, however, is dependent on the prior expression of EE proteins, 
while expression of the L genes is dependent upon viral DNA synthesis and expression of E
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gB; gC etc is a terminology relating to the homologous gene products in HSV-1.
genes (Misra et al., 1981). Viral DNA synthesis is dependent upon the synthesis of early 
gene products, which include the proteins required for viral DNA synthesis (eg. viral DNA 
polymerase).
There may be as many as 74 open reading frames in the BHV-1 genome. Writh et 
al., (1989) have identified the temporal distribution of 54 BHV-1 transcripts; 4 immediate 
early (IE), 21 early (E), and 12 late (L). The classification of the remaining 17 transcripts 
could not be determined (Writh et al., 1989). Misra et al., (1981) have identified up to 33 
BHV-1 structural polypeptides, of which 11 were identified as glycoproteins. In addition to 
the structural proteins, 15 non-structural protein were also identified in BHV-1 infected 
cells (Misra et al., 1981).
Four major glycoproteins, involved in the formation of the projecting spikes
observed on the viral envelope have been identified; gl (gB), gll (gE), gin (gC), and glV
(gD) (Collins et al., 1984). gl consist of combination of three glycoproteins; 130K, 74K,
and 55K, gE is a 108K glycoprotein, gDI is a 91K glycoprotein (also existing as a dimer
with a molecular weight of 180K), while glV is a 140K/71K dimeric protein (Van Drunen 
Hu/K
Little- Van den and Babiuk, 1986). These glycoproteins have an essential role in binding of 
f\
the virus to the cellular receptor (attachment), and virus penetration [gl, gin, and glV are 
involved in virus attachment, with gffl playing a predominant role (Liang, et al., 1991), 
while glV is essential for virus penetration (Fehler, et al., 1992)]. The four major 
glycoproteins are also important in induction of an immune response to BHV-1 infection 
(both humoral and cellular response). These glycoproteins have been used individually, or 
in combination, as subunit vaccine against BHV-1 (Babiuk et al., 1987; Marshall et al.,
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1986; Collins et al., 1984). However, neither vaccines, nor natural infection protects
against establishment of BHV-1 latent infection.
Another protein involved in induction of an immune response from BHV-1 infected
cells is VP8 . The VP8  is a 742 amino acid phosphoprotein, and is a major constituent
protein in the tegument of virus particle. This protein is present in the nucleus of infected
cells as early as 2 h postinfection, suggesting that the protein might have some regulatory
function in IE gene expression (Van Drunen Little-Van Den, 1995). VP8  has homology to
A
HSV-UL47, with protein kinase activity and is thought to be involved in the 
phosphorylation of BHV-1 tegument proteins (Carpenter and Misra 1991), however, its 
precise role is unclear.
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1.4. PURPOSE AND AIM OF THE PRO TECT.
The work described here further investigates the mechanism by which triterpenoid 
compounds exert an anti-retrovirus effect. The antiviral activity of triterpenoid compounds 
on the replication of two non-human retroviruses (FIV and FeLV-A) and a herpesvirus 
(BHV-1) was studied and compared. The aim was to identify cell lines resistant to the drug 
and to use these cell lines to investigate the effect of triterpenoid compounds on FIV and 
FeLV-A replication at the level of infectious virus yield and at the level of viral protein 
synthesis. The data generated should illuminate the mechanism of antiviral action.
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2. CHAPTER TWO
MATERIALS AND METHODS
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2.1. MATERIALS
2.1.1. CHEMICALS.
The following chemicals were obtained from the Sigma Chemical Company (U.K): 
Ficoll type 400.
Bovine serum albumin conjugated to protein-A sepharose beads.
Haemocyanin from Keyhole limpet.
Hydrogen peroxide (30% w/w) solution.
Polybrene [Hexadimethrine bromide (1, 5-dimethyl-1, 5-diazaundecamethylene 
poly methobromide].
Haemotoxyline was obtained from Difco, while Cyanogen bromide-activated 
sepharose 4B was obtained from Pharmacia.
All tissue culture solutions except Eagle’s medium lacking methionine (E met*) or 
inorganic phosphate (EP‘) were supplied by Gibco-Life science technologies, Paisley, 
Scotland. E met' and EP' were produced by the Institute’s Media department.
2.1.2. FINE CHEMICALS
Cicloxolone sodium (CCX) and Carbenoxolone sodium (CBX) were kindly supplied 
by Miss L. Baxendale and Dr. P. Thornton of the Biorex Laboratories limited company 
(London, U.K.).
Glycyrrhizic acid ammonium salt was purchased from Fluka.
The following chemicals were obtained from the Sigma Chemical Company: 
Ouabain octahydrate [ 4(3, 20 (22)-cardenolide-1 (3, 3(3, 5a, 1 la , 14, 19-hexol-3 (6 - 
deoxy-al-L-mannopyranosyl); G-stophanthin ].
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H7 [l-(5-Isoquinolinylsulfonyl)-2-methyl piperazine ].
3-amino-9-ethyl-carbazole.
Monensin (product, M5273).
Tunicamycin (product, T7765).
DAMP [ 3-(2, 4-dinitroanilino)-3/-aminoN-methyl-dipropylamine] (product, D09), 
was bought from Oxford Biomedical research, INC. (USA).
Horseradish peroxidase streptavidine (product, SA-5004) was purchased from 
Vector Laboratories (USA).
2.1.3. ANTIBODIES
The FTV antiserum from infected cats; and the monoclonal antibody (IE2) directed 
against FTV p24 (Pederson et al, 1990) were generously supplied by Dr. Robert Osborne, 
Veterinary School, University of Glasgow. Biotinylated horse anti-mouse IgG (H+L) 
(product, BA-2000) was obtained from Vector laboratories (USA).
Monoclonal antibodies directed against the p58 (product, G-2404) and p-COP 
(product, G-2279) Golgi marker proteins; the anti-mouse IgG (FC- specific) FITC 
conjugate (product, F-5387), and the anti-rabbit IgG (whole molecule) FITC conjugate 
(product, F-0511) were purchased from the Sigma Chemical Company.
Protein-A purified, anti-dinitrophenol (anti-DNP) monoclonal antibody (product, 
D09) was obtained from Oxford Biochemical Research, INC. (USA).
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2.1.4. RADIOCHEMICALS
All radiochemicals were purchased from Amersham International PLC, Amersham 
Bucks, England:
[32P]-inorganic orthophosphate (specific activity 10 mci/ml) (product, PB SI 1).
L-[35S] Methionine (specific activity, 1000 ci/mmol) (product, SJ 123) .
[35S] Cysteine (specific activity, 1000 ci/mmol) (product, SJ 232).
D-[1-I4C] Glucosamine hydrochloride (specific activity, 54 mci/mmol) (product, 
CFA. 475).
2.1.5. MEDIA
Dulbecco’s MEM containing 25mM hepes (DMEMh) supplemented with; 2% 
(4mM) L-glutamine, 2% penicillin-streptomycin (i.e. 20 units/ml penicillin, 20pg/ml 
streptomycin), 1% non-essential amino acids, 1% (ImM) sodium pyruvate, and 10% foetal 
calf serum (FC); (DMEMh 10% FC) was used for growth of FeA and QN10S cells.
Dulbecco’s modified Eagle’s medium ( DMEgM ) supplemented with, 2% (4mM) 
L-glutamine, 2% penicillin-streptomycin, 1% nonessential amino acids, and 10% FC 
(DMEgM 10% FC) was used for the growth of CrFK and MDBK cells.
Glasgow Eagle’s medium (Eg) lacking either methionine or phosphate, as 
appropriate, was supplemented with 2% FC (Eg met' 2% FC, or Eg p' 2% FC respectively) 
and used for radioactive labelling experiments.
RPMI 1640 medium lacking either D-Glucose (RPMI glu'), or L-Cysteine and L- 
Methionine (RPMI cysteine/methionine) supplemented with; 2% L-glutamine, 2%
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penicillin-streptomycin, 1% nonessential amino acids, and 2% FC was used in the FIV and 
FeLV-A radioactive labelling experiments.
2.1.6. CELL CULTURES
Crandell Feline kidney (CrFK) cells: This epithelial cell line was the kind gift of 
Dr. Robert Osborne, Veterinary School, University of Glasgow, and was used for the 
propagation of the FIV virus. CrFK cell cultures were grown in DMEgM 10% FC and 
routinely passaged 1:6.
Feline Embryo Fibroblast (FeA) cells: This fibroblast cell line was used for the 
propagation of the FeLV-A virus, and were routinely passaged 1:4 in DMEMh 10% FC.
QN10S cells: This fibroblast cell line grown in DMEMh 10% FC medium,
routinely subcultured 1:4, and was used only for the titration of FeLV-A. QN10S cells 
were derived from a clone of AH927 feline fibroblast cells into which the provirus of the 
Molony murine sarcoma virus had been introduced (O. Jarrett-unpublished data) and 
therefore harbour an endogenous virus. When QN10S cells are infected with FeLV-A, 
neither the FeLV-A nor the Molony murine sarcoma virus are capable of independent 
plaque formation, but the Molony murine sarcoma virus/FeLV-A pseudotype i.e. FeLV-A 
packaged in a Molony murine sarcoma virus envelope is able to plaque on the QN10S cell 
monolayers. QN10S and FeA cells were the gift of Professor O. Jarret Veterinary School, 
University of Glasgow.
Madin-Darby Bovine Kidney (MDBK) cells: This epithelial cell line was grown 
in DMEgM 10% FC medium and subcultured 1:6. The MDBK cell line was obtained from
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Dr. D. Dargan and originally supplied by Dr. H.J. Field School of Veterinary Medicine 
University of Cambridge.
Bovine Embryo Kidney (BEK) cells and Bovine Embryo Lung (BEL) cells,
were both grown in Eagle’s 10% FC medium and passaged 1:4. These cell cultures were 
the kind gift of Dr. Richard Elliot, Institute of virology, University of Glasgow.
2.2 METHODS.
2.2.1. CELL CULTURE PASSAGE.
All cell lines were subcultured by washing the confluent cell monolayer twice with 
versene (0.6mm ethylenediaminetetra acetic acid , 1% Phenol Red) containing 10% trypsin, 
followed by incubation of the cells at 37°C for 5 minutes. The detached cells were 
resuspended in 20ml of the appropriate tissue culture medium, and re-seeded, at the 
appropriate cell density, in tissue culture flasks or dishes.
2.2.2. STORAGE AND RECOVERY OF FROZEN CELL CULTURES.
Cells were prepared for cryo-preservation by resuspending trypsinized cell cultures 
in storage medium (80% normal growth medium 10% DMSO, and 10% FC). The cell 
suspensions (2xl06 cells/ml) was dispensed into 1ml aliquots in glass vials, and frozen 
slowly by incubating at -70°C overnight in a polystyrene container, after which the vials 
were transferred to the gaseous phase of a liquid nitrogen container (-170°C) for long term 
storage of the cells.
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Cell suspensions were recovered from liquid nitrogen storage by thawing in a water 
bath at 37°C. The storage medium was then diluted 1:1 with tissue culture medium, added 
one drop, at a time, after which 2xl06 cells were seeded on a small (75ml) tissue culture 
flask and incubated at 37°C in a C 0 2 gassed incubator.
2.2.3. PREPARATION OF CICLOXOLONE. CARBENOXOLONE.
GL Y C YRRHIZIN. MONENSIN. AND TUNIC AM Y CIN SOLUTIONS.
CCX (Mwt 668.8) and CBX (Mwt 614.7) were prepared as 10 mM solutions in 
sterile Mono-Q double-distilled ultra pure water, then diluted to 5mM with sterile 10% 
bovine serum albumin (BSA) fractionV (Sigma A-2153), BSA was sterilised by filtration 
through a 0.22|X Acrodisc (Gilman Science) filter. The BSA stabilises CCX and CBX in 
solution. CCX and CBX solutions were freshly prepared for each experiment.
GL was dissolved in a small volume of PBS (170mM NaCl, 3.4mM KC1, lOmM 
Na2H P 04, 2mM KH2P 0 4) ( pH was adjusted to 7.2 with 1.0M NaOH in order to allow the 
GL to dissolve), and then brought to a final concentration of lOmg/ml. The GL stock 
solution was sterilised by filtration through a 0.45|i and then a 0 . 2 2 j i  sterile Acrodisk filter, 
and stored at -20°C.
Monensin (MON) was prepared as a lOmM stock solution in ethanol and stored at -
20°C.
Tunicamycin was prepared at 2mg/ml in DMSO and stored at -20°C.
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2.2.4. THE EFFECT OF CCX. CBX OR GL ON FeA. ONIOS. AND CrFK CELLS 
IN CULTURE.
2.2.4.I. DRUG CYTOTOXICITY TESTS.
Cell viability was determined by trypan-blue dye exclusion:
Trypan-blue dye solution was made by dissolving 0.5g of trypan-blue in 100ml of 
phosphate-buffered saline and filtering through a 0.45u Acrodisc filter (Gilman Science) 
before use.
FeA, CrFK, and QN10S cells were seeded at 5x105 cells/ 60mm tissue culture dish 
in DMEMh 10% FC, DMEgM 10% FC, or DMEMh 10% FC medium respectively. 
Following overnight incubation at 37°C, the culture medium overlays were replaced with 
the appropriate medium, either drug-free or containing various concentrations of CCX, 
CBX, or GL. Cell cultures were harvested for determination of cell viability and 
enumeration of the total cell number. At the time of drug addition (Oh), and every day for a 
period of 10 days, the cultures were treated as follows:
1. The culture medium was decanted into a 15ml Falcon tube.
2. The monolayer was washed twice with trypsin/versene solution.
3. The washes were pooled with the growth medium in the Falcon tube.
4. The detached cells from the monolayer were pelleted by low speed centrifugation 
(~1000g./5 minutes/4°C).
5. The supernatant was discarded and the cell pellet resuspended in 1ml of tissue culture
medium.
7 6
6. The resuspended cell pellet was pooled with, and used to resuspend, the cells from the
trypsinised monolayer.
7. lOOpl of the pooled cell suspension was mixed with lOOjil of trypan blue dye, and
the dye allowed to penetrate the cells for 5 minutes.
8. The total cell number and the number of blue-stained cells (non-viable) in each 
samples were counted microscopically using a Neubar haemocytometer.
2.2.4.2. REVERSAL OF THE EFFECT OF CCX TREATMENT ON DRUG 
TREATED CELL CULTURES.
FeA and CrFK cell cultures were seeded at 5xl05 cells/ 60mm tissue culture plates 
in DMEMh 10% FC or DMEgM 10% FC respectively. After overnight incubation at 37°C, 
the growth medium was replaced with the appropriate medium supplemented with 2% FC, 
and containing either no drug , or various concentrations of CCX. Sets of cell cultures were 
treated with the drug for 1, 2, or 3 days. One set of cultures were treated as follows: At the 
time of drug addition, and at daily intervals thereafter, the percentage cell viability and the 
total number of cells in each culture were measured. The medium was removed from the 
other sets of cultures at daily intervals, and the residual drug removed by washing with 
PBS 5% FC. These washed cell cultures were then overlaid with normal drug-free 
medium, and incubated at 37°C for a further five days, after which the total cell number and 
percentage cell viability were determined.
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2.2.5. VIRUS CULTURES
2.2.5.1. VIRUSES
Feline immunodeficiency virus (FIV) was the gift of Dr. R. Osborne, and 
Professor O. Jarret.
Feline Leukaemia Virus type A (FeLV-A) was the gift of Professor O. Jarret, 
Veterinary School, University of Glasgow.
Bovine Herpes virus (BHV-1 strain 6666) was supplied by Dr D. Dargan and 
originally obtained from Dr. Hugh Field (School of Veterinary Medicine University of 
Cambridge).
2.2.5.2. PREPARATION OF VIRUS STOCKS.
2.2.5.2.I. BHV-1
Confluent monolayers of MDBK cells on 80oz roller bottles were infected with 
BHV-1 (strain 6666) at a m.o.i. of 0.01 p.f.u./cell. Following the virus absorption period 
(lh  at 37°C) the inoculum was removed by washing with PBS, and the infected monolayer 
overlaid with DMEgM 10% FC. At 48h PI virus was harvested by scraping the cells into 
the medium with a rubber policeman, and sonicating the cell suspension. Cellular debris 
was pelleted, and the clarified virus stock stored at -70°C. BHV-1 stocks so prepared 
generally contained about 109 p.f.u./ml.
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2.2.5.2.2. FeLV-A. AND FIV.
FeA or CrFK cells were seeded at 2 x 107 cells/roller bottle and incubated overnight 
at 37°C. Sub-confluent monolayers of FeA or CrFK cells were infected with 1.42xl07 
p.f.u./roller bottle FeLV-A or lxlO3 FTV p.f.u./roller bottle in 40ml of the appropriate 
medium respectively. Following 48-72h incubation at 37°C, each roller bottle was 
subcultured 1:6. The six infected roller bottle cultures were incubated at 37°C for 48h, 
after which the medium was decanted and replaced with 25ml of fresh medium. After a 
further 24h incubation at 37°C, the supernatant medium was decanted from the infected 
roller bottle cultures. The cellular debris was removed from the virus containing medium 
by centrifugation at 1000 g at 4°C for 10 minutes. The supernatant was collected, 
aliquoted, and stored at -70°C. FeLV-A stocks prepared in this way generally contained 
5xl06 to lxlO7 p.f.u./ml, while FIV stocks yielded approximately lxlO3 p.f.u./ml.
2.2.5.3. FeLV-A TITRATION.
QN10S cells were seeded at 2xl05 cells/60mm tissue culture plate in 4 ml of
DMEMh 10% FC and incubated overnight at 37°C. Serial ten-fold dilutions of FeLV-A 
were prepared in tissue culture medium containing 4ug /ml polybrene. The growth medium 
was decanted from the monolayers, which were then infected with 1ml of virus suspension 
and incubated at 37°C for 2 h, shaking the infected cell cultures every fifteen minutes to 
assist virus adsorption. The virus inoculum was washed from the cultures, and overlaid 
with tissue culture medium. The cultures were incubated at 37°C for 5 to 7 days in a well
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humidified (90%) incubator, after which they were fixed , stained with Giemsa, and the 
virus plaques counted using a dissecting microscope (Figure I).
2.2.5A. TITRATION AND IMMUNOSTAINING OF FIV PLAQUES ON CrFK 
CELL MONOLAYERS.
2.2.5.4.1. FIV TITRATION
Crandell feline kidney cells (CrFK) were seeded at lxlO5 cells/well on 24 well 
Nunc trays and incubated overnight at 37°C. Serial ten-fold dilutions of FIV stock were 
prepared in DMEgM 10% FC. The growth medium was decanted from the monolayers, 
which were then infected with 200(il of titrated FIV. After virus absorption (75 minutes at 
37°C) the inoculum was removed, the cell monolayers washed 3 times with DMEgM 10% 
FC, and overlaid with one ml of DMEgM 10% FC.
The infected cell monolayers were incubated for a further 4 days at 37°C in a well 
humidified incubator (90%). The resulting virus plaques were identified by immunostaining 
using an FIV antiserum.
2.2.5.4.2. IMMUNOSTAINING
The medium from infected cell monolayers was emptied to a beaker containing 
chloros, and the Nunc tray further evacuated by tapping against a surface covered with 
blotting paper. Cell monolayers were then fixed with 200pl of 1% acetic acid (Analar 
99%) in ethanol for 20 minutes at RT. The monolayers were then washed 3 times with 
immunostaining buffer- tapping the Nunc tray to evacuate (as described), and then treated 
with 200pl of immunostaining buffer containing 5% heat-inactivated goat serum (blocking
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FIGURE I.
FeLV-A plaque on FeA cells, fixed and stained with Giemsa,
FIV plaque on CrFK cells immunostained and visualised with Streptavidine 
peroxidase and Aminoethyl-Carbazol.
Arrow shows typical FIV syncytium
buffer) at 37°C for 60 minutes, or overnight at 4°C. After three cycles of washing with 
immunostaining buffer the infected cells were probed with a 1/4500 dilution of anti-FIV 
p24 monoclonal antibody (IE2)- shaking at 37°C for 75 minutes. The cell monolayers were 
then washed 3 times with immunostaining buffer and treated with 200pl of biotinylated 
horse anti-mouse serum (Vector) (1/3500 dilution in immunostaining buffer) for 15 
minutes at 37°C. Following another three cycles of washing with immunostaining buffer 
the infected cell monolayers were treated with streptavidin/ peroxidase (Vector) (1/2250 
dilution in immunostaining buffer) and incubated at 37°C for 15 minutes. Finally the cell 
monolayers were washed one last time with immunostaining buffer and then once with 
freshly prepared 0.05M acetate buffer pH. 4.8-5.0. The FIV plaques were visualised by 
staining with 200jil of amino-ethyl carbazole (AEC) staining solution. After 10 to 15 
minutes incubation at RT a distinct red-brown coloration appeared over the FIV plaques. 
When the infected cell background began to show coloration, the reaction was stopped by 
immersing the cell layers in water. The cell monlayer was counter-stained with 200|nl/well 
of Meyer’s haemotoxylin (diluted 1:1 with water) for 10 minutes at RT. Plates were 
allowed to air-dry after which the FIV plaques were counted using a dissecting microscope 
(Figure I).
2.2.5.5. BHV-1 TITRATION.
30mm tissue culture plates were seeded with MDBK cells at lx l0 6 cells/plate, and 
allowed to form a monolayer overnight. Serial ten-fold dilutions of BHV-1 stocks were
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prepared in PBS+ 5% FC, and the cell monolayers infected with lOOjxl of virus dilution and 
incubated for lh at 37°C. After virus absorption, the monolayers were washed 3 times and 
overlaid with DMEgM 10% FC. At 48h post-infection the cell monolayers were fixed and 
stained (24h at RT) with Giemsa (improved R66 stain solution). The stained cell layers 
were washed, dried, and the BHV-1 plaques counted using a dissecting microscope.
2.2.5.6. VIRUS PURIFICATION.
2.2.5.6.1. Virus concentration.
Cell cultures were infected with FeLV-A or FIV and crude virus stocks prepared as 
previously described (section 2.2.5.2.2). After clarification of the virus stock, the virus 
particles were pelleted by centrifugation at 12000 r. p. m. at 4°C for 3h in a Sorvall GSA 
rotor.
2.2.5.6.2. Gradient purification.
The pelleted FIV or FeLV-A virus particles were gently resuspended overnight in 
Eagles medium lacking phenol red (Epr") (allowing 500 j l l 1 Epr'/roller bottle). The virus 
particle suspension was layered onto Ficoll 400 gradients (5-15% made in Epr") prepared in 
37 ml Beckman ultra clear AH629 tubes. The virus particles were banded by centrifugation 
at 12000 r.p.m. for 3h at 4°C in a Sorvall AH629 rotor. The virus band was collected by 
side puncture of the tube. The purified virus fraction was then made to 37 ml with Epr" and 
pelleted by centrifugation at 12000 r.p.m. in the Sorvall AH 629 rotor at 4°C. The pellet of 
purified virus was gently resuspended in Epr" (50pJ/roller bottle) and stored at-70°C.
8 2
2 .2 .6 . SINGLE-CYCLE REPLICATION OF FeLV-A IN RESTING OR NON­
RESTING FeA CELL CULTURES. 
2.2.6.1. Non- Resting Cell cultures.
FeA cells were seeded in 24 well Nunc trays at 2xl05 cells/well, and allowed to 
form a monolayer (16h at 37°C). The medium was then decanted and the cells infected 
with 100|il/well FeLV-A at a m.o.i. of 5 p.f.u./cell in the presence of 4p,g/ml of polybrene. 
After virus absorption (2h at 37°C) the infected monolayers were washed three times with 
PBS, overlaid with DMEMh 10% FC, and incubated at 37°C. At 0, 3, 6, 9, 12, 18, 24, 36, 
and 48 h post-infection (PI), the virus yield was harvested by taking the supernatant of the 
infected monlayers, and clarifying it by low speed centrifugation (lOOOg./lO minutes/4°C). 
The virus yield was titrated on QN10S cell monolayers.
2.2.6.2. RESTING CELL CULTURES
60mm tissue culture plates were seeded with 5xl05 FeA cells/plate in DMEMh 
0.5% FC, incubated at 37°C and allowed to grow for seven days after which time the cell 
layer had appeared to have stopped growing. The conditioned medium from resting cell 
layers- depleted in growth factors- was decanted to a sterile flask and retained for later use. 
Resting cell monolayers were infected with FeLV-A at a m.o.i. of 5 p.f.u./cell in the 
presence of 4(ig/ml of polybrene, using conditioned medium from extra resting cell cultures 
as the virus diluent. After the 2h virus adsorption period, the cells were washed three times
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with PBS, overlaid with conditioned medium and incubated at 37°C. Infected cell culture 
medium was harvested at 0, 3, 6, 9, 12,18, 24, 36, and 48 h PI, clarified by centrifugation 
(lOOOg for 10 minutes), and the infectious vims yield titrated on QN10S cell monolayers.
2.2.7. FELINE IMMUNODEFICIENCY VIRUS PLAQUE REDUCTION ASSAY.
CrFK cell monolayers were seeded on 24 well Nunc trays at lxlO5 cells/well in one 
ml of DMEgM 10% FC. Following overnight incubation the growth medium was decanted 
and the cell layers infected with FIV at 100 p.f.u./well. The cells were allowed 75 minutes 
at 37°C to absorb the vims after which the inoculum was removed by washing three times 
with DMEgM 10% FC. The infected cell layers were then overlaid with DMEgM 10% FC 
containing various concentrations of either CCX, or CBX, and incubated at 37°C for 4 
days, after which the cultures were fixed, and FIV plaques identified by immunostaining, 
as described previously.
2.2.8. DRUG INFECTIOUS VIRUS YIELD DOSE-RESPONSE 
EXPERIMENT.
2.2.8.I. FELV-A
FeA cells were seeded on 24 well Nunc tray at 2xl05 cells/well and incubated 
overnight at 37°C. The growth medium was then decanted, and the monolayers infected 
with FeLV-A at a m.o.i. of 5 p.f.u./cell, and allowed 2h (shaking every 15 minutes) at 37°C 
to absorb the virus. The infected cell layers were washed three times with DMEMh 2% FC 
to remove unbound vims, overlaid with 1ml DMEMh 2% FC (containing various 
concentrations of CCX, CBX, or GL) and then incubated at 37°C for 48h. The cell-
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released virus fraction (CR) was obtained from the supernatant of the tissue culture 
medium, clarified by low speed centrifugation (1000 g./lO minutes/4°C). The tissue culture 
medium pellet (containing cell debris and detached cells) was resuspended in 1ml of tissue 
culture medium and pooled with the cells remaining attached to the plate. The cell- 
associated (CA) virus fraction was obtained after scraping the infected cells into the 1ml 
resuspended cell pellet, and sonicating the cell suspension to release the cell-associated 
virus. The infectivity in CA and CR virus fractions were then titrated on QN10S cell 
monolayers.
2.2.8.2. BHV-1.
30 mm tissue culture plates were seeded with MDBK cells at lxlO6 cells/plate and 
incubated overnight at 37°C. The resulting monolayers were infected with BHV-1 at a 
m.o.i. of 5 p.f.u./cell and allowed to absorb the virus for lh at 37°C. The infected cell 
monolayers were then washed three times with DMEgM 2% FC to remove unbound BHV- 
1, and overlaid with 2 ml of DMEgM 2% FC, containing various concentrations of CCX , 
or CBX. The cells were then incubated at 37°C for 24h, after which the CA and CR virus 
yields were harvested (as previously described for FeLV-A). The infectious BHV-1 yield 
in both CA and CR virus fractions were titrated on MDBK cells.
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2.2.9. INVESTIGATION OF THE ANTIVIRAL MECHANISM OF CCX. CBX. 
AND GL.
2.2.9.1. VIRUCIDAL ACTIVITY.
0.5 ml of FIV (lxlO3 p.f.u./ml), FeLV-A (1.4xl07 p.f.u./ml), or BHV-1 (2.31 x 109 
p.f.u/ml) were mixed with 0.5 ml tissue culture medium containing either no drug or 
increasing concentrations of CCX, CBX, or GL. lOOul of the drug- free virus suspension 
was withdrawn and titrated immediately (Oh sample). The drug-free and drug-treated virus 
suspensions were each then split, and half the volume incubated at 4°C, and half at 37°C. 
The FIV, FeLV-A, and BHV-1 infectivity remaining in drug-free or drug-treated cultures 
after 24h incubation was then determined by titration. Although the numbers of infectious 
virus particles (FIV, FeLV-A, and BHV-1) varied in each case, the total protein content of 
the samples would have been much the same as the virus stocks were prepared in medium 
containing 10% foetal calf serum. Variation in the protein content of samples is therefore 
unlikely to have influenced the virucidal activity obtained for triterpenoid drugs against the 
different viruses.
2.2.9.2. POLYACRYLAMIDE GEL ELECTROPHORESIS OF POLYPEPTIDES 
(SDS PAGE).
Virus and cellular polypeptides were separated on polyacrylamide gels in the 
presence of 0.1 % SDS. (Marsden, et al, 1976)
The ratio of acrylamide to bisacrylamide for all of the gels was 37:5:1. The 
separating gel contained 7.5%, 9%, or 10% acrylamide, while the stacking gel contained
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5% acrylamide. 4ml (10%) polyacrylamide minigels were used to resolve FIV and FeLV-A 
polypeptides, while 65ml (9%, or 10%) polyacrylamide gels were used for BHV-1 studies. 
7.5% polyacrylamide gels were also used on occasion to resolve proteins of certain 
molecular weights.
SDS PAGE gel preparation and pouring were as described by Marsden et al (1976). 
After pouring, the resolving gel was overlaid with Butan-2-ol in order to obtain a smooth 
gel surface upon polymerisation (large gels l-2h, minigels 15 minutes). The butan-2-ol was 
removed by washing with tap water, and the surface of the gel dried using a Whatman Seed 
test paper grade 182, before the stacking gel was poured and bonded to the resolving gel. 
Large gels were electrophoresed with a constant current of 60mA, while minigels were 
electrophoresed at 150volts at maximum current. The molecular weights of the viral or 
cellular polypeptides were estimated by comparison with Rainbow protein molecular 
weight markers (Amersham Life Science).
2.2.9.3. FIXING. STAINING. AND DESTAINING OF SDS PAGE GELS.
Polyacrylamide gels were fixed/stained with SDS PAGE fix/stain solution (see 
solutions) for a minimal period of lh at RT. The polypeptide bands were then visualised by 
treating the gel with destain solution overnight, while gently agitating the gel on a shaker at 
RT.
Gels containing protein samples which were labelled, to a low level with 
radioactivity, were soaked in enhancer En‘ Hance (New England Nuclead) for lh at RT, 
washed three times in water, (10 minutes each), and then soaked in water for 30 minutes at
87
RT. After which the gel was vacuum dried (30 in/Hg, at 80°C for 2h) onto Whatman Seed 
test paper grade 182 using a Bio-Rad model 583 gel dryer.
Dried gels were exposed to X-OMAT S film at RT for varying periods of time then 
developed in a Kodak X-OMAT Processor model ME-3.
2.2.9.4. SILVER-STAINING OF PROTEINS IN SDS PAGE GELS.
Polyacrylamide gels containing non-radioactive protein samples from uninfected or 
virus infected cells were treated with ethanol, acetic acid, and water mixture (at a ratio of 
30:10;60) for by shaking gently at RT for lh. The gel was then fixed by treatment for lh at 
RT with (30% ethanol, 0.5M NaOAC, 0.5% gluteraldehyde, and 0.2% sodium thiosulfate). 
The gel was then washed 3 times with double-distilled water, and impregnated with 0.1% 
silver nitrate, in 0.02% formaldehyde for 30 minutes at RT. Protein bands in the gel were 
visualised after colour development following (5-15 minutes) treatment with a solution of 
25% Na2C0 3 , and 0.01 % formaldehyde. Colour development was stopped by soaking of 
the gel in a solution of 0.05% EDTA for 5 minutes. To obtain a permanent copy of the 
silver-stained gel, the gel was washed in distilled water and photographically reproduced by 
contact printing using X-OMAT duplication film and a Wardray duplicator machine.
2.2.9.5. WESTERN IMMUNOBLOTTING.
Protein extracts were separated on 10% polyacrylamide gels, using the Biorad 
minigel electrophoresis apparatus. The banded proteins were then transferred to Hybound- 
ECL nitrocellulose membrane (Amersham) by electro-blotting (50v for lh). The membrane 
was then incubated overnight at 4°C on a rotary shaker with blocking buffer (5% Marvel™,
0.05% Tween 20 in PBS) to reduce non-specific binding of the antibodies. Excess blocking 
buffer was removed by three washes in PBS +0.05% Tween 20 (15 minutes each), and the 
membrane then probed with antibody (either anti-FIV or anti FeLV-A 1/50 dilution in
0.05% Tween 20; 1% BSA, in PBS) overnight at 4°C. After the antibody solution was 
decanted, the membrane was washed three times in 0.05% Tween 20 in PBS (15 minutes
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each), incubated for lh at 37°C with protein-A/ horse- raddish peroxidase (diluted 1/1000 
in PBS containing 0.05% Tween 20, and 1% BSA) and then washed twice (15 minutes 
each) with 0.05% Tween 20 in PBS. Protein bands tagged with virus specific antibody 
were visualised using enhanced chemoluminescence (ECL) westem-blot detection solution 
(Amersham Life Science) as follows:
1. Equal volumes of ECL solutions 1 and 2 were mixed together and pipetted 
gently over the blots for approximately 1 minute.
2. The membrane was removed from the ECL solution, placed between two 
sheets of Melanex film, and exposed to X-OMAT S film for a range of time to obtain short, 
medium, and long exposures of the blot..
3. The film was then developed using Kodak X-OMAT Processor model ME-3.
2 .2 .9 .6 . IM M U N O PRECIPITATIO N .
2.2.9.6.I. PREPARATION OF PROTEIN EXTRACTS FOR IMMUNO­
PRECIPITATION.
The growth medium was removed from virus infected cells, they were then washed 
twice with PBS, and a protein extract prepared by addition of the extraction buffer. The 
growth medium from the infected cell layer was clarified by low speed centrifugation, and 
the virus particles pelleted from the clarified supernatant by centrifugation at 20,000 r.p.m. 
for 2h (4°) in a Sorvall SS-34 rotor. A protein extract of the pelleted particles was then 
prepared by the addition of the extraction buffer.
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2.2.9.6.2. PREPARATION OF PROTEIN-A SEPHAROSE BEADS
1. 0.2 g of protein-A sepharose beads were placed in a 15ml Falcon tube, and 
soaked in 10-15ml of the immunoprecipitation extraction buffer for 15 minutes.
2. The swollen beads were washed three times in the extraction buffer, pelleting the 
beads after each wash by centrifugation at 1000 r.p.m. for 5 minutes at 4°C.
3. After the final wash , the pelleted beads were resuspended in a volume of the 
extraction buffer equal to the volume of the pellet. The resuspended stock of 
protein A sepharose beads was kept at 4°C.
2.2.9.6.3. IMMUNOPRECIPITATION REACTION.
1. 50 ptl of infected cell extract, or the pelleted virus extract, were mixed with FIV 
or FeLV-A infected cat sera, as appropriate (each at 1/20 dilution) in an 
Eppendorff tube, and incubated at 4°C overnight on a rotary mixer.
2. 60ul of protein-A sepharose beads were added to each antibody /antigen mixture, 
and incubated for lh at 4°C on a rotary mixer at RT.
3. 600ul of wash buffer ( 0.6M lithium chloride, 0.1M Tris pH 8, 1.4M 
mercaptoethanol) was added to each sample .
4. Samples were microfuged at 3000 r.p.m. for 30 sec at room temperature.
5. Supernatant was removed, and 600ul of wash buffer was added to each pellet.
6. The pellet was gently resuspended by inversion of the tube.
7. The cycle was repeated four times
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After the final wash the supernatant was removed from the pelleted beads, and 20ul 
of SDS PAGE extraction buffer was added to each pellet. The immunoprecipitated proteins 
were eluted from the beads by boiling for five minutes, after which the beads were pelleted 
and the supernatant containing the eluted proteins examined by SDS PAGE.
2.2.9.7. RADIOLABELING OF VIRUS AND CELLULAR PROTEINS.
2.2.9.7.I. r14Cl-GLUCOSAMINE LABELLING OF MOCK-INFECTED AND FIV 
SPECIFIC POLYPEPTIDES AND PELLETING OF THE VIRUS 
PARTICLES MADE IN THE PRESENCE OF CCX.
60mm tissue culture plates were seeded with third passage persistently infected cells 
at 5x l05 cells/plate. After overnight incubation the growth medium was replaced with 
glucose-free RPMI 1640 + 2% FC (either drug-free or containing CCX). Following further 
incubation for 30 minutes at 37°C, the persistently infected cell cultures were washed three 
times with glucose-free medium, and finally overlaid with RPMI 1640 (either drug-free or 
containing CCX). The cultures were then labelled 3h to 48h after drug addition, with 14C 
glucosamine (5pci/pl) (Hosie and Jarrett, 1990) after which the tissue culture medium was 
decanted and centrifuged to pellet the cell-free virus. The cell monolayers and the pelleted 
virus particles were lysed with the extraction buffer, and used in immunoprecipitation 
reactions with anti-FIV serum.
9 2
2.2.9.7.2. r35Sl-METHIONINE/CYSTEINE LABELLING OF MOCK-INFECTED
AND FELV-A OR FIV INFECTED CELL POLYPEPTIDES. AND
PELLETING OF THE VIRUS PARTICLES MADE IN THE PRESENCE 
OF CCX.
Third passage, FIV persistently infected CrFK cell monolayers or third passage 
FeLV-A persistently infected FeA cells were seeded at either 5x10s cells/60mm plate or 
2x l05 cells/well in 24 well Nunc trays. Following overnight incubation at 37°C, the tissue 
culture medium was replaced by RPMI 1640 2% FC lacking methionine and cysteine 
(either drug-free or containing CCX). Cell cultures were pre-treated with CCX for 30 
minutes at 37°C. Drug-treated cultures were then washed 3 times, and overlaid with 
methionine/cysteine-free medium (either drug-free or containing CCX). ' S meth/cys 
mixture (50pci/ml) was added to the cell culture at 3h after drug addition, after which the 
monolayers were incubated at 37°C until 48h after drug addition. The infected cell
monolayers were then harvested as follows:
1. The culture medium was removed and clarified by centrifugation at 2000 r.p.m/ 
30 minutes.
2. The supernatant was filtered through a 0.22p Acrodisc filter, and centrifuged at 
12000 r.p.m. for 3h in the TST 41 rotor to pellet the virus particles.
3. The virus particle protein extract was prepared by resuspension of virus particles 
in 50ul of SDS PAGE extraction buffer.
4. The infected cell extract was prepared by adding 250ul of SDS PAGE extraction 
buffer to the infected cell layers.
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5. Protein extracts were boiled for 3 minutes, after which lOul samples were 
spotted onto Whatman *1 filter discs. The discs were washed twice in ice-cold 
5% TCA, twice in 100% ethanol at RT, and allowed to air dry at RT. The filters 
were then placed in plastic vials containing 5 ml of Ecoscint (National 
Diagnostics) and the amount of the radioactivity in each sample determined by 
liquid scintillation counting using a Beckman model LS 5000 CE Scintillation 
Counter.
6. The radioactivity contained in each samples was standardised. Protein extracts 
containing equal CPM were loaded into each gel slot, and electrophoresed on 
SDS PAGE gels at 150 volts.
7. Finally the gel was fixed/stained, dried, and autoradiographed.
2.2.9.7.3. r35Sl-METHIQNINE AND r32PHNORGANIC PHOSPHATE LABELLING 
OF MOCK-INFECTED AND BHV-1 INFECTED CELL POLYPEPTIDES.
Monolayers of MDBK cells (3 xlO5 cells/well on 24 well Nunc trays) were either 
mock-infected (MI) or infected with BHV-1 at a m.o.i. of 20 p.f.u./cell. After virus 
absorption (lh  at 37°C), the cell monolayers were washed three times, and overlaid with 
either methionine-free or phosphate-free Eagles medium 2% FC as appropriate (either drug- 
free or containing various concentrations of CCX). [35S]-methionine (10 (ici/ml) or [32P]- 
orthophosphate (50|ici/ml) was added to each cell culture at 3h or 4h PI respectively. 
Following overnight labelling, the infected cell monolayers were harvested as follows:
9 4
3 5  iThe [ S] methionine-containing tissue culture overlay was discarded and the cells 
washed once with PBS. The infected cell protein extract was prepared by the addition of 
250pl of SDS PAGE extraction buffer to the monolayers.
3 2  •The [ P] inorganic phosphate containing overlay was discarded and each cell layer 
quickly and carefully washed with distilled water, then lysed with 200pl of distilled water. 
250|il of DNAase/RNAase mixture (50(ig/ml DNAase; 50|ig RNAase) was then added to 
each lysed sample which was then incubated at 37°C for 15 minutes. 150pl of SDS PAGE 
extraction buffer was then added to each lysed cell preparation. Protein extracts were 
electrophoresed on 9% SDS-PAGE gels. The gel was finally fixed/ stained, dried, and 
autoradiographed.
2.2.10. ELECTRON MICROSCOPY.
2.2.10.1. NEGATIVE STAINING.
5ul of vims suspension was mixed with 5ul of sodium silico tungstate, containing 
latex beads at 1.43 x 101()/ml. The vims/bead suspension was incubated for 2 minutes at 
RT, then 5p.l was applied to a cellulose nitrate coated EM grid and allowed to stand for 2 
minutes. Excess sample was removed by blotting with a piece of Whatman # 1 filter paper. 
The virus/latex bead coated grid was then examined with a GL 100S electron microscope 
operating at 60KV and at the magnification of 40,000 times.
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2.2.10.2. EPOXY-RESIN (EPON 812) EMBEDDING AND THIN SECTIONING OF
TISSUE CULTURE SAMPLES
30mm tissue culture plates were seeded with MDBK cells at lxlO6 cells/plate, and 
incubated overnight at 37°C. The cell layers were infected with BHV-1 at a m.o.i. of 5 
p.f.u./cell, and allowed lh at 37°C to absorb the virus. Infected cultures were washed 3 
times in DMEgM 2% FC and overlaid with DMEgM 2% FC containing various 
concentrations of CCX. The growth medium was removed after 24h incubation at 37°C, 
and the cell layers harvested by scraping into 0.5ml of PBS. The cell suspension was 
pelleted at 9000 r.p.m. for 5 minutes in the MSE microfuge. The cell pellet was fixed with
0.5 ml of 2.5% gluteraldehyde (EM grade) in PBS, and stored overnight at 4°C. After three 
washes with PBS, the pellet was post-fixed and stained with 1% osmium tetroxide in PBS 
for 2h. Following further washes in PBS the cell pellet was dehydrated by sequential 
treatment with increasing concentrations of ethanol for ranging period of time (30% 3h, 
50% 3h, 70% 18h, 90% 3h, 100% 18h). The cells were then permeated with Epon:ethanol 
(1:1), at RT overnight, after which, the cells were embedded in fresh, undiluted, Epon 
which was polymerised by baking at 60°C for 48h.
Thin sections approximately lOOnm thick were, cut from the cell pellet using a 
Richert Jung ultramicrotome fitted with a diamond knife. Thin sections were stained with 
uranyl acetate in 50% ethanol for at least lh, after which the sections were washed in 
double-distilled water. The thin sections were counter-stained with lead citrate for 5 
minutes, washed in double-distilled water, and examined in a GL 100S electron microscope 
operating at 60KV and at a magnification of 20,000 to 40,000 times.
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2 .2 .1 1 . PRECLEA N IN G  OF ANTI-MOUSE-FITC-CON.TUGATE.
The anti-mouse FITC conjugate purchased from the Sigma Chemical Company 
consistently gave non-specific labelling of cells in the absence of primary antibody. To 
remove this non-specific activity, 30mm tissue culture plates were seeded, overnight with 
MDBK cells at concentration of 2xl06 cells/plate. The resulting monolayers were fixed in 
90% ethanol in PBS for 4 minutes at RT, washed 3 times (5 minutes each) in PBS, overlaid 
with 1 ml of anti-mouse FITC conjugate (diluted 1/20 in PBS), and incubated for lh on a 
shaker at RT. The anti-mouse FITC conjugate was then pipetted off, and centrifuged at 
1000-1500g for 10 minutes at 4°C to pellet cellular debris. The anti-mouse FTTC-conjugate 
was then tested on fresh monolayers of uninfected MDBK cells, to check for non-specific 
labelling. If fluorescence was detected the cycle of cleaning was repeated (three pre­
cleaning steps were generally sufficient).
2.2.12. DETECTION OF GOLGI APPARATUS IN CCX TREATED CELLS BY 
IMMUNOFLUORESCENCE USING ANTI-GOLGI ANTIBODIES AS 
MARKERS.
13mm glass coverslips were de-greased by boiling in undiluted chloros for 3 
minutes, washing in DI water , rinsing with 100% ethanol followed by air drying. Each 
coverslip was then polished using a Whatman lens tissue. Finally the coverslips were 
sterilised by dry-oven baking at 160°C for 2h.
MDBK or CrFK cells were seeded at 2xl05 cells/well on glass cover slips in 24 well 
Nunc trays. After overnight incubation at 37°C, the growth medium was replaced with 
drug-free medium , or medium containing CCX, and the cells incubated for 5h at 37°C.
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The cell layers were then washed three times ( 5 minutes, each) with PBS and 
fixed/permeabilized, at RT, with 90% ethanol in PBS (4 minutes). The fixed cell layers 
were washed 3 times (10 minutes, each on a shaker) with PBS, and then treated with the 
primary antibody [anti-P58 (1/50), or (3COP (1/20) in PBS] for 60 minutes at RT. The cells 
were again washed 3 times with PBS, then treated for 60 minutes with the secondary 
antibody (pre-cleaned anti-mouse IgG-FITC conjugate diluted 1/80). Finally the 
monolayers were again washed 3 times with PBS, and then mounted on glass slides using 
(CmFLUOR mounting solution, and nail varnish was used to seal the edges of the 
coverslip). The cells were then examined for fluorescence under UV illumination using a 
Nikon microphot-SA fluorescent microscope.
2.2.13. DETECTION OF ACIDIC COMPARTMENTS IN CCX-TREATED CELLS 
BY IMMUNOFLUORESCENCE USING THE DAMP ANTI-DAMP 
SYSTEM.
MDBK cells were seeded at 2xl05 cells/well on sterile 13mm glass coverslips in a 
24 well Nunc tray and allowed overnight to form a monolayer. The medium decanted and 
replaced either with fresh drug-free medium or medium containing CCX , and incubation at 
37°C continued for 5h. Cell cultures were then washed 3 times with PBS (10 minutes, 
each), before adding growth medium containing 30uM [3-(2,4-dinitroanilino)-3'- aminoN- 
methyl-dipropylamine] (DAMP) and continuing incubation at 37°C for 30 minutes. The 
medium containing DAMP was then decanted, and the cell cultures fixed with 3% 
paraformaldehyde for 15 minutes at RT. The cell layers were then washed once (10
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minutes) in 50 mM ammonium chloride and twice (10 minutes, each) in PBS. The cell 
layers were pre-cooled and kept on ice prior to, and during, permeablization with 0.1% 
triton X-100 for 5 minutes. The permiabilized cells were then incubated with 3% BSA in 
PBS at, RT, for 15 minutes, and then treated with the primary antibody (1/10 dilution of 
anti-DNP antibody in 0.2% BSA/PBS) for lh at 37°C. The monolayers were washed 3 
times with 0.2% BSA/PBS(10 minutes, each), and then treated with the secondary antibody 
(pre-cleaned anti-mouse IgG-FITC conjugate diluted 1/80) for lh at 37°C. The monolayers 
were finally washed 3 times again with PBS, and mounted on glass slides (using 
CITIFLUOR mounting solution). The cell layers were then examined for fluorescence 
under UV illumination using a Nikon microphot-SA fluorescent microscope.
2.2.14. INVESTIGATION OF THE EFFECT OF OUABAIN IN COMBINATION
WITH CCX ON P58 GOLGI STAINING OF MDBK CELLS.
MDBK cells were seeded at 2xl05 cells/well on coverslips in 24 well Nunc trays. 
After overnight incubation at 37°C, the growth medium was replaced with either drug-free 
medium, medium containing 300|llM CCX (4h), or medium containing 25jiM Ouabain 
(lh). Additional cell layers which had been treated with 25|iM Ouabain for lh were, then 
treated with 300|iM CCX for 4h at 37°C. The cells were washed three times with PBS (5 
minutes each) and fixed/permeabilized at RT with 90% ethanol in PBS for 4 minutes. 
Fixed cell layers were washed with PBS three times (10 minutes each on a shaker) then 
treated with the primary antibody (anti-P58 diluted 1/50) for 60 minutes at RT. The cells 
were again washed three times with PBS, and then treated for 60 minutes with the 
secondary antibody (pre-cleaned anti-mouse IgG-FITC conjugate diluted 1/80), after which
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the cells were again washed and the coverslips mounted on a glass slide. The cells were 
studied for fluorescence under UV illumination using a Nikon microphot-SA fluorescent 
microscope.
2.2.15. PREPARATION OF A RABBIT ANTIBODY DIRECTED 
AGAINST CCX.
2.2.15.1. PREPARATION OF CCX-BSA. AND CCX-KLH CONJUGATE.
In order to increase the probability of obtaining an antibody against CCX (Mwt
668.8) the drug was conjugated to BSA, or to Keyhole Limpet Haemocyanin (KLH) 
(ELISA). EDC was used to form a covalent bond between an amino group on BSA or 
KLH, and the COONa group on CCX. 20ji Mole of CCX was mixed with 600p.l of 0.33M 
EDC by stirring in the dark for 5 minutes. 400p.l of BSA solution (20mg/ml) was then 
added and allowed to mix overnight at RT.
In order to monitor the coupling of CCX to BSA a small amount of 3H CCX was 
included in the reaction. After overnight mixing the CCX/BSA/EDC mixture was dialysed 
against; double distilled water for 5-6h at RT, followed by dialysis against 1% acetic acid 
overnight at RT, and finally dialysed against 3 changes of PBS over 2 days at 4°C. The 
dialysed material was then passed through a PD10 column (Sephadex G 25). The column 
was washed with PBS before adding the dialysed sample. The sample flow through was 
collected in 0.5ml fractions (-30 fractions).
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2.2.15.2. ESTIMATION OF THE CCX IN THE CCX/BSA/EDC COMPLEX
Specific activity of 3H-CCX = 6.5 mci/mg
used 2pl/ml 3h-CCX =1.5jLig 3H-CCX/ml. lpg =2.83 x 105 cpm/pl.
20p moles of CCX =13,360 pg 
ratio cold/hot =13,360/1.5 =8960/1 
after dialysis 3.35 xlO3 cpm/pl.
3.35x1 03/2 .83x  105 = 0.0118pg; or 1 2 n g  3HCCX 
How much cold CCX present after dialysis?
8906/1 x Xpg/0.012pg= 10.7 pg/pl. =10.7 mg/ml
2.2.15.3. INJECTION OF RABBITS WITH CCX/BSA CONJUGATE AND 
COLLECTION OF THE SERA.
Four rabbits were injected with the EDC linked CCX/BSA conjugate prepared in 
either complete (first injection) or incomplete Freund’s adjuvant (400ul of Freund’s 
adjuvant was mixed with 400ul of CCX/BSA conjugate and vortexed for 5 minutes to form 
an immulsion). Two rabbits were injected with 200ul of the conjugate (containig lmg of 
CCX), and two rabbits with lOOul of the conjugate (containing 500pg of CCX).
The rabbits were injected intramuscularly once every month, and bled 2 weeks later. 
Pre-immunisation and post-immunisation bleeds were collected, the blood allowed to clot, 
the blood clot cut and the sera collected. The serum was centrifuged at lOOOg for 10 
minutes to pellet debris and the clarified serum then pipetted out, and stored at -20°C prior 
to passage through an anti-BSA antibody binding column.
101
2.2.15.4. COUPLING OF THE CNBr■ ACTIVATED SEPHAROSE BEADS WITH
BOVINE SERUM ALBUMIN (BSA).
1. One gram of BSA was dissolved in 5ml of bicarbonate buffer (0.1M NaHCCh; 
0.5NaCl; pH 8.0).
2. Sepharose beads were placed in a sintered-glass filter funnel, and allowed to 
swell in 200ml of ImM HC1 solution (10 minutes), then washed with 
approximately 1 litre of ImM HC1 solution.
3. The beads were further washed with 200 ml of bicarbonate buffer.
4. The sepharose beads were then resuspended in 5ml BSA/bicarbonate buffer 
solution, followed by of 50ml of bicarbonate buffer to wash the beads into a 
500ml beaker. The glass filter funnel was rinsed with a further 50ml bicarbonate 
buffer, and the wash was added to the 500ml beaker.
5. The BSA/sepharose beads were then dispensed into 50ml Falcon tubes, placed 
on a rotary mixer, and swirled for 2h at RT to assist coupling BSA to the 
sepharose beads.
6. The beads were then pooled by decanting the content of the tubes in to the 
sintered glass filter funnel, and the flow through volume measured .
7. After determining the optical density of the solution (by spectrophotometry), the 
coupling efficiency of BSA to the beads was measured as follows:
mg of BSA bound to the column = O.D. x volume of the flow through solution
0.5 x 100ml =50mg of BSA was not bound to the beads.
Initially one gram of BSA was added to the beads therefore; lOOOmg -50mg = 
950 mg.
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Coupling efficiency = 950/1000 x 100 = 90 %
8. The beads were then resuspended in 50 ml of ethanolamine and poured in to a 
clean 500ml beaker.
9. The sintered glass filter funnel was rinsed with 50ml of ethanolamine, and the 
rinse pooled with the beads in the 500ml beaker.
10 The content of the beaker was then dispensed in to 50ml falcon tubes, which 
were placed on a rotary mixer, and mixed for 2h at RT to block any remaining 
protein binding sites in the beads.
11. Ethanolamine was removed from the BSA/sepharose beads, which were then 
washed once with bicarbonate buffer, once with PBS, and stored at 4°C in PBS 
+0.01 % sodium azide.
2.2.15.5. REMOVAL OF ANTI-BSA ANTIBODY BY PASSAGE OF THE SERUM 
THROUGH AN ANTI-BSA ANTIBODY BINDING COLUMN.
A 20ml syringe barrel was plugged using a glass fibre filter paper disk (Whatman 
GF/C). BSA-conjugated sepharose beads in PBS were pipetted into the syringe barrel and 
allowed to form a column. Rabbit serum was then gently pipetted onto the top of the 
column and allowed to penetrate into the column, thereafter PBS was used to wash the 
serum through the column. Progress of the rabbit serum through the column could be 
monitored by observing the descent of the coloured band of the serum in the column. 
When the serum was close to the bottom the flow through the column was stopped, and the 
column barrel incubated for 2h at RT, after which flow through the column was resumed 
and serum samples were collected and stored at -20°C.
103
2.2.15.6. DETECTION OF ANTI-CCX ANTIBODY IN THE RABBIT SERA BY
ELISA.
In order to determine whether anti-CCX antibody was present in the rabbit serum an
ELISA test was designed.
1. 5 0 jll1 of CCX/KLH (containing 0.5pg CCX/well) was added to 96 well plates and 
incubated at 37°C overnight
2. The wells were washed 3 times with double-distilled water, and residual water 
removed by tapping the tray on absorbent paper.
3. The wells were then coated with 200ul of PBS+Tween20 (blocking buffer), and 
incubated at 37°C for lh.
4. Plates were washed with double-distilled water three times and the residual water 
removed by tapping the plates on absorbent paper.
5. The immune or pre-immune serum as appropriate was then added to each well 
(50ul/well) and incubated at R.T for lh.
6. Wells were again washed 3 times in double distilled water.
7. 50 ul of Horse-raddish peroxidase/ protein-A in PBS(lfig/ml) was added to each 
well, and the plates were incubated at R.T for lh.
8 . The plates were then washed 6 times in double distilled water.
9. 50|il of 2,2',-Azino-Bis (3-Ethylbenz-Thiazoline-6-sulfonic acid) diammonium 
salt (ABTS) at o.5mg/ml (3pl of FLCL was added/10ml of ABTS solution), in 
citrate/phosphate buffer (pH 4) was added per well. The plates covered, and
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incubated at R.T in the dark for 10-15 minutes, after which the light absorbance at 405nm 
was read using a Titertek Multiskan spectrophotometer.
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2.3. SOLUTIONS.
SOLUTIONS AND BUFFERS USED IN ELISA
ANTIBODY- 1:50 dilution of anti-CCX antibody immune sera, or pre-immune in 
PBS 0.02% Tween20.
BLOCKING BUFFER (PBT)- 0.02% Tween20 in PBS.
CITRATE/PHOSPHATE BUFFER- 0.1M citric acid +0.1 M Na2 P 0 4 pH. 4, 
dissolved in 100 ml of double distilled ultra-pure water.
SUBSTRATE-ABTS/H2O2- 0.5mg/ml of ABTS in citrate/phosphate buffer, 3ul of 
H20 2 was added for every 10ml of ABTS solution.
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SOLUTIONS AND BUFFERS USED IN SDS POLYACRYLAMIDE GEL 
ELECTROPHORESIS.
RESOLVING GEL BUFFER. TRIS HC1 18.15g
SDS 0.4g
Bring up the volume to 100 ml with double distilled ultra-pure water, pH. 8.9.
STACKING GEL BUFFER. TRIS HC1 5 9g
SDS 0.4g
Bring up the volume to 100 ml with double-distilled ultra-pure water, pH. 6.7.
25 % AMMONIUM PERSULFATE. (APS). 0.25g in 1 ml of double-distilled 
ultra-pure H20.
TANK BUFFER. TRIS 6.32g
GLYCINE 4g 
SDS lg
Bring up the volumes to 1 litre with DI water.
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RESOLVING GELS
30% ACRYLAMIDE BIS ACRYLAMIDE 0.6g
ACRYLAMIDE 29.4g
Volume was brought up to 100 ml, solution was passed through a Whatman #1 filter 
paper.
A - 10% POLYACRYLAMIDE GEL. 60mls gels mini-gels
GEL BUFFER 15ml 2.5 ml
DOUBLE-DISTILLED ULTRA PURE -H20  24.9ml 2 ml
30% ACRYLAMIDE/0.8% BIS ACRYLAMIDE (SCOTLAB) 20.1ml 3.5 ml
25% APS 60|il
10% APS - IOOjllI
TEMED 150|il lOpl
B- 9% POLYACRYLAMIDE.
GEL BUFFER 15ml
DOUBLE-DISTILLED ULTRA PURE H20  27ml
30 % ACRYLAMIDE/0.8% BIS ACRYLAMIDE (SCOTLAB) 18ml
25% APS 60pl
TEMED 150pl
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c- 7.5 % SEPARATING MINIGEL.
GEL BUFFER 1.8 ml
DOUBLE DISTILLED ULTRA PURE WATER 3.6 ml
30% ACRYL AMIDE/0.8 % BIS ACRYLAMIDE (SCOTLAB) 1.8 ml
10% APS 200fil
TEMED 10pJ
D- STACKING GEL FOR 60ML GELS.
STACKING- GEL BUFFER 5ml
DOUBLE DISTILLED ULTRA PURE WATER 12.34ml
30% ACRYLAMIDE 2.66ml
25% APS 60|ll1
TEMED ISOfJLl
D- STACKING GEL FOR MINI-GEL SYSTEM.
STACKING GEL BUFFER 1.5 ml
DOUBLE DISTILLED ULTRA PURE WATER 3.5 ml
30% ACRYLAMIDE/0.8% BIS ACRYLAMIDE (SCOTLAB) 1 ml
10% APS IOOjlxI
TEMED lOjLil
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SDS PAGE GEL FIX/STAIN SOLUTION- 0.2% commassie blue R 250 in 
methanol, water, acetic acid in the ratio of 50: 43: 7.
SDS PAGE GEL DESTAIN SOLUTION- methanol, water, acetic acid in the ratio 
of 50, 880, 70
SDS PAGE EXTRACTION BUFFER.
SPACER GEL BUFFER 1ml
25% SDS 0.8ml
p-MERC APT OETH AN OL 0.5ml
GLYCEROL 1ml
BROMOPHENOL BLUE 25|il
Extraction buffer was diluted 1+2 with double distilled ultra-pure water before use. 
BLOTTING BUFFER (TOWBIN)
25mMTris 15.1g
192mM Glycine 72g
20% Methanol 1000 ml
Made up to 5 litre with DI water, 1.5 ml of concentrated HC1 was added pH. 8.3.
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SOLUTION AND BUFFERS USED IN FIY IMMUNOSTAINING
IMMUNOSTAINING BUFFER-0.5% Goat serum (Goat serum) in PBS. 
BLOCKING BUFFER- 5% Goat serum in PBS.
0.05M ACETATE BUFFER- 50mM sodium acetate, mixed with 50mM acetic 
acid pH. 4.8-5.0.
STAINING SOLUTION- 0.8% AMINO ETHYL CARBAZOLE (AEC) IN 
FORMAMIDE.
0.8% AEC 0.5ml
0.5 M ACETATE BUFFER 9.5ml
30% H20 2 75|il
The mixture was filtered through a Whatman #1 filter paper.
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SOLUTION AND BUFFERS USED IN IMMUNOPRECIPITATION.
IMMUNOPRECIPITATION EXTRACTION BUFFER
0.1 M TRIS pH.8.0 
10% GLYCEROL 
5% NP40 
0.2mM PMSF 
0.5 %S ODIUMDEOX Y CHOL ATE
WASH BUFFER(LiCl). 0.6 M LiCL
0.1 M TRIS, pH. 8.0 
1.4M Mercaptoethanol 
Volume was brought up to 100 ml with double-distilled ultra-pure water.
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3. CHAPTER THREE
RESULTS
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3.1. INVESTIGATION OF THE EFFECTS OF TRITERPENOID
COMPOUNDS ON UNINFECTED CELLS IN CULTURE
Dargan and Subak-Sharpe (1985), and Galt et al (1990) have classified different cell 
lines according to their tolerance to treatment with CCX concentrations up to, 300[iM. The 
work described here extends these studies to include the cell lines used in this thesis. The 
effect of the triterpenoid compounds on percentage cell viability, and cell culture growth of 
feline (FeA, QN10S, and CrFK), and bovine (MDBK, BEL, and BEK) cells, was 
determined by trypan-blue dye exclusion tests, and enumeration of total cell number in cell 
cultures treated with increasing concentration of drugs over several days.
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3.1.1. THE EFFECT OF CCX. OR CBX TREATMENT ON THE GROWTH
AND PERCENTAGE VIABILITY OF CrFK CELLS IN CULTURE.
The effect of CCX treatment on CrFK cell cultures is shown in Fig 7A. The 
percentage cell viability of the drug-free control culture remained >90% for up to 8 days, 
but dropped to 80% after 10 days incubation. The cell viabilities of CrFK cultures treated 
with up to lOOpM CCX for three days remained about 90%, but treatment with 150p,M 
CCX reduced cell viability to 65%. After 6 days CCX treatment, cultures treated with 
25|iM, or 50[iM CCX remained about 90% viable, while those treated with 75|llM, 100|liM , 
or 150|iM were 83%, 77.1%, and 66% viable respectively. After 10 days treatment, 
cultures treated with 25jiM, or 50|iM CCX had percentage viabilities of 73.5%, and 18.8% 
respectively, while those cultures treated with higher drug concentrations were non-viable.
The effect of CCX treatment on the growth of CrFK cells is shown in Fig 7B. A 
replication index (R.I= total number of cells at time of harvesting divided by the total 
number of cells at time zero) was used to measure growth. The replication indices for the 
drug-free control culture increased to 4.3 after 3 days incubation, reached a plateau value 
of 9.1 after 6 days and gave a value of 9.2 after 10 days incubation. Three days treatment 
with 25pM, 50pM, or 75pM CCX had no effect on the rate of cell culture growth. 
Treatment with lOOpJM CCX for 3 days resulted in a small impairment of cell culture 
growth (RI. 3.72), while 150|iM CCX significantly impaired cell culture growth (RI. 2.44). 
Six days treatment with 25pM, or 50|iM CCX had no significant effect on the rate of cell 
growth, but treatment with 75|iM, IOOjiM, or 150)iM CCX inhibited culture growth (RI’s.
4.6, 4.4, and 1.1 respectively) and the RI range reached a plateau. After 10 days treatment
115
with 25p,M or 50fiM CCX , there was a small decrease in the total number of cells (RTs. 
6.28, and 6.81 respectively) possibly suggesting some lysis of cells in the culture. Only 
cellular debris was present in cultures treated with 75pM, lOOpM, or 150|iM CCX 
indicating complete lysis of the culture after 10 days treatment.
The duration of the FIV replication cycle in CrFK cells is 3 days. It was, therefore, 
of particular interest to determine the effect of the drugs on uninfected CrFK cell cultures 
during this period. The data in Figures 7A and 7B show that, there was little evidence for 
CCX-induced cytotoxic effect when CrFK cells were treated with up to 100|iM CCX for 3 
days.
The effect of CBX on CrFK cell viability is shown in Fig 8A. The percentage cell 
viability of the drug-free control cultures remained at greater than 90% throughout the 10 
days incubation period. Three days treatment with drug concentrations up to 150jiM CBX 
had no significant effect on cell viabilities (greater or equal to 90%). Six days treatment 
with up to lOOpM CBX also had no significant effect on cell viabilities, but 6 days 
treatment with 150|iM CBX resulted in a small decrease in cell viability to 86.5%. After 10 
days treatment with 25|llM, or 50|iM CBX there was no significant effect on cell viability, 
but 10 days treatment with 75pM, 100|iM, or 150|iM CBX resulted in progressive 
reduction in cell viability to 73.8%, 69.5%, and 0% respectively.
The effect of CBX treatment on the growth of CrFK cells is shown in Fig 8B. The 
replication indices for the drug-free control culture increased to a value of 4.4 after 3 days 
incubation, reached a plateau value of 9.1 after 6 days incubation, and fell to 6.8 after 10
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days incubation indicating some lysis of cells in over-confluent drug-free cultures at late 
times after incubation.
Three days treatment with up to lOOfiM CBX had no significant effect on the rate of 
cell growth, but treatment with 150p.M CBX impaired replication of the cell culture (RI. 
2.6). Six days treatment with 25|iM, 50jiM, 75jliM, IOOjiM, or 150|iM CBX resulted in a 
decrease in RI values to 8.0, 7.5, 6.0, and 4.0 respectively compared to the drug-free 
control. Treatment with CBX concentrations greater than 25|iM for 6 days resulted in the 
RI curve either reaching a plateau or declining. After 10 days treatment there was little 
difference between the control RI value and the RI values obtained in the cultures treated 
with up to 75jaM of CBX. Treatment with IOOjiM CBX gave an RI value of 5.1, while 
only cellular debris was present in cultures treated with 150|iM CBX for 10 days, 
suggesting complete lysis of the culture.
The data in Figures 8A and 8B show that there was no evidence for cytotoxicity 
after 3 days treatment with up to 1 OOpM CBX.
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Figure. 7A
THE EFFECT OF CCX ON CrFK
CELL VIABILITY.
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Figure. 7B
THE EFFECT OF CCX ON CrFK CELL GROWTH
(REPLICATION INDEX).
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Figure. 8A
THE EFFECT OF CBX ON CrFK
CELL VIABILITY.
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Figure. 8B
THE EFFECT OF CBX ON CrFK CELL GROWTH
(REPLICATION INDEX).
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3.1.2. THE EFFECT OF CCX. CBX . OR GL TREATMENT ON GROWTH AND
PERCENTAGE VIABILITY OF ONIOS CELLS IN CULTURE.
The effect of CCX on QN10S cell viability is shown in Fig 9A. The percentage cell 
viability of the drug-free control cultures remained at greater than 85% throughout the 10 
days incubation period.
Treatment of QN10S cells with 25p.M, or 50(iM CCX for 3 days had no effect on 
cell viability, however treatment with 75|iM, or IOOjiM CCX reduced viabilities to 86%, 
and 85% respectively. Six days treatment with 25p,M CCX had little effect on QN10S cell 
viability (93%), but treatment with 50pM, 75pM, or lOOpM reduced the cell viabilities 
dramatically (28%, 14%, and 0% respectively). Ten days treatment with 25|iM CCX 
decreased cell viability to 59.5%, while 10 days treatment with concentrations of 50pM or 
greater resulted in non-viable cultures.
The effect of CCX treatment on the growth of QN10S cell cultures is shown in Fig 
9B. The replication indices of the drug-free control progressively increased until day 7. 
After 3 days incubation the control RI was 3.7, and at 6 days the RI value was 5.0. Three 
days treatment with 25jiM CCX gave an RI value of 1.9, but treatment with 50pM, 75p,M, 
100|iM CCX gave RI values of 0.9, 0.9, and 0.8 respectively indicating complete 
impairment of cell replication from the time of drug addition. The RI curves of all drug- 
treated cultures reached a plateau between 1 and 3 days after drug treatment. At 6 days 
after treatment with 25|iM CCX the RI value was 2.3 compared with the drug-free control
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value at 8.3. After 10 days treatment with 25pM CCX the RI value was 1.35, while 
treatment with higher drug concentrations resulted in lysis of the culture.
The effect of CBX treatment on the viability of QN10S cell cultures is shown in Fig 
10A. The drug-free control was the same as that given in Fig 9A. Three days treatment 
with up to 100pM CBX gave percentage cell viabilities of greater or equal to 90%, while 6 
days treatment resulted in viabilities of 94.5%, 88%, 76%, and 62% in cultures treated with 
25pM, 50jllM, 75p,M, or 100pM CBX respectively. Ten days treatment with 25p.M, or 
50pM CBX resulted in viabilities of 84%, and 79% respectively, while treatment with 
higher drug concentrations resulted in non-viable cultures after 10 days incubation.
The effect of CBX treatment on the growth of QN10S cell cultures is shown in Fig 
10B. The drug-free control was that described in Fig 9B. After three days treatment with 
25pM, or 5 0 |liM  CBX there was no significant difference in the rate of cell growth 
compared to the drug-free control. Treatment with 75pM, or IOOjiM CBX for three days, 
however, impaired cell replication slightly (RI’s values of 1.6, and 1.3 respectively 
compared with 3.7 for control). The RI values for 50pM, and 75pM CBX reached a 
plateau value after 3 to 4 days drug treatment, indicating that the culture had stopped 
growing. Cultures treated with 100pM CBX failed to grow from the time of drug addition. 
There was no detectable effect on cell culture growth after 6 days treatment with 25|iM 
CBX. Treatment with 50|iM, or 75|iM, CBX, however, impaired cell replication (RI’s. 2.1, 
and 1.57, respectively). After 10 days treatment with 25|iM, 50p,M, or 75}iM, CBX, the RI 
values were 5.1,1.84, and 1.2, respectively, while the drug-free control RI value was 8.22.
119
The effect of GL treatment on the percentage cell viability of QN10S cells in culture 
is shown in Fig 11 A. The percentage viability of the drug-free control was greater than 
85% throughout the 9 days incubation period. Three days treatment with GL 
concentrations up to 5000p,M had no significant effect on QN10S cell viability (greater than 
85% viability). After six days treatment with up to 2000|iM GL there was no significant 
effect on cell viability, but the percentage viabilities of cultures treated with 2500|iM, 
3000|iM, 4000}iM or 5000|iM decreased to 61%, 38%, 38%, and 16% respectively. There 
was no detectable effect on the viability of QN10S cell cultures treated with 500|iM, or 
lOOOfiM GL for 9 days, but treatment with 1500|iM, 2000p,M, 2500p.M, 3 0 0 0 j iM , 
4000}iM, or 5 0 0 0 j iM  resulted in viabilities of 43.5%, 18%, 18%, 16%, 0%, and 0% 
respectively.
The effect of GL treatment on the growth of QN10S cell cultures is shown in Fig 
1 IB. The replication indices for the drug-free control culture increased progressively until 
5 days incubation (RI. 8.6), and then progressively declined to 5.45 after 9 days. Three days 
treatment with 500p,M, lOOOpM, 1500|iM, 2 0 0 0 |liM , 2 5 0 0 j iM , 3000|iM, 4000|iM, or 
5000jiM GL resulted in progressive inhibition of cell culture growth; the RI. values 
reached were 4.6, 4.2, 3.6, 2.7, 3.3, 1.7, 1.16, and 1.7 respectively. The RI curves for 
cultures treated with IOOOj iM , 1500p,M, 2000p,M, 2500|iM, 3 0 0 0 j iM , 4 0 0 0 jliM , or 5000p,M 
GL reached near plateau values or declined after 2 to 4 days incubation (RI values; 4.57, 
4.2, 3.0, 1.6, 1.3, 1.15, and 0.8 respectively). After 6 days treatment only the cultures 
treated with 500}iM GL provided evidence for cell culture growth (RI. 6.43) compared with 
the 3 day RI value of 4.6. After 9 days incubation there was no significant difference
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between the RI value obtained from the culture treated with 500fiM GL and the drug-free 
control culture, while cultures treated for 9 days with lOOOfiM, 1500pM, 2000|iM, 
2500 jiM , 3000pM, 4000|iM, or 5000 |liM GL resulted in RI values o f 5.71, 4.68, 2.17, 
1.49, 1.81, 1.60, and 1.03 respectively.
The data in Figures 9, 10, and 11 indicate that QN10S cells tolerate treatment with 
25jiM CCX, 50|iM CBX, or lOOOjiM GL for up to 3 days. Although the QN10S cell line is 
sensitive to triterpenoid-induced cytotoxicity, it was used only for titration of the FeLV-A 
virus. During virus titration any residual drug would have been diluted below these critical 
concentrations. Furthermore the exposure of QN10S cells to the drugs was limited to the 
2h virus absorption period, after which the cell layers were washed.
In conclusion, residual drug, carried over in virus titration samples is unlikely to 
induce cytotoxicity in the QN10S indicator cell line.
121
PE
RC
EN
TA
G
E 
CE
LL
 
VI
A
B
IL
IT
Y
Figure. 9A
THE EFFECT OF CCX ON QN10S
CELL VIABILITY.
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Figure. 9B
THE EFFECT OF CCX ON QN10S CELL GROWTH 
(REPLICATION INDEX).
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Figure. 10A
THE EFFECT OF CBX ON QN10S
CELL VIABILITY.
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Figure. 10B
THE EFFECT OF CBX ON QN10S CELL GROWTH
(REPLICATION INDEX).
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Figure. 11A
THE EFFECT OF GL ON QN10S
CELL VIABILITY.
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Figure. 11B
THE EFFECT OF GL ON QN10S CELL GROWTH
(REPLICATION INDEX).
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3.1.3. THE EFFECT OF CCX . OR CBX TREATMENT ON GROWTH AND 
PERCENTAGE VIABILITY OF FeA CELLS IN CULTURE.
The effect of CCX treatment on FeA cell percentage cell viability is shown in Fig 
12A. The percentage viability of the drug-free control was >90% throughout the 10 days 
incubation period. Six days treatment with CCX concentrations of up to 100|iM had no 
significant effect on FeA cell viability. After 10 days drug treatment, 25|iM, or 50pM CCX 
had no significant effect on FeA cell culture viability, while treatment with 75pM, or 
100|lM CCX reduced cell viability to 84%, and 76.5% respectively.
The effect of CCX treatment on growth of FeA cells is shown in Fig 12B. The RI 
values for drug-free control cultures increased to 38.9 on day 7, after which a plateau was 
reached. Three days treatment with up to 75pM CCX had little effect on the replication of 
FeA cell cultures; lOOpM CCX treatment, however, impaired cell culture growth. (RI. 8.7 
compared to the drug-free value of 17.3). Six days treatment with 25pM, or 50|iM had no 
effect on the rate of cell culture growth, but treatment with 75|iM, or lOOpM CCX 
impaired cellular growth (RI values of 26.6, and 17.6 respectively compared to the drug- 
free value of 31.8). With the exception of 25pM CCX the drug-treated and the drug-free 
control cultures reached a plateau after 7 days incubation. The RI value obtained after 10 
days incubation showed that treatment with up to 50|iM CCX had no effect on the rate of 
FeA cell growth, while treatment with 75|iM, or IOOjiM impaired cell replication (RI
values of 23.8, and 15.5 respectively compared to the drug-free value of 40.5)
The effect of CBX on percentage cell viability of FeA cell culture is shown in Fig 
13A. The drug-free control is the same as that shown in Fig 12A. The data shows that even
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10 days treatment with up to IOOjhM CBX had no effect on the viability of FeA cell 
cultures.
The effect of CBX on the growth of FeA cell cultures is shown in Fig 13B. The 
drug-free control is that shown in Fig 12B. The RI curves obtained for drug-treated cell 
cultures closely approximates that of the drug-free control, indicating that FeA cell growth 
is not impaired by treatment with up to IOOjiM CBX.
The data in Figures 12 (A and B) and 13 (A and B) show that significant 
cytotoxicity was not encountered when FeA cell cultures were treated with up to lOOpM 
CCX or lOOpM CBX for 3 days (the maximum duration of antiviral experiments). Clearly, 
CBX was less toxic, than CCX to FeA cell cultures.
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Figure. 12A
THE EFFECT OF CCX ON FeA
CELL VIABILITY.
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Figure. 12B
THE EFFECT OF CCX ON FeA CELL GROWTH
(REPLICATION INDEX).
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Figure. 13A
THE EFFECT OF CBX ON FeA
CELL VIABILITY.
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Figure. 13B
THE EFFECT OF CBX ON FeA CELL GROWTH
(REPLICATION INDEX).
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Concentration of CCX inhibiting cell replication bv 10%. 25%. or 50% (ICIO. IC25. IC-50) 
48h after drug treatment.
Cell Line IC10 IC25 IC50
FeA 19uM 70uM > lOOuM
QN10S 8uM 22uM 48uM
CrFK 136uM > 150uM > 150uM
Concentration of CBX inhibiting cell replication bv 10%, 25%, or 50% (IC10, IC25. IC50)at 
48h after drug treatment.
Cell Line IC10 IC25 IC50
FeA 9uM 24uM > lOOuM
QN10S 30uM 59uM > lOOuM
CrFK 115uM 140uiM > 150uM
3.1.3. THE EFFECT OF 24h CCX TREATMENT ON THE VIABILITIES OF
MADIN-DARBY BOVINE KIDNEY (MDBK). BOVINE EMBRYO LUNG 
(BEL). AND BOVINE EMBRYO KIDNEY (BEK) CELLS IN CULTURE.
The following cell lines (MDBK, BEL, and BEK) were available for experiments 
involving BHV-1. The effect of CCX treatment on the percentage viabilities of these cell 
lines is shown in Fig 14. The MDBK cell line proved to be the most CCX-tolerant of the 
three cell lines (percentage MDBK cell viability remained greater than 95%, when treated 
with up to 200|iM CCX, and fell to only 89% when treated with 300pM CCX). The BEK 
cell line also showed good tolerance to CCX treatment, with only 22% loss of cell viability 
when treated with 300|iM CCX. The BEL cell cultures, however, proved the most 
sensitive to CCX treatment and cell viability fell rapidly with increasing drug 
concentrations (only 50% of the cells were viable after 24h treatment with 300pM).
In conclusion, the MDBK cells displayed the highest level of resistance to CCX- 
induced cytotoxicity, and were selected for subsequent antiviral studies with BHV-1. The 
data in Fig 14 for MDBK cells is consistent with the earlier findings of Galt et al (1990) 
who classified the MDBK cells as CCX-resistant.
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Figure. 14
THE EFFECT OF 24 h TREATMENT WITH CCX
ON MDBK, BEL, AND BEK CELL VIABILITY.
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3.1.5. RECOVERY OF CCX-TREATED FeA AND CrFK CELL CULTURES
AFTER DRUG REMOVAL.
While even 6 days treatment of FeA and CrFK cell cultures with up to lOOpM CBX 
did not give rise to significant cytotoxicity, the situation with CCX treatment was not so 
clear. Concentrations > 50pM CCX impaired cell growth in cultures incubated for periods 
greater than those used for antiviral experiments(i.e. 2-3 days).
To investigate whether the effect of CCX was reversible, drug recovery experiments 
were performed (Material and Methods section 2.2.2.2.). The data obtained define the 
highest concentration of CCX, and the maximum time that the FeA and CrFK cell lines can 
be exposed to that concentration of drug without affecting their subsequent growth. From 
these data, concentrations of drugs were chosen for the subsequent antiviral experiments.
Sets of FeA and CrFK monolayers were treated with CCX for various periods of 
time, after which the total number of cells and the percentage cell viability was determined. 
In addition, at each time point, drug was washed from parallel sets of monolayers which 
were then overlaid with drug-free medium. After incubation for a further 5 days, cell 
viability and total cell number were determined for each culture.
3.I.5.I. REVERSIBILITY OF THE EFFECT OF CCX ON FeA CELLS IN 
CULTURE.
Table 1A shows the effect of CCX on FeA cell culture growth, and percent cell 
viability after treatment with increasing concentrations of CCX for 0, 1,2, and 3 days. The 
drug-free control shows that the total number of FeA cells in the culture approximately 
double in a 24h period, and that cell viabilities remain high ( > 90%) throughout the
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experiment. The data show that cell viability was not impaired until cultures were treated 
with 200|iM CCX or greater for 2 days or longer. Cell culture growth was significantly 
impaired as a result of 3 days treatment with lOOpM, 2 days treatment with 150|iM, or 1 
day treatment with 200[iM CCX or greater.
Table IB shows cell culture growth and percentage viability in parallel FeA cultures 
5 days after CCX removal, following 1, 2, or 3 days treatment with the drug. The drug-free 
control culture shows a pattern of decreasing rises in total cell number multipliers due to 
increasing confluence of the monolayer with time and contact inhibition of the cells,. Cell 
cultures which had been treated with up to 100|iM CCX for 3 days replicated with similar 
kinetics to the drug-free control culture. Cell cultures, which had been treated with 150pM 
CCX for 2 days, failed to replicate after drug release, even though cell viability was 95%. 
Similarly, cultures which had been treated with 200pM or 300p.M CCX for only 1 day 
failed to grow after the drug was removed, even though cell viability was > 80%.
It was concluded that the effect of treatment of FeA cell cultures with up to 150p,M 
CCX for 1 day was partially reversible, while 3 days treatment with lOOpM CCX was fully 
reversible. Thus lOOpM CCX treatment of FeA cell cultures for 3 days, or 150pM CCX 
for 1 day were taken as the upper limits for subsequent antiviral studies.
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REVERSIBILITY OF THE EFFECT OF CCX ON FeA CELLS IN
CULTURE. 
Table 1 A. The effect of CCX on FeA cell number and 
percentage viability before drug removal.
DAYS OF DRUG TREATMENT
uM CCX ZERO ONE TWO THREE
0 6* (97)** 11 (97) 33 (99) 100 (96)
50 16(96) 29 (98) 78 (96)
100 13(95) 28 (97) 43 (93)
150 10(97) 10(96) 13 (89)
200 8 (98) 6(84) 4(64)
300 8 (96) 4(58) 4(16)
* Numbers indicate the percent of total cell number in each 
culture, relative to the total number of cells in the drug free 
control at 3 days.
** Percent cell viability in each culture.
REVERSIBILITY OF THE EFFECT OF CCX ON FeA CELLS IN
CULTURE. 
Table 1 B. The effect of CCX removal on FeA cell number and 
cell viability, after 1, 2, or 3 days drug treatment.
DAYS OF DRUG TREATMENT
UM CCX ONE TWO THREE
0 14.1’ (97)" 5.2 (96) 2.7 (98)
50 14.6 (98) 5.1 (96) 3.0 (97)
100 10.3 (97) 5.8 (98) 3.9 (97)
150 5.0 (94) 1.2 (95) 1.2 (93)
200 0.7 (97) 0.6 (86) 0.6 (88)
300 0.6 (81) 0.6 (63) 0.1 (0)
* Numbers are multipliers indicating the increase in total cell 
number during the 5 day recovery period, and are relative to 
the numbers observed in individual cultures (table 1 A) after 1, 
2, or 3 days drug treatment
** Percentage cell viability.
3.I.5.2. REVERSIBILITY OF THE EFFECT OF CCX ON CrFK CELLS IN
CULTURE.
Table 2A shows the effect of CCX treatment on CrFK cell culture growth and cell 
culture viability after treatment with increasing concentrations of CCX for 0, 1, 2, or 3 
days.
The drug-free control culture shows that total CrFK cell number approximately 
doubled in 24h, and that the percentage viability in the experiment ranged from 87% to 
90%. The data show that cell viability was not affected until cultures were treated with 
200|xM CCX or greater for 2 days (76%), or 300pM CCX for 1 day (17%). Suprisingly, 
CrFK cell culture growth was impaired (RI. value of 19.6 compared to drug-free value of 
28.2), after 1 day treatment with lOOpM CCX in this experiment, but as shown in Fig 7B 
CrFK cell culture replication is not usually impaired under these conditions.
Table 2B shows cell culture growth and percentage viability in parallel CrFK cell 
cultures 5 days after CCX removal, following 1, 2, or 3 days treatment with the drug. The 
drug-free control culture shows a trend toward decreasing rises in total cell number 
multipliers with time. The percent viabilities of the drug-free culture remain > 80% 
throughout the experiment. Cell cultures which had been treated with 50|iM CCX for 3 
days, or IOOjliM CCX for 2 days grew either more rapidly, or at about the same rate as, the 
drug-free control cultures. Treatment with 150|iM CCX, or greater, however resulted in 
partial (150fxM for 1 day), or irreversible impairment of cell culture growth, even though 
cell culture viabilities generally remained at about 70%.
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In conclusion, impairment of cell culture growth caused by treatment of CrFK 
cultures with up to lOOpM CCX for 2 days is reversible. Thus lOOpM CCX treatment of 
CrFK cell cultures for 2 days was taken as the upper limits for subsequent antiviral studies.
3.1.6. PREPARATION OF AN ANTI-CCX ANTIBODY GENERATED IN 
RABBITS AND ITS DETECTION BY ELISA TESTS.
In order to investigate the intracellular location of CCX molecules in uninfected 
cells, an attempt was made to generate an antibody against CCX in New Zeland White 
rabbits. Since CCX is a relatively small molecule (Mw. 668.8) EDC was used to mediate 
an amino-carboxy coupling to link CCX via its COONa grouping to amino groups on BSA 
(Material and Methods section ).
Four New Zeland white rabbits (age 6 weeks) were injected intramuscularly with 
the CCX/BSA conjugate in the presence of Freund’s adjuvant. Rabbits 1 and 2 were 
injected with the mixture at final concentration of 500|ig CCX/rabbit, while rabbits 3 and 4 
each were injected with the mixture containing lmg of CCX. Prior to immunisation, 
rabbits were bled to collect pre-immune sera (PI), which was processed, then stored at ' 
20°C. The rabbits were injected with the CCX mixture once a month, and bled two weeks 
later, a total of 7 bleeds were taken, and after processing the immune sera were also stored 
at -20°C. To enrich the immune sera for potential anti-CCX antibodies, the serum samples 
were then passed through a BSA sepharose beads to remove antibodies directed against 
BSA proteins.
In order to detect anti-CCX antibody present in the serum samples, representative 
serum samples from bleeds 1, 2, 3, 4, 5, 6, and 7 from the four rabbits and their pre-immune
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REVERSIBILITY OF THE EFFECT OF CCX ON CrFK CELLS IN
CULTURE. 
Table 2 A. The effect of CCX on CrFK cell number and 
percentage viability before drug removal.
DAYS OF DRUG TREATMENT
uM CCX ZERO ONE TWO THREE
0 18* (94.5)" 28(90) 79 (90) 100(87)
50 27 (96.5) 70 (87) 100(82)
100 20(93) 32(91) 63 (86)
150 20 (86) 39(80) 40 (89)
200 18(95) 18(76) 24 (86)
300 17(17) 21 (9) 9 (22)
* Numbers indicate the percent of total cell numbers in each culture, relative 
to the total cell number in the drug free control at 3 days.
** Percent cell viability in each culture.
REVERSIBILITY OF THE EFFECT OF CCX ON CrFK CELLS IN
CULTURE.
Table 2 B. The effect of CCX removal, on CrFK cell number 
and cell viability after 1. 2. or 3 days drug treatment.
DAYS OlF DRUG TREA1rM ENT
uM CCX ONE TW O TH REE
0 9’ (87)** 2(83) 3 (82)
50 7(85) 2(67) 2(77)
100 7(89) 3 (78) 0.8 (88)
150 3(79) 0.62 (68) 0.8 (69)
200 2(68) 1 (69) 0.8 (57)
300 ND ND ND
* Numbers are multipliers indicating the increase in total cell 
number during the 5 day recovery period, and are relative to the 
numbers observed in individual cultures (table IB) after 1, 2, or 3 
days drug treatment.
** Percentage cell viability
ND. Cell number not determined, no viable cells observed.
sera were investigated using an ELISA protocol. CCX alone, or conjugated to KLH was 
added directly to wells in a 96 well microtitre tray, while BSA, protein-A, and ABTS 
controls were added to other wells. Protein-A and ABTS constitute the ELISA detection 
system and give a colour change in the presence of antigen + antibody reaction.
Table3 shows the values obtained for wells containing the controls. The antigen 
(CCX/KLH) alone gave negative or extremely low values, while the test serum in the 
absence of antigen gave a negative value. Various test sera in the absence of antigen, but in 
the presence BSA gave negative values. Test sera in wells coated with CCX alone (not 
bound to KLH) gave either negative values or low positive values.
The PI, from the four rabbits gave negative values for CCX/KLH coated wells, 
while the immune sera gave positive values ranging from 0.378 to 1.727 (most of the 
values were grouped around one) (table 4). The data suggest that a specific anti-CCX 
antibody was detected by ELISA.
Much time and effort was spent in attempting to detect CCX molecules in drug- 
treated uninfected cells by immunofluorescence. Several problems were encountered. The 
PI sera strongly and non-specifically labelled the cytoplasm of drug-treated MDBK and 
control cells (titrating out at 1/3200) (data not shown). In contrast the immune sera strongly 
labelled the nucleus of drug-treated cells and less strongly the nucleus of control cells. This 
nuclear fluorescence was finally determined to be non-specific (titrating out at 1/400) (data 
not shown).
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TABLE 3. DETECTION OF AN-ANTI-CCX ANTIBODY: ELISA 
CONTROLS.
SERA UNBOUND
CCX
CCX/KLH BSA PROTEIN A ABTS VALUES
B1/S3 - - + + + -0.059
B2/S3 - - + + + -0.169
B7/S3 - - + + + -0.137
PI/S3 - - + + + -0.028
B1/S3 + - - + + -0.038
B2/S3 + - - + + +0.14
B6/S3 + - - + + -0.003
PI 1 + - - + + +0.089
PI 2 + - - + + -0.063
PI 3 + - - + + -0.084
B-BLEED
S-SAMPLE
PI-PREIM M U N E SAMPLE
+ = presence in control^ experiment
- = absence in control experiment.
Values
+ = positive ELISA OD reading
- = negative ELISA OD reading
Numbers do not indicate strength of the antibody response, only its presence.
= 
negative 
values 
on 
ELISA 
OD 
readings, indicating 
the 
absence 
of the 
anti-CCX 
antibody.
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3.1.7. INVESTIGATION OF THE EFFECT OF CCX ON MDBK AND CrFK
CELLS. USING GOLGI-SPECIFIC ANTI-P58 ANTIBODY.
Previous studies have suggested that CCX impaired glycosylation of HSV, VSV, 
and SFV glycoproteins (Dargan et al., 1992). The effect of CCX treatment on the Golgi 
apparatus of uninfected CrFK or MDBK cells was investigated using an antibody directed 
against the trans-Golgi p58 protein in immunofluorescence experiments. P58 is localised in 
the trans cisternae of the Golgi apparatus where it binds to microtubules. Presence of p58 
in the Golgi is thought to provide anchorage site for microtubules on the outer surface of 
the Golgi (Bloom, G., and Brashear, T., J. 1989)
MDBK and CrFK cells were seeded at 2xl05 cells/well on glass coverslips in a 24 
well Nunc tray. Following overnight incubation at 37°C, the growth medium was replaced 
with either drug-free medium or medium containing CCX. After 5h incubation at 37°C the 
cells were processed for immunofluorescence studies using the anti-p58 antibody as a tag 
for the Golgi apparatus, and FITC-conjugated anti-mouse antibody to detect the p58
Representative micrographs giving the results of these experiments are shown in 
Figures 15 and 16. In the absence of CCX, p58 gave perinuclear (Golgi) fluorescence with 
both CrFK and MDBK cells (Figs 15A, and 16A respectively). In the case of MDBK cells, 
however, there was also some diffuse cytoplasmic fluorescence (Fig 16A). After treatment 
of either cell line with 300|iM CCX for 5h there was a reduction in perinuclear (Golgi) and 
cytoplasmic (MDBK cells only) fluorescence (Figs 15B and 16B). In the MDBK cells there 
was a concomitant manifestation of punctate fluorescence in the nucleus of cells (16B). 
Punctate nuclear fluorescence was also observed in CrFK cells but only in small percentage
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of cells (15B). The reduction in the p58 tagging of the Golgi suggests an effect of the drug 
on that organelle.
Commercially available antibody directed against another Golgi marker protein (p- 
cop) failed to tag any structure in MDBK or CrFK cells even in the absence of CCX.
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FIGURE 15.
Immunofluorescent labelling of Golgi apparatus of CrFK cells with anti-p58 antibody.
A. Drug-free.
B. Drug-treated.
Drug concentration used was 300uiM CCX
Total of 300 cells were counted of which in drug treated and untreated 89% show ed  
perinuclear staining.
B
FIGURE 16.
Immunofluorescent labelling of Golgi apparatus of MDBK cells with anti-p58 
antibody.
A. Drug-free.
B. Drug-treated.
Drug concentration used was 300uM CCX
Total of 300 cells were counted of which 91% of untreated cells showed p e rin u c lea r  
or cytoplasmic staining, while i n  drug treated cells only 11% showed p e r in u c le a r  or
cytoplasmic staining.
* >"sK
3.1.8. INVESTIGATION OF THE EFFECT OF OUABAIN IN COMBINATION
WITH CCX. ON THE P58 GOLGI STAINING OF MDBK CELLS.
One of the known effects of triterpenoid treatment of cells is perturbance of Na+/K+ 
ATPase regulation, resulting in decreased intracellular level of Na+ and concomitant 
increase in the level of intracellular K+. In order to investigate whether the Na+/K+ ATPase- 
induced ion fluxes played a role in the effect of the drug on the Golgi apparatus, the effect 
of the Na+/K+ATPase inhibitor ouabain on the p58 Golgi p ro te in  was investigated in 
immunofluorescence experiments either by itself or when in combination with CCX.
MDBK cells were seeded at 2xl05 cells/well on glass coverslips in 24 well Nunc 
trays. After overnight incubation the cells were maintained in the absence of any drug or 
overlaid with medium containing, CCX, ouabain, or ouabain and CCX in combination and 
incubated at 37°C for 5h. The cells were then processed for immunofluorescence with the
antibody against the p58 Golgi protein as previously described.
Figures(17A, 17B, and 17C) show representative micrographs obtained from this 
experiment. In the absence of any drug cytoplasmic and perinuclear(Golgi) staining are 
evident (17A). Cells treated with CCX alone lacked perinuclear or cytoplasmic (Golgi) 
staining (17B). The combination of CCX and Ouabain resulted in the detection of 
cytoplasmic and perinuclear (Golgi) staining (17C).
The data suggest firstly that the modulation of Na+/K+ ATPase activity by CCX is 
involved in the effect of the drug on the Golgi apparatus, and secondly that Ouabain 
ameliorates the effect of CCX treatment on the Na+/K+ ATPase activity.
Ouabain alone had no effect (data not shown).
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FIGURE 17.
Immunofluorescent labelling of Golgi apparatus of MDBK cells with anti-p58 
antibody.
A-Untreated
B-CCX-treated
C-CCX + Ouabain-treated
Drug concentration used was 300uM CCX
Total of 300 cells were counted of which 71 % showed perinuclear staining in the 
untreated cells. In Ouabain + CCX-treated cells 78% showed perinuclear staining, 
while in cells treated with CCX only < 1 % showed perinuclear staining. 
Ouabain alone had no effect on the pattern of perinuclear staining of the cells and 
resembled the untreated cells (data not shown).

3.1.9. DETECTION OF THE ACIDIC COMPARTMENTS OF MDBK CELLS
TREATED WITH CCX. USING DAMP/ANTI-DAMP SYSTEM.
Some cell types have acidic trans-Golgi compartments. To investigate whether 
MDBK cells have an acidic Golgi compartment and to determine the effect of CCX 
treatment on acidic compartments in these cells, the cells were treated with DAMP [3-92, 
4-dinitroanilino 0-3'-amino-N-methyldipropylamine]. DAMP permeates the cells and 
precipitates at low pH; when the cells are washed the DAMP is removed from the cells 
except where it has been precipitated in acidic compartments. The acidic compartments, so 
tagged were detected by monoclonal anti-DfWand visualised by immunofluorescence.
Figure (18) shows representative micrographs obtained from this experiment. In the 
absence of CCX perinuclear immunofluorescence was evident, although many discrete 
spots throughout the cytoplasm were also labelled (18A). The tagged structures illuminated 
by the FITC-anti DAMP antibody are expected to include Golgi apparatus, trans-Golgi 
transport vesicles, endosomes, and lysosomes (18A). In CCX treated cell cultures however 
no perinuclear (Golgi) staining was evident although punctate cytoplasmic staining was 
seen (Fig 18B).
As the MDBK cells displayed perinuclear fluorescence typical of the Golgi 
apparatus, it is concluded that MDBK cells have an acidic Golgi compartment. The 
fluorescence pattern obtained in the presence of CCX can be explained by the suggestion 
that CCX treatment neutralises the acidic compartments of the Golgi apparatus, or that the 
acidic compartments of the Golgi apparatus have been dispersed in the form of multiple 
vesicles and does not exist as in the form of a discrete trans-Golgi stack.
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FIGURE 18.
Immunofluorescent labelling of MDBK cells with DAMP, anti-DAMP antibody.
A.untreated
B.CCX-treated
Drug concentration used was 300uM CCX
Total of 300 cells were counted of which 88% of untreated cells showed perinuclear 
staining while, <1% of drug-treated cells showed perinuclear staining.
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3.2. INVESTIGATION OF THE ANTIVIRAL EFFECT OF
TRITERPENOID COMPOUNDS ON THE REPLICATION 
OF FELINE LEUKAEMIA VIRUS TYPE-A (FeLV-A).
3.2 .1 . ONE STEP GROWTH CURVE OF FeLV-A IN RESTING AND NON­
RESTING FeA CELL CULTURES.
As triterpenoid drug treatment can impair the replication of FeA cells [e.g. one day 
treatment with 150pM CCX inhibited FeA cell culture growth by 10% (table 1 A) ] without 
having an effect on cell culture viability (table 1A), it was important to investigate the 
replication of FeLV-A in dividing and non-dividing FeA cell cultures.
FeA resting cell cultures were prepared as described in Material and Methods, 
(section 2.2.4.). FeA cell monolayers [2xl05 cells/well (non-resting cells), and 5xl05 
cells/60mm tissue culture plate (resting cells)] were infected with FeLV-A at a m.o.i. of 5 
p.f.u./cell. After the absorption period the infected monolayers were washed 3 times with 
PBS, and incubated at 37°C. At 0, 3, 6, 9, 12, 24, 36, and 48h PI, the culture medium was 
pipetted-off the infected cells, and the infectivity titrated on QN10S cell monolayers.
Fig 19 shows the one step growth cycle of FeLV-A in resting and non-resting FeA 
cell cultures. The curve obtained for FeLV-A infected non-resting cell cultures shows that 
the virus exited the eclipse phase at about 12h PI, replicated exponentially until about 24h 
PI yielding 0.44 p.f.u./cell, and reached a maximum infectious yield of 3.7 p.f.u./cell at 48h 
PI. In other FeLV-A one step growth experiments (data not shown) the growth curve 
reached a plateau at 24h PI (yielding 6.5 p.f.u./cell and reaching 8 p.f.u./cell after 48h PI),
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therefore it was concluded that the length of the FeLV-A growth cycle in FeA cell cultures 
was between 24-48h PI In resting cell cultures, infectious progeny virus was not detected 
before 24h PI, but thereafter there was a small increase (0.002 p.f.u./cell) in the infectious 
virus yield at 36-48h PI.
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FIGURE. 19
ONE STEP GROWTH OF FeLV-A IN 
RESTING AND NON-RESTING FeA 
CELL CULTURES.
7 20 2 4 4 8 6 01 2 3 6
NON-RESTING
RESTING
TIME POST-INFECTION (h)
3.2.2. FeLV-A INFECTIOUS VIRUS YIELD/ CCX: CBX: AND GL 
DOSE-RESPONSE EXPERIMENTS.
Infectious virus yield, dose-response experiments were performed firstly to 
determine whether or not FeLV-A replication was impaired by the presence of triterpenoid 
compounds in the culture medium, and if so, to investigate the kinetics of inhibition of 
virus replication. Finally it was of interest to compare the dose-response curves obtained 
for each of the drugs; CCX, CBX, and GL.
FeA cell monolayers were seeded on 24 well tissue culture trays at 2 xlO5 cells/well. 
The monolayers were then infected with FeLV-A at a m.o.i. of 5 p.f.u./cell. After the virus 
absorption period the cells were overlaid with drug-free medium, or medium containing 
various concentrations of drug and incubated at 37°C. At 24h PI the cell-released (CR) and 
cell-associated (CA) virus fractions were harvested (Material and Methods section 2.2.5.1).
Although retroviruses (FeLV-A and FIV) assemble and bud from the plasma 
membranes of cells, it was considered possible that the effect of the drugs on the Golgi 
apparatus might inhibit intracellular transport of the vims glycoproteins and result in 
intracellular assembly of infectious virus particles. Such a situation was found with Semliki 
Forest Vims (SFV), where the CA titre increased with dmg concentration (Dargan et al., 
1992). Figure 20 shows the effect of CCX treatment on the 24h infectious yield of FeLV-A 
from FeA cell cultures. CR and CA infectious vims yield titres in the dmg-free control 
cultures were 8.7xl04 p.f.u./ml, and 1.05xl04 p.f.u./ml respectively. Treatment with 25|iM 
CCX resulted in 7 and 1.6 fold reductions in CR and CA infectious titres respectively. 
Treatment with 50pM, 75pM, or 100pM CCX resulted in 11.5, 12.6 and 24 fold reductions 
in CR infectious virus titres respectively. CA infectivity also decreased in a dose-dependent
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manner; treatment with 50pM, 75pM, or lOOpM CCX resulted in 1.7, 3.7, and 3.5 fold 
reductions in infectious virus yield respectively. Treatment with 150pM CCX resulted in a 
more pronounced decrease in CR and CA infectious virus yield titres (155, and 191 fold 
reductions respectively). The data show; that CCX has antiviral activity against FeLV-A, 
inhibiting virus replication by up to 190 fold; that the CR infectivity diminishes at a faster 
rate than the CA infectivity (except at 150pM CCX); and that the kinetics of the CR curve 
are tri-phasic, i.e. a pronounced loss of infectivity at low concentration, followed by a near 
plateau in the curve until about lOOpM CCX, then a greater decrease with 150pM CCX..
Fig 21 shows the effect of CBX treatment on the 24h infectious yield of FeLV-A 
from FeA cell cultures. The CA and CR infectious virus yields from drug-free control 
cultures were those given in Fig 20. Treatment of FeLV-A infected cell cultures with 25pM 
CBX resulted in 11, and 2.3 fold reductions in the CR and CA infectious virus yields 
respectively. Treatment with 50p,M, 75pM, or lOOpM CBX resulted in 6.6, 14.7, and 17.1 
fold reductions in the CR infectivity respectively, and 4.6, 3.5, and 8.1 fold reductions in 
the CA infectivity respectively. Treatment with 150pM CBX resulted in 102 and 12 fold 
reductions in CR, and CA infectious virus yields respectively.
The data show that CBX treatment of FeLV-A infected FeA cell cultures inhibited 
virus replication by up to about 100-fold. The kinetics of the CR dose-response curve was 
similar to that obtained after treatment with CCX. CR infectivity decreased at a faster rate 
than CA infectivity, and the CR curve displayed the tri-phasic kinetics seen with CCX 
treatment. In this experiment, uninfected cultures were treated with CBX in parallel; these 
controls for CBX-induced cytotoxicity revealed that cell culture viability remained > 90%
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(for all of the drug concentrations), while replication indices of 1.5, 1.6, 1.4, 1.2, 1.6, and
I.2 were obtained for FeA cell cultures treated with OpM, 25|llM, 50jiM, 75|jM, lOOpM or 
150p,M CBX respectively. The replication indices suggest that it is unlikely that the more 
pronounced decrease in infectious yield of FeLV-A observed after treatment with lOOpM- 
150|iM CBX can be explained simply by inhibition of the growth of FeA cell culture.
Figure 22 shows the effect of GL treatment on the 24h infectious virus yield of 
FeLV-A from FeA cell cultures. The infectious virus yields from the CR and CA fractions 
for the drug-free control cultures were 1.34xl05 p.f.u./ml, and 2xl04 p.f.u./ml respectively. 
Treatment of the infected FeA cell cultures with 500|iM GL resulted in 5.6 and 3 fold 
reductions in CR and CA infectious virus yields respectively. Treatment with IOOOjiM, 
1500jxM, 2000pM, or 2500}iM GL resulted in decreases in the CR infectivity of 5.9, 6.5,
II.1, and 128 fold respectively, while decreases in CA infectivity were 8, 4.7, 7.9, and 33 
fold respectively. Uninfected FeA control cell cultures treated in parallel with GL revealed 
that cell culture viability was > 90% for all drug concentrations, and RI values were 2.5, 
1.7, 1.7, 1.4, 1.5, and 1.0 for cultures treated with OpM, 500pM, lOOOpM, 1500|iM, 
2000}xM, or 2500pM GL respectively.
The kinetics of the CR dose-response curve were similar to those obtained with 
infected FeA cell cultures treated with CCX, or CBX. The CR curve kinetics were tri­
phasic, reaching a plateau when treated with > 500|iM GL and decreasing again when 
treated with 1500|iM GL. Although the decrease in CR infectivity was greater than the CA 
infectivity decease when cell cultures were treated with 500jiM GL, the CA titre reduction
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was greater than the CR titre reduction when the cultures were treated with lOOOjxM or 
2000|liM GL.
It is concluded, from the data shown in Figures 20, 21, and 22 that each of the 
triterpenoid compounds has antiviral activity against FeLV-A. Treatment of the infected 
cell cultures with 150p,M CCX or CBX resulted in an infectious yield reduction of about 
100-150 fold, while treatment with 2500}iM GL gave 128 fold reduction.
r *
In general, the infectivity in the CR fractions decreased at a faster rate, than the CA 
infectivity. At least two explanations can be given for this; Firstly the drug might have 
virucidal activity and so directly inactivate virus particles in the culture medium, secondly 
the drug might impair release of infectious virus from the infected cell surface.
The kinetics of the CR dose-response curves obtained for each drug were similar; an 
initial pronounced decrease in the CR titre when cell cultures were treated with low 
concentrations of drugs, followed by a near plateau in the curve when treated with higher 
concentrations. Two possible explanations present themselves; Firstly there might exist a 
low level population of CCX resistant (CCXr) virus in the virus stock used. Secondly the 
drug might inhibit a function which enhances, but is not strictly essential for virus growth.
It is possible that impairment of cell culture replication might have contributed to 
the loss of CR and CA infectivity in the cell cultures treated with 150|iM CCX or CBX. 
150|iM CCX or CBX were the limiting concentrations determined from earlier cytotoxicity 
tests, and it is probable that the physiological condition of the cell cultures used in each 
experiment could affect the precise concentration of the drugs at which cell culture growth 
is impaired.
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FIGURE. 20
The EFFECT OF CCX TREATMENT ON 
THE 24H INFECTIOUS YIELD.
OF FeLV-A FROM FeA CELLS.
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The effect of CCX, or CBX on the 24h 
infectious yield of FeLV-A 
from FeA cells.
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FIGURE. 21
THE EFFECT OF CBX TREATMENT ON 
THE 24H INFECTIOUS YIELD.
OF FeLV-A FROM FeA CELLS.
Concentration of the drug inhibiting FeLV-A cell released yield bv 25%, 50%, or 90% fF im  
ED50. ED90)
Compound ED25 ED50 ED90
CCX 3.9uM 8uM 42uM
CBX 2.8uM 5.6uM 24uM
GL 48uM 191uM 2000uM
Determination of selectivity index of CCX and CBX on FeLV-A yield.
Compound IC25 ED25 selectivity index
CBX 24uM 2.8uM 8.6
CCX 70uM 3.9uM 18
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FIGURE. 22
THE EFFECT OF GL TREATMENT ON 
THE 24H INFECTIOUS YIELD.
OF FeLV-A FROM FeA CELLS.
uM GL
3.2.3. ESTIMATION OF THE VIRUCIDAL ACTIVITY OF CCX.
CBX. AND GL AGAINST FeLV-A.
Drug-dose response experiments showed that CR infectivity decreased more 
rapidly than CA infectivity in cultures treated with increasing concentrations of drug: 
virucidal activity was a possible explanation. To investigate whether CCX, CBX, or GL 
had virucidal activity against FeLV-A; Virus stocks were treated with CCX or CBX ( 
150|iM, or 300|iM), or GL (750|iM, or 1500p,M) for 24h at either 4°C, or 37°C. The data 
shown in table 5 shows that treatment with 150p,M CCX or 150|xM CBX, or 750(i,M GL at 
4°C resulted in 1.7, 1.8, and 1.5 fold reductions in FeLV-A infectivity respectively, while 
treatment with double the concentration of drugs (300|iM CCX or CBX, or 1500|iM GL) at 
4°C approximately doubled the virucidal effect, giving reductions of 4, 3.6, and 2.5 fold 
respectively. Treatment of the virus stock with CCX or CBX (150p,M), or GL (750pM) at 
37°C resulted in 2.3, 1.8, and 1.5 fold reductions in infectivity. Doubling the drug 
concentrations had little further effect (2.7, 2, and 2.1 fold reductions respectively).
In conclusion, the triterpenoid drugs exhibit small, but detectable, virucidal activity 
against FeLV-A (loss of infectivity ranging 1-4 fold). While the temperature of incubation 
had no effect on the virucidal activity in samples treated with 150jiM CCX or 150|iM CBX 
or 1500|iM GL, doubling the drug concentrations doubled the virucidal activity at 4°C but 
had little effect on virucidal activity at 37°C. The magnitude of the virucidal activity was 
too low (by itself) to account for the differences observed between CR and CA infectivity 
in dose-response experiments, suggesting that other factors (impaired release) were also 
involved.
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TABLE 5. FeLV-A: VIRUCIDAL ACTIVITY OF CCX. CBX. 
AND.GL DETERMINED AFTER 24H INCUBATION AT 4°C 
(A) OR 37°C (B).
DRUG TITRE FOLD REDUCTION % REDUCTION*
Drug free Oh 1.42 xlO7 p.f.u^ml - -
Drug free 6.6 x 106 p.f.u./ml - -
CCX-150(i.M 3.95 x 106 p.f.u./ml 1.7 40.15
CCX-300p.M 1.65 x 106 p.f.u^ml 4 75
CBX-150|iM 3.65 xlO6 p.f.u7ml 1.8 44
CBX-300(iM 1.85 x 106 p.f.u./ml 3.6 72
GL-750(iM 4.35 x 106 p.f.u./ml 1.5 34.1
GL-1500|iM 2.65 x 106 p.f.uJml 2.5 59.8
DRUG TITRE FOLD REDUCTION % REDUCTION*
Drug free Oh 1.42 x 107 p.f.u7ml - -
Drug free 5.25 x 106 p.f.uVml - -
CCX-150|iM 2.25 x 106 p.f.uJml 2.3 57.14
CCX-300(iM 1.95 x 106 p.f.uV ml 2.7 62.85
CBX-150|iM 2.85 x 106 p.f.u7ml 1.8 45.71
CBX-300|liM 2.65 x 106 p.f.u./ml 2.0 49.5
GL-750pM 3.55 x 106 p.f.uVml 1.5 32.8
GL-1500pM 2.45 x 106 p.f.uiml 2.1 53.3
* Relative to the drug-free titre after 24h incubation.
3.2.4. PURIFICATION OF FeLV-A BY FICOLL DENSITY GRADIENT
CENTRIFUGATION. AND INVESTIGATION OF THE SDS PAGE 
POLYPEPTIDE PROFILE OF PURIFIED VIRUS.
In order to identify FeLV-A protein bands in FeA infected cell protein extracts, it 
was necessary to obtain an SDS PAGE polypeptide pattern from purified FeLV-A virion 
proteins. FeA cells were seeded at 2xl07 cells/roller bottle. After overnight incubation, 
the cell monolayers were infected in the usual way with 1.4xl07 p.f.u./roller bottle, and 
incubated at 37°C. The infected FeA cell cultures were harvested 5 days later as described 
in Material and Methods (section 2.2.3.1). The infected tissue culture medium was clarified 
by low speed centrifugation, after which virus particles were pelleted by centrifugation at 
12000 r.p.m., at 4°C, for 3h, in a Sorvall GSA rotor. The resuspended virus pellet was 
layered on top of a 5-15% Ficoll gradient, which was then centrifuged to obtain a purified 
virus preparation (Material and Methods section 2.2.3.4.). A representative example of the 
density gradient banded virus preparation is shown in Figure 23. The material from the 
three visible bands were removed from the tube by side puncture and then pelleted 
(Material and Methods section 2.2.3.4.). The banded materials were examined by electron 
microscopy. The top band was composed of cellular membrane debris; the middle band 
contained spherical FeLV-A particles (Fig 24) at 2.9xl09/ml and a tailed form of FeLV-A 
particles at 5.32x1011 /ml. The bottom band contained only the tailed form of FeLV-A 
particles at 1.1 lx 10n /ml (Fig 25). The infectivity associated with each band was as 
follows; top band 4xl04 p.f.u./ml, middle band 5xl06 p.f.u./ml, and bottom band 2.2xl06 
p.f.u./ml. Particle/p.f.u. ratios calculated for the vims bands Middle 1.05x 105/1; and 
Bottom 5.05x105/l reveal that most of the virus particles were non-infectious.
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FIGURE 23.
FeLV-A particles purified on a 5-15% Ficoll gradient. (Bands 1, 2, and 3 are 
identified by arrows).

FIGURE 24.
Electron micrograph of purified Ficoll-banded FeLV-A virus, middle band. 
Scale bar lOOnm.

FIGURE 25.
Electron micrograph of purified Ficoll-banded FeLV-A virus, bottom band. 
Scale bar lOOnm.

FIGURE 26.
Silver-stained polypeptide profiles of purified FeLV-A particles obtained on a 10% 
SDS PAGE minigel.
Virus particles were banded on Ficoll gradients.
Molecular weight marker (M) (lane 1), top band (lane 2), middle band (lane 3) and bottom 
band (lane 4)
•  Identified viral proteins (VPs).
GP70
P65
The banded materials were solubilized with SDS PAGE extraction buffer and 
electrophoresed on a 10% SDS PAGE minigel. The resulting gel was silver-stained and is 
shown in Figure 26. The material in the top band contained mostly cellular proteins, 
although some FeLV-A proteins (particularly gp70) were present in small amounts. The 
material in the middle band contained the FeLV-A virion proteins gp70, p65, p27, p i5, and 
plO, but was also contaminated with cellular proteins (as determined by comparison with 
the polypeptide profile of the top band). The bottom band seemed to contain less protein 
overall, although the FeLV-A proteins were clearly identified against a background of 
cellular protein contamination.
Western-immunoblotting (Material and Methods section 2.2.6.3.7) of FeLV-A 
proteins from the material in the middle band using an infected cat sera, confirmed the 
identification of the FeLV-A gp70, p27, and p 15 bands (Fig 27, lane 8). The antiserum 
failed to recognise the band of 65K which is probably the p65 FeLV-A reverse transcriptase 
protein (RT).
142
3.2.5. SDS PAGE POLYPEPTIDE ANALYSIS OF FeLV-A INFECTED FeA CELL
EXTRACTS
In order to investigate the inhibition of FeLV-A replication in the presence of 
triterpenoid drugs, it was necessary to study the synthesis and processing of FeLV-A 
proteins in infected cells. This proved a difficult task.
Initial attempts were made to identify FeLV-A proteins in infected cell extracts, by 
infecting the cell cultures at a m.o.i. of 3-5 p.f.u./cell, labelling with 35S methionine for 24h 
or 48h, followed by SDS PAGE analysis. However FeLV-A proteins could not be 
identified in the autoradiographs. Another attempt was made using the same m.o.i. and 
radiolabelling conditions; except that the infected cell proteins were extracted with 
immunoprecipitation extraction buffer, immunoprecipitated using an FeLV-A-infected cat 
serum, and analysed by SDS PAGE. However, again no virus proteins were detected, even 
after prolonged exposure of the gels. An alternative approach using western- 
immunoblotting was then investigated; FeA cell cultures were infected with FeLV-A at 
m.o.i. of 5 p.f.u./cell, incubated at 37°C for 24h or 48h, the infected cell extracts 
electrophoresed on SDS PAGE gels, and the FeLV-A proteins labelled by western- 
immunoblotting using the FeLV-A-infected cat serum. As before, no FeLV-A proteins 
were detected. The experiment was again repeated but FeLV-A proteins were first 
immunoprecipitated, electrophoresed on SDS PAGE gel, and then western- immunoblotted 
using the infected cat serum, but again no FeLV-A proteins were detected. It was 
concluded that infection of the cell cultures with FeLV-A at a m.o.i. of 5 p.f.u./cell 
followed by incubation for 48h either resulted in a poor infection, or yielded insufficient
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viral proteins for analysis. Consequently, we were forced to use persistently infected cell 
cultures in order to obtain infected cell polypeptide profiles on SDS PAGE gels.
Figure 27 shows western-immunoblotting of the persistently infected or MI FeA cell
r
cultures. Persistently infected cell cultures were pre-treated with the drug (as appropriate), 
washed 3 times, and overlaid with growth medium containing either no drug or 50pM, or 
100|iM CCX. The western blot showed that there was no significant difference in the 
quantities, or the apparent molecular weights of FeLV-A proteins (gp70, p27, or p i5) 
produced in FeA cell cultures treated with increasing concentrations of drug. As expected, 
the anti-FeLV-A antibody failed to tag any protein band in extracts of MI cell cultures.
It is concluded from Fig 27 that the drug had either, no significant effect on FeLV- 
A protein synthesis, or more probably, that the pool of pre-formed FeLV-A proteins in 
persistently infected cell cultures masked any effect of the drug.
1 4 4
FIGURE 27.
Western blot of the polypeptide profiles obtained on a 10% SDS PAGE gel of FeLV-A 
infected (lanes 2, 3, and 4) and MI (lanes 5, 6, and 7) FeA cells.
Virus bands were identified using FeLV-A infected cat serum.
Cells were either drug-free (lanes 2 and 5), or treated with 50 , or 100(iM CCX 
(lanes 3 and 6; 4 and 7 respectively). The polypeptide profiles of purified FeLV-A is shown 
in lane 8, and the molecular weight markers in lane 1.
•  Identified viral proteins (VPs).
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3.2.5.I. SDS PAGE ANALYSIS OF RADIOLABELLED PROTEINS IN PROGENY
VIRUS PARTICLES. AND IN THE CELL EXTRACTS OF FeLV-A 
PERSISTENTLY INFECTED CELL CULTURES TREATED WITH CCX.
In order to investigate the effect of CCX on nascent protein synthesis in persistently 
infected FeA cell cultures, 35S*methionine/cysteine was used to label the infected cell 
proteins. The virus particles, made in the presence of the drug and extruded to the tissue 
culture medium, were pelleted and their polypeptide composition investigated by SDS 
PAGE.
Figure 28A, shows the polypeptide profile of mock-infected (MI) FeA cell cultures, 
treated with increasing concentrations of CCX. Each gel track was loaded with an equal 
number of c.p.m. Treatment with lOOpM CCX resulted in a decrease in the intensities of 
the 42K, 30K, and 2 IK cellular bands. Figure 28B, shows the polypeptide profile of the 
infected cell extracts, treated with increasing concentrations of CCX. The only FeLV-A 
band which could be unambiguously identified was gp70, and this appeared to be largely 
unaffected, when treated with up to 125(iM CCX.
Figure 29, shows the polypeptide profile of the material pelleted from the MI and 
the FeLV-A persistently infected cell cultures. Due to the low level of radioactivity in the 
pelleted samples these were investigated by western-immunoblotting using the infected cat 
serum. Little, or no, labelling of the material pelleted from the MI culture supernatant was 
detected (Fig 29A). In the western blot profile of the purified FeLV-A virus control, gp70, 
P27, and p i5 were identified by the FeLV-A antiserum (Fig 29B). The intensity of the 
gp70 band slightly decreased with increasing concentrations of drug, while the p i5 band 
appeared to be unaffected by drug treatment. The P27 band barely detectable in the drug-
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free control, was clearly present in the purified virus polypeptide profile, and in the extracts 
from virus made in the presence of 25jiM CCX.
The amount of gp70 in infected cell extracts was virtually unaffected by CCX 
concentrations up to 125|iM (Fig 28B), but the amount of gp70 in the pelleted virus 
particles was decreased at IOOjiM CCX (Fig 29 B), suggesting that less gp70 proteins was 
incorporated into the progeny virus particles. The alternative explanation that fewer virus 
particles were present at the higher drug concentration samples seems unlikely, given that 
equal number of c.p.m. were loaded in each gel tract.
FIGURE 28.
Polypeptide profile obtained on a 10% SDS PAGE gel of 35S-methionine/cysteine 
labelled proteins in the extracts from MI (A), or FeLV-A infected (B) FeA cells.
Cells were either drug-free (lane 1, Figures A and B), or treated with 25, 50, 100, or 
125 juM CCX (lanes 2, 3, 4, 5, and 6 respectively, Figures A and B).
The location of the molecular weight markers (M) (non-radiolabelled) resolved on the same 
gel, have been transferred from the dried gels.
A Identified viral proteins.
•  Bands of unknown origin.
M
•200
• 97
• 69
• 46
• 30
•  21 
•14
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FIGURE 29.
Polypeptide profiles obtained on a 10% SDS PAGE gel of 35S-methionine/ 
cysteine labelled proteins pelleted from the culture medium of MI (A), or FeLV-A 
infected (B) Fe A cells.
Virus bands were identified by western immunoblotting using FeLV-A infected cat 
serum. Cells were either drug-free or treated with 25, 50, 100, 125 JJ.M CCX (lanes 1, 2, 3, 
4, 5 figure A and lanes 2, 3, 4, 5, and 6 Figure B respectively).
The polypeptide profile of purified FeLV-A is shown in lane 1 of Figure B.
The location of molecular weight markers (M) (non-radiolabelled) resolved on the same gel 
have been transferred from the dried gels.
Identified viral proteins (VPs).
A1 2 3 4 5
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3.3. INVESTIGATION OF THE ANTIVIRAL EFFECT OF
TRITERPENOID COMPOUNDS ON THE REPLICATION OF 
FELINE IMMUNODEFICIENCY VIRUS (FIV).
3.3.1. THE EFFECT OF CCX AND CBX TREATMENTS ON THE PLAOUING 
EFFICIENCY OF FIV ON CrFK CELL MONOLAYERS.
Due to the low titres generally obtained for FIV stocks, dose-response curve 
experiments of the type used to investigate FeLV-A could not be performed. To investigate 
whether the triterpenoid compounds had antiviral activity against FIV, and to obtain a 
measure of antiviral potency, the CCX and CBX ED50 concentrations for FTV were 
determined.
CrFK cells were seeded on 24 well Nunc trays at lxlO5 cells/well and incubated 
overnight at 37°C to form a monolayer. The monolayers were infected with FIV at 100 
p.f.u./monolayer. After the virus absoiption period, unbound virus was removed by 
washing, and the cells overlaid with DMEgM 10%FC containing OjiM, 25(iM, 50pM, 
75pM, lOOpM, or 150pM CCX or CBX. The monolayers were incubated at 37°C for 4 
days, after which the cell cultures were fixed and virus plaques identified by immuno- 
staining.
The results are shown in Fig30. Treatment with CCX or CBX resulted in a 
progressive drug-dose dependent reduction in the number of virus plaques produced. The 
ED50 concentrations obtained were 75|lM, and 101 jiM for CCX and CBX respectively. 
Thus CCX was more potent than CBX in inhibiting FIV plaques. The tri-phasic kinetics of
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the plaquing efficiency curves (particularly that of CBX curve) are reminiscent of the tri­
phasic kinetics of the CCX, CBX, and GL dose-response curves obtained for FeLV-A 
(Figures; 14, 15, and 16 respectively). Treatment with 25|iM CCX or CBX resulted in an 
initial decrease in plaquing efficiency of 27%, and 31% respectively. At intermediate 
concentrations of CCX or CBX the rate of decrease in plaquing efficiency was slowed until 
cultures were treated with 150|iM CCX or CBX, when there was a large decrease in plaque 
number. It is concluded that CCX and CBX have antiviral activity against FTV, and that 
CCX is slightly more potent than CBX.
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Concentration of the drug inhibiting FIV yield bv 25%, 50%, or 90% (ED25. EDSO^  F.nor))
Compound ED25 ED50 ED90
CBX 21uM lOluM N.D.
CCX 24uM 75uM 121uM
N.D. Not Determined
Determination of selectivity index of CCX and CBX on FIV vield.
Compound IC25 ED25 selectivity index
CCX 140uM
/
24uM 5.8
CBX N.D. 21uM N.D.
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Figure. 30
THE EFFECT OF CCX, AND CBX ON 
PLAQUING EFFICIENCY OF FIV.
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3.3.2. ESTIMATION OF THE VIRUCIDAL ACTIVITY OF CCX . CBX. OR
GL AGAINST FIV.
In order to investigate whether CCX, CBX, or GL had virucidal activity against 
FIV, virus particles were mixed with CCX, or CBX (150|iM, or 300|llM), or GL at (750|iM, 
or 1500|iM) for 24h at 4°C or 37°C. Virus preparations treated with 150|llM CCX, 150|iM 
CBX, or 750|liM GL at 4°C were decreased 2, 2.9, and 3.9 fold respectively (table 6). When 
CCX or CBX concentrations were doubled to 300p,M the decrease in infectivity rose to 3.6 
and 3.9 fold reductions respectively. Doubling the GL concentration had no further effect 
on FIV infectivity. The virucidal activity was generally greater for virus suspensions 
incubated at 37°C; 150|iiM CCX, 150jiM CBX, or 750pM GL gave 3.4, 2.8, and 4.4 fold 
reductions respectively. Doubling the drug concentrations at 37°C increased the loss of 
infectivity to 10 fold for CCX, 6.1 fold for CBX, and 5.8 fold for GL.
Thus, the triterpenoid drugs exhibit virucidal activity against FTV ranging in 
magnitude, from 2-10 fold in these experiments. Comparison of these data with those of 
table 3 shows that FIV is more sensitive than FeLV-A to the virucidal activity of 
triterpenoid drugs.
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TABLE 6. FIV: VIRUCIDAL ACTIVITY OF CCX. CBX. AND GL 
nFTERMINED AFTER 24H INCUBATION AT 4°C (A), 
nr 37°C (B)
A ________________________
DRUG TITRE FOLD REDUCTION % REDUCTION*
Drug free Oh 9.5 x 103 p.f.u./ml
- -
Drug free 1.6 x 103 p.f.u7ml
— _
CCX-150|iM 7.92 x 102 p.f.u7ml 2 50.5
CCX-300|iM 4.5 x 102 p.f.uVml 3.6 71.9
CBX-150|iM 5.42 x 102 p.f.uVml 2.9 66.1
CBX-300(J.M 4.1 x 102 p.f.u7ml 3.9 74.4
GL-750|iM 4.12 x 102 p.f.uVml 3.9 74.25
GL-1500(i.M 6.4 x 102 p.f.u7ml 2.5 60
B
DRUG TITRE FOLD REDUCTION % REDUCTION**
Drug free Oh 9.5 x 103 p.f.u/ml - -
Drug free 1.1 X 103 p.f.uVml - -
CCX-150fiM 3.2 x 102 p.f.u-/ml 3.4 71
CCX-300(iM 1.1 x 102 p.f.uVml 10 90
CBX-150jj.M 1.8 x 102p.f.u /ml 2.8 64.6
CBX-300p.M 3.9 x 102 p.f.u7ml 6.1 83.6
GL-750fiM 2.5 x 102 p.f.uVml 4.4 77.3
GL-1500fiM 1.9 x 102 p.f.u7ml 5.8 82.73
* Relative to the drug-free titre after 24h incubation.
3.3.3. PURIFICATION OF FIV BY FICOLL GRADIENT CENTRIFUGATION. 
AND INVESTIGATION OF THE SDS PAGE POLYPEPTIDE PROFILE
OF PURIFIED VIRUS.
In order to identify FIV proteins in infected cell extracts, it was first necessary to 
obtain an SDS PAGE polypeptide profile for the purified virus particles. CrFK cells were 
seeded overnight at 2xl07 cells/roller bottle, and the resulting monolayers then infected 
with FIV at a m.o.i. of 0.001 p.f.u./cell. The infected CrFK cell cultures were harvested 5 
days later; The tissue culture medium from the infected culture was clarified by low speed 
centrifugation, after which the virus particles were pelleted (12000 r.p.m./4°C/3h in a 
Sorvall GSA rotor). The resuspended virus pellet was layered on top of 5-15% Ficoll 
gradients, which were then centrifuged (12000 r.p.m./4°C/3h in the Sorvall TST 41 rotor) 
to band the purified virus. The banded virus preparation is shown in Fig 31. Two broad 
bands runing close together were just visible. After extraction of the banded material, by 
side-puncture of the tube, the material constituting the bands was examined by electron 
microscopy. The top band contained spherical FIV particles at l.lx lO 11 per ml (Figure 32
A), and the bottom band contained the same type of particles at 2.75x10*1 per ml (Figure 32
B). The infectivity associated with each band was as follows; 3.25xl03 p.f.u./ml (top 
band), and 2.8x103 p.f.u./ml (bottom band). The particle/p.f.u. calculated for each band 
were; 3.4 x 107/1 (top band), and 9.8 x 107/1 (bottom band), indicating that most of the 
viruses produced were non-infectious. The banded virus particles were solubilized with 
SDS PAGE extraction buffer, and the protein extract electrophoresed on a 10% SDS PAGE 
gel. The resulting gel was silver- stained and is shown in Fig 33A. The polypeptide profile 
obtained from the top and the bottom bands were virtually identical except that the bottom
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band seemed to contain more protein. Comparison of the silver-stained polypeptide profile 
with a western-blot of the same material using an FTV infected cat serum as the probe, 
allowed the identification of the FIV gpl20, gp41, p24, and pl7 proteins. Two further 
proteins tentatively identified as the FIV p55, and plO were also resolved in the silver- 
stained gel.
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FIGURE 31.
FIV particles purified on a 5-15% Ficoll gradient, (bands 1, 2 and are identified by 
arrows).

FIGURE 32.
Electron micrograph of purified FIV particles banded on Ficoll gradients.
A-Top band 
B-Bottom band.
Scale bar lOOnm.
A
FIGURE 33.
A . Silver-stained polypeptide profile of purified FIV particles obtained on a 10% SDS 
PAGE gel.
Top band (1), bottom band (2), and molecular weight markers (M).
• Identified viral proteins (VPs).
B. W estern blot o f FIV particle proteins, separated by SDS PAGE (10% minigel).
FIV proteins were identified using FIV-infected cat serum.
Top band (1), bottom band (2), and molecular weight marker (M).
• Identified viral proteins (VPs).
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3.3.4. SDS PAGE INVESTIGATION OF PROGENY FIV VIRUS PARTICLE
PROTEINS. AND PROTEIN EXTRACTS FROM FIV PERSISTENTLY 
INFECTED CrFK CELL CULTURES TREATED WITH CCX.
The effect of CCX treatment on FIV polypeptide synthesis in persistently infected 
CrFK cell cultures, and on the polypeptide composition of the virus particles made in the 
presence of the drug have been investigated by SDS PAGE. Mock-infected or persistently 
infected CrFK cell cultures were treated with 25|iiM, or IOOjjM  CCX (in medium deficient
3 5  * • 3 5in methionine and cysteine).Three hours after drug addition, 50p,ci/ml o f ' S methionine/ S 
cysteine mixture was added to the tissue culture medium, and the infection allowed to 
proceed until 48h post drug addition. The medium was then removed from the MI and 
persistently infected cell cultures, then passed through a 0.22p, filter (Acrodisc) to obtain a 
partially purified preparation of the cell-released virus. The material was then pelleted by 
centrifugation at 12000 r.p.m. in a TST41 rotor. The cell-released virus particles were then 
solubilized with SDS PAGE extraction buffer, and the FTV structural proteins investigated 
by SDS PAGE.
The SDS PAGE polypeptide profiles obtained (on a 10% gel) for materials pelleted 
from the tissue culture medium of MI or FIV cell cultures treated with 0|iM, 25pM, or 
lOOpM CCX are shown in Figure 34 A. The MI control shows the polypeptides; 175K, 
100K, 70K, 66K, 58K, 38K, 32K, and 30K in material pelleted from the culture fluid. 
Treatment with 25pM CCX resulted in an increase in the amount these proteins, and in the 
appearance of additional proteins (150K, 54K, and 47K). Comparison of the polypeptide 
profile obtained from the MI drug-free control cultures and that of the MI cultures treated
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with 100|liM CCX show that several polypeptide bands were increased in intensity (70K, 
66K, 58K, 54K, 52K, 48k, 47K, and 40K). While 175K, 150K, 100K, 38K, 32K, and 30K 
bands decreased in intensity, indicating drug-induced changes in the amounts and/or the 
molecular weights of proteins pelleted from MI CrFK cell culture medium.
The nature of the material pelleted from the culture medium of uninfected cells has 
not been investigated by electron microscopy, but probably includes very small cell 
membrane fragments, membrane-bound vesicles, and possibly precipitation of complexed 
secreted proteins. The quantitative and qualitative changes in the pattern of proteins 
pelleted from uninfected cells might result from CCX-induced effects on the integrity, or 
protein permeability of the plasma membrane, effects on the Golgi apparatus, or post-Golgi 
vesicles of drug-treated cells.
The proteins pelleted from the tissue culture medium of drug-free FTV-infected cell 
cultures are shown in Fig 34 A. The following FIV proteins were identified; p55, p24, and 
p i7. Although not examined by electron microscopy, the material pelleted from FIV 
infected cell culture medium is expected to contain, predominantly, FIV particles, with a 
low level of contaminating cellular material. FIV particles made in the presence of 25|iM 
CCX gave a polypeptide profile virtually identical to that of the drug-free control, except 
that the p55 protein band was increased in intensity. FIV particles made in the presence of 
1 0 0 |liM  CCX, however, exhibited a different polypeptide profile; the intensities of the p24, 
and p i7 bands were dramatically reduced, while that of the p55 band was again increased. 
The intensities of additional protein bands of; 90K, 85K, 70K, 66K, 60K, 54K, 52K, 47K, 
45K, 42K, 38K, and 36K Mwt were also increased. The identities of these proteins are 
unknown, but most of these bands appear to be the same as those increased in the material
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pelleted from the tissue culture of MI cell cultures treated with lOOpM CCX, suggesting 
that these proteins are of cellular origin. The 90K, 85K, 60k, 45K, 42K, 38K, and 36K 
bands however were only increased in the material pelleted from tissue culture of FTV 
infected cell cultures, but it is not known if these bands represent virus specific proteins.
The simplest interpretation of the observed reduction in the amount of p24, and pl7 
levels would be that very few virions were released from the infected cell cultures treated 
with lOOpM CCX. However the observation that the amount of p55 (the precursor of p24 
and p i7) increased, could also be interpreted as suggesting that the virus particles were 
released, but that the post-release processing of p55 into p24 and p l7  was impaired in the 
presence of CCX. Because of the low numbers of FIV particle produced it was not possible 
to resolve this problem by EM examination.
The SDS PAGE profile of proteins present in FIV infected or MI cell extracts is 
shown in Fig 34B. The polypeptide profile obtained from MI cell extract of cultures treated 
with 25pM CCX was virtually identical to that obtained from the drug-free control extract. 
MI cell cultures treated with IOOjiM CCX showed an altered polypeptide profile. Bands of 
70K, 66K, 58K, and 23K were increased in intensities, while the 29K band was decreased 
in intensity. The 70K and 66K bands appear to correspond to the 70K and 66K bands 
pelleted from the cell culture medium of MI cells treated with IOOjiM CCX (Fig 34A). The 
polypeptide patterns of MI and FIV infected cell extracts, grown in the absence of CCX, 
differ in the intensities of only two bands; (39K and 30K were considerably reduced in the 
intensity in the MI cell extracts), but FIV proteins with these molecular weights have not 
been previously reported. Protein extracts from infected cell cultures treated with 25pM
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CCX gave a polypeptide pattern virtually identical to the FTV control except that the 
intensity of the novel 39K band was reduced.
The polypeptide profiles obtained from protein extracts of the FIV infected cell 
cultures treated with 100|iM CCX was markedly different from the FTV infected control 
culture. Bands of 97K, 80K, 68K, 62K, 55K, 52K, 50K, 44K, 42K, 4 IK, 38K, 37K, 34K,
3 IK, 30K, 27K, 24k, 22K, 2 IK, and 15K, were all increased in intensity; while bands of; 
175K, 150K, 100K, 70K, 67K, 48K, 40K, 29K, 19K, and 18K were decreased in intensity. 
However, with the exception of the 55K and the 41K bands none of these proteins have 
molecular weights corresponding to those of known FIV proteins.
Comparison of the polypeptide profiles of the pelleted FIV particles (Figure 34A) 
and FIV infected cell extracts (Figure 34B) treated with lOOpM CCX shows that the 55K 
band, (tentatively identified as the FIV p55 protein) increased in intensity both in the 
pelleted material from tissue culture supernatant and in the infected cell extracts. 
Suggesting impairment of both particle assembly and post-release processing of p55. As 
expected the cleavage products of p55 (p24 and p i7) were not detected in the infected cell 
extracts as these arise from post-release cleavage of p55.
It is concluded from the data in Fig 34 that treatment of FIV infected CrFK cell 
cultures with 25pM CCX had little effect on protein synthesis in infected cells, and yielded 
vims particles whose polypeptide composition was virtually identical to that made in the 
absence of the drug. Treatment with lOOpM CCX, however resulted in a dramatic change 
in the polypeptide profile of the infected cell extract; a number of polypeptide bands 
appeared to increase in intensity in infected cell extracts only (among these polypeptides the 
band of 55K tentatively identified as FIV p55 was increased in intensity). The material
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pelleted from tissue culture medium from infected cell cultures treated with IOOjiM CCX 
also had an increased level of p55 and reduction in the amount of p24, and p i7. The data 
might suggest a reduction in the number of virus particles produced in cultures treated with 
lOOpM CCX or an increase in the extracellular release of a set of proteins including p55.
To further investigate the effect of CCX on FIV glycoprotein synthesis; MI and FIV 
infected cell cultures were treated with 5jxM monensin, or 2|ig/ml tunicamycin (Fig 34). 
The sodium ionophore, monensin is well-known to inhibit maturation of glycoproteins in 
the Golgi apparatus (Gareth et al 1983), while tunicamycin inhibits the N-linkage of the 
initial set of core sugars to the native precursor protein, at a stage prior to its translocation 
to the Golgi apparatus, and while the protein is resident in the lumen of the ER.
There was no evidence in the SDS PAGE polypeptide profiles for the presence of 
the FIV env, glycoprotein non-glycosylated precursor gp(160), nor any evidence of 
partially-processed precursor glycoproteins packaged into the virus particles made in the 
presence of monensin or tunicamycin. Similarly, the gpl60 or partially processed products 
were not detected in the SDS PAGE polypeptide profiles obtained from extracts of FTV 
infected cell cultures grown in the presence of monensin or tunicamycin. Furthermore, 
while monensin and tunicamycin treatment had no effect on the level of p55 in infected cell 
cultures or in virus particles, treatment with either of the compounds reduced the intensity 
of p24, and p l7  bands in the pelleted virus particles, suggesting that fewer virus particles 
were produced in the presence of the glycosylation inhibitors.
Treatment of MI cell cultures with monensin had no significant effect on the SDS 
PAGE polypeptide pattern, but tunicamycin treatment resulted in an increase in the
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intensities of 3 other proteins (66K, 38K and 18k), thought to be host cell glycoprotein 
precursors (Figure 34B).
Previous studies in which the effect of CCX and monensin treatments on the HSV 
or SFV infected cell cultures were compared, have shown broad similarities between the 
effect of CCX and monensin and suggest that CCX affects glycosylation at the level of 
processing in the Golgi apparatus (Dargan et al., 1992). The studies reported here, however, 
provide no information on FIV glycosylation processing in cells treated with CCX, 
monensin, or tunicamycin.
To further investigate the effect of CCX on FTV glycoprotein processing, MI and 
FIV infected cell were labelled with l4C-glucosamine, and the virus proteins 
immunoprecipitated with an FIV infected cat serum. The 14C-glucosamine labelled 
proteins were electrophoresed on the same SDS PAGE gel with 35S-methionine/cysteine 
labelled proteins to allow identification of the 35S-labelled glycoproteins. As before, 
material pelleted from supernatant culture fluid and infected cell extracts were investigated. 
In this experiment 7.5% acrylamide gels were used to enhance the resolution of the FTV 
glycoproteins (gp 120, gp 160)
The effect of 25pM, and 100pM CCX on the proteins pelleted from the tissue 
culture medium of MI, and FIV infected, cell cultures is shown in Fig 35. Four, high- 
molecular weight bands labelled with 14C glucosamine were immunoprecipitated non- 
specifically by the FIV infected cat serum in the material pelleted from drug-free MI CrFK 
cell cultures. The intensities of these bands were markedly reduced by treatment of the 
cultures with 25|iM CCX, and were not detectable when the cultures were treated with
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FIGURES 34 A.
Polypeptide profiles obtained on a 10% SDS PAGE gel of 35S-methionine/cysteine 
labelled proteins pelleted from the culture medium of MI (lanes 4, 5, 6, 7, and 9), or 
FIV-infected (lanes 1, 2, 3, 8, and 10) CrFK cells.
Cells were either drug-free (lanes 1 and 4), or treated with 25, or lOOpM CCX 
(lanes 2 and 5; 3 and 6 respectively), 5pM monensin (lanes 7 and 8) or 2jig/ml tunicamycin 
(lanes 9 and 10).
The location of the molecular weight markers (M) (non-radiolabelled) resolved on the same 
gel, have been transferred from the dried gel.
A Identified viral proteins.
•  Protein bands of unknown origin.
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FIGURE 34 B.
Polypeptide profiles obtained on a 10% SDS PAGE gel of 35S-methionine/cysteine 
labelled proteins in the extracts from MI (lanes 4, 5, 6, 7, and 9), or FIV-infected 
(lanes 1, 2, 3, 8, and 10) CrFK cells.
Cells were either drug-free (lanes 1 and 4) or treated with 25, or lOOfiM CCX (lanes 
2 and 5; 3 and 6 respectively), 5|nM monensin (lanes 7 and 8), or 2pg/ml tunicamycin (lanes 
9 and 10).
The location of molecular weight markers (M) (non-radiolabeiled) resolved on the same gel 
have been transferred from the dried gels.
A Identified virus proteins.
•  Bands decreasing in intensity with increasing drug concentration, 
o Bands increasing in intensity with increasing drug concentration.
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100|iM CCX, suggesting that the glycosylation or secretion of these proteins was altered by 
CCX treatment (Fig 35A). The SDS PAGE polypeptide profile of 35S-labelled material 
pelleted from the culture medium of MI cell cultures was not affected by 25[iM CCX 
treatment but was altered when treated with 100|iM CCX (Figure 35A).
The material pelleted from the supernatant of FIV infected cell cultures labelled 
with 14C-glucosamine or 35S-methionine/cysteine is shown in Fig 35B. Only three bands are 
detectable in 14C-glucosamine labelled material from drug-free infected cell cultures, one of 
these is a 170K host cell polypeptide band [non-specifically immunoprecipitated by the anti 
FIV serum (Figure 35B)], while the other two correspond to FIV gpl20 (barely detectable), 
and gp41. It is expected that gpl20 and gp41 should be present in equimolar amount in 
virus particles, scrutiny of the gel (14C glucosamine labelling) shows that in FIV particles 
made in the absence of the drug, gp41 was present in greater amounts than gpl20. This is 
probably due to pelleting of the virus resulting in a reduction in the number of gpl20 
molecules present on the virion envelope. Gpl20, and gp41 were not detected in tne 
material pelleted from the infected cell cultures treated with only 25|iM CCX, although the 
170K host protein band was detected and slightly reduced in intensity. No 14C glucosamine 
labelled protein was detected in the material pelleted from the medium of the infected cell 
cultures treated with lOOpM CCX.
Gp41 and gpl20 bands were not detected in the drug-free material pelleted from the 
infected cell cultures labelled with 35S-methionine/cysteine. A band in the region of 41K 
increased in a drug-dose dependent manner, however it is not clear whether this is gp41 or 
whether it is a host cell protein that does not behave in the same way in MI cell cultures.
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FIGURE 35.
Polypeptide profiles obtained on a 7.5% SDS PAGE gel of proteins pelleted from MI 
(A), or FIV-infected (B) CrFK cells. Cells were labelled with either 35S-methionine/ 
cysteine (lanes 4, 5, and 6; Figures A and B ), or 14C-glucosamine (lanes 1, 2, and 3; 
Figures A and B).
Cells were either drug-free (lanes 1 and 4), or treated with 25, or 100|iM CCX 
(lanes 2 and 5; 3 and 6 respectively, Figures A and B).
The location of the molecular weight markers (M) (non-radiolabelled) resolved on the same 
gel, have been transferred from the dried gel.
A Identified viral proteins.
•  Protein bands of unknown origin.
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Similarly in the material pelleted from cultures treated with 25|iM, or IOOjiM CCX, several 
bands in the region of 120K band increased in intensity, but it is not known whether any of 
these bands are the FIV gpl20 or whether they represent host cell proteins. The following
3 5  •S-methionine/cysteine labelled bands increased in intensity with increasing concentration 
of CCX; 145K, 130K, 115K, 106K, 97K, 86K, 83K, 63K, 55K, 49K, 45K, 44K, 43K, 41K, 
35K, and 30K, while bands of 170K, 156K, 69K, 66K, 33K, and 24K decreased in 
intensity. Stephens et a l, (1991) have shown that the FIV precursor glycoprotein is 
decorated with core sugars. Bands of 115K, 106K, and 97K which were increased in 
intensity with increasing CCX concentration co-run with the broad band of 14C 
glucosamine-labelled gpl20, and it is possible that one or more of these bands represent a 
partially glycosylated form of gpl20. It is difficult without data from either a western blot, 
or immunoprecipitation reactions to identify, which if any of these 35S-labelled bands 
represent the viral glycoproteins. A band of 55K was increased in intensity, in the 
polypeptide profile of material pelleted from drug-free FIV infected cell cultures, with
i
increasing concentrations of CCX. This band co-runs with a host band of about the same 
molecular weight in the tissue culture medium of MI cell cultures. However the intensity of 
the MI band decreased with increasing drug concentration.
Figure 36 shows the SDS PAGE polypeptide profile of MI and FIV infected cell 
extracts obtained from cultures labelled with l4C-glucosamine or 35S-methionine/cysteine 
and treated with increasing concentration of CCX. The 14C-glucosamine labelled proteins
or
were immunoprecipitated using an FIV-infected cat serum. The ' S-labelled proteins were 
not immunoprecipitated As expected no 14C-glucosamine labelled MI cell glycoproteins 
were detected after immunoprecipitation (Fig 36A). Only one 35S-labelled band (60K) was
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FIGURE 36.
Polypeptide profiles obtained on a 7.5% SDS PAGE gel of extracts from MI (A), or 
FIV-infected (B) CrFK cells. Cells were labelled with either 35S-methionine/cysteine 
(lanes 4 ,5 , and 6 Figures A and B) or 14C-glucosamine (lanes 1, 2, and 3 Figures A and
B).
Cells were either drug-free (lanes 1 and 4) or treated with , 25, or IOOjiM CCX
#
(lanes 2 and 5; 3 and 6 respectively, Figures A and B)
The location of molecular weight markers (M) (non-radiolabelled) resolved on the same gel 
have been transferred from the dried gel.
A Identified virus proteins.
•  Protein bands of unknown origin.
A9 P 1 6 0  
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increased in intensity in cell extracts from cells treated with lOOpM CCX. Most , but not 
all other bands were reduced in intensity.
The FIV gpl20 band was detected by immunoprecipitation of 14C glucosamine 
labelled infected cell extracts (Fig 36B). Treatment with 25|iM CCX had little or no effect 
on the intensity of the gpl20 band, but treatment with lOOpjn CCX resulted in a failure to 
detect the gpl20 band. The FTV Gp 41 band was not detected in the drug-free infected cell 
extracts.
The following bands were observed to increase in intensity, with increasing CCX 
concentration, in the extracts from 35S-labelled infected cells; 160K, 120K, 115k, 106K, 
97k, 80K, 60K, 55K, 50K, 43K, 41K, 36K, 36K, 34K, and 30K, while bands of 200K, 
170K, 5 IK, 42K, 39K, and 37K were decreased. Although the gpl20 band was not detected
ic
in the drug-free S- methionine/cysteine labelled infected cell extracts. A band which co­
runs with 14C- glucosamine labelled gpl20 was observed to increase in intensity with 
increasing drug concentrations in the 35S-labelled extracts (Fig 36B). It is not known if this 
band is gpl20, or whether it represents a host cell protein that behaves differently in FTV 
infected cell cultures. A higher molecular weight band of about 160K (thought to be the 
FTV precursor gp 160) increased in intensity in cell extracts from cultures treated with 
25}iM, or lOOpM CCX (Fig 36B). Similarly a band, thought to be gp41, also increased in 
intensity in extracts from drug-treated cell cultures. The band of 55K molecular weight 
(thought to be FIV p55) also increased in intensity in a drug-dose dependent manner in FTV 
infected cell extracts (Fig 36B).
In conclusion, CCX treatment of infected cell cultures resulted in a reduction in the 
amount of sugar-labelled gpl20, suggesting that either the glycosylation or the synthesis of
160
gpl20 was impaired. If, however, the identification of 35S-labelled gpl20 and gpl60 is 
correct then these partially glycosylated proteins (poorly labelled with 14C-glucosamine, but 
not with 35S-methionine) accumulate in the cells treated with IOOjiM CCX. The 
accumulation of gpl60 would imply that cleavage of gpl60 into gpl20 and gp41 was 
impaired by treatment with lOOpM CCX. The p55 protein band increased in FTV infected 
cell extracts in a drug-dose dependent manner, this protein also increased in a dose 
dependent manner in vims particles pelleted from the tissue culture medium of drug- 
treated infected cell cultures. The p24 band decreased in intensity in the material pelleted 
from infected cell cultures treated with the drug. It is concluded from this set of the data 
that FIV assembly, release and possibly the post-release maturation of FIV are impaired by 
treatment with lOOpM CCX.
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3.4. INVESTIGATION OF THE EFFECT OF TRITERPENOID
COMPOUNDS ON THE REPLICATION OF BOVINE HERPESVIRUS 
TYPE 1 (BHV-1)
Among the herpesviruses, the anti-HSV-1 activity of CCX has been most 
extensively studied, however the herpesvirus which exhibited the highest degree of 
sensitivity to CCX treatment was BHV-1 (Galt et al, 1990).
3.4.1. THE EFFECT OF CCX TREATMENT ON THE 24H INFECTIOUS BHV-1 
YIELDS FROM MDBK CELLS IN CULTURE.
Figure 37, shows the effect of CCX treatment on the 24h infectious yield of BHV-1 
from MDBK cell cultures. lxlO6 cells/30mm culture plate were infected with BHV-1 at 
m.o.i. of 5 p.f.u./cell. After a lh virus absorption period, the plates were washed and 
overlayed with medium containing increasing concentrations of CCX. The infected cell 
cultures were incubated at 37°C, for 24h, after which the CA and the CR vims yields were 
harvested. Drug-free, infected cell cultures yielded 1.065xl08 p.f.u./ml and 4.59xl08 
p.f.u./ml in the CR and CA fractions respectively. Treatment with IOOjiM , 200|iM, or 
300(iM CCX gave 200, 2.45 xlO4, and 4.73 x 105 fold reductions in the infectivity of CR 
fractions respectively, while the CA infectivity was reduced by 26.2, 1.25 x 103, and 6.95 x 
104 fold respectively. Thus, while infectivity decreased in a more or less linear fashion with 
increasing drug concentrations, CR infectivity decreased at a faster rate than CA infectivity.
This suggests either a vimcidal activity of the drug on extracellular vims particles, 
or impairment of the release of virus into the extracellular fluid.
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* Numbers calculated based on the total virus yield i.e. cell released plus cell associated.
Figure. 37
THE EFFECT OF CCX TREATMENT ON THE 24H 
INFECTIOUS BHV-1 YIELDS FROM MDBK CELLS
3.4.2. INVESTIGATION OF THE VIRUCIDAL ACTIVITY OF CCX. CBX. AND
GL AGAINST BHV-1.
In order to investigate whether the triterpenoid compounds (CCX, CBX, or GL) have 
virucidal activity against BHV-1, suspensions of BHV-1 particles prepared in medium 
containing different concentrations of each drug were incubated, at either 4°C or 37°C, for 
24h after which, the remaining infectivity was titrated. Table 7, shows that treatment with 
150jiM CCX, 150jiM CBX, or 750|iM GL had a small virucidal activity at 4°C (2.2, 2.7, 
and 3.3 fold reductions in infectivity respectively). Doubling the concentrations of the 
drugs had little or no effect on the virucidal activity. Incubation at 37°C had little effect on 
the virucidal activity obtained with 150|iM, 150p.M CBX, or 750p,M GL compared to that 
obtained at 4°C. However, doubling the drug concentrations in suspensions incubated at 
37°C increased the magnitude of the virucidal effect (3.3, 4.1, and 4.2 fold).
It is concluded that while virucidal activity (3 fold) can be detected in suspension 
treated with 300|iM CCX at 37°C, this is insignificant compared to the 29.3 fold difference 
in infectivity between the CR and CA fraction obtained from infected cells treated with 
300|iM CCX. Thus the data suggest that CCX treatment results in impairment of BHV-1 
egress.
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TABLE 7. BHV-1: VIRUCIDAL ACTIVITY OF CCX, CBX. AND GL 
DETERMINED AFTER 24H INCUBATION AT 4°C (A). OR 
37°C (B).
A ______________
DRUG TITRE FOLDREDUCTION % REDUCTION*
Drug free Oh 1.71 x 109 p.f.u^ml — —
Drug free 1.18 x 108 p.f.uVml _ _
CCX, 150(j.M 5.4 x 107 p.f.u7ml 2.2 54.3
CCX, 300p.M 5.47 x 107 p.f.u./ml 2.2 53.6
CBX, 150(iM 4.34 x 107 p.f.u./ml 2.7 63.2
CBX, 300fiM 5.41x 107p.f.u./ml 2.2 54.15
GL, 750|iM 3.52 x 107 p.f.u./ml 3.3 70.2
GL, 1500pM 3.15 x 107 p.f.uVml 3.7 26.7
B
DRUG TITRE FOLD REDUCTION % REDUCTION*
Drug free Oh 1.71 x 109 p.f.uyml
Drug free 5.83 x 108 p.f.uiml
- -
CCX- 150|iM 3.75 x 108 p.f.uVml 1.5 35.7
CCX- 300|iM 1.74 x 108 p.f.u7ml 3.3 70.15
CBX- 150p.M 1.89 x 108 p.f-uVml 3.1 67.6
CBX-300pM 1.43 x 108 p.f.u7ml 4.1 75.5
GL-750(iM 1.87 x 108 p.f.u7ml 3.1 67.9
GL-1500jiM 1.4 x 108 p.f.u./ml 4.2 7
* Relative to the drug-free titre after 24h incubation.
3.4.3. THIN-SECTION TRANSMISSION ELECTRON MICROSCOPE
STUDIES OF BHV-1 INFECTED AND M I M DBK CELL CULTURES  
TREATED WITH INCREASING CONCENTRATIONS OF CCX.
To further investigate the effect of CCX on BHV-1 replication, monolayers of 
MDBK cells on 30mm tissue culture plates were either MI, or infected with BHV-1 at 5 
p.f.u./cell. After the virus absorption period, cell cultures were overlaid with either drug- 
free medium, or medium containing, 50pM, 150pM, 200pM, or 300pM CCX. At 24h PI, 
the cell cultures were fixed with gluteraldehyde and prepared for transmission electron 
microscopy ( Material and Methods section 2.2.6.4.2-3.).
Forty cell sections were scored for the numbers of DNA containing, empty, or 
partially filled nucleocapsids within the nucleus or cytoplasm; the numbers of enveloped or 
non-enveloped virus in the cytoplasm, and the numbers of virus particles in the 
extracellular matrix. The effect of CCX treatment on the number of total, empty, and core 
containing virus particles and number of enveloped vims particles is shown in table 8. The 
effect of increasing CCX concentration on; the percentage of cell sections containing vims 
particles; the percentage of empty and DNA containing particles; the percentage of 
enveloped virus particles in the cytoplasm; and the percentage of vims particles present in 
the extracellular medium shown in table 9. The results in column 2 (table 8) show a 
general reduction in the total number of capsids (core containing, and empty) with 
increasing concentration of CCX. The percentage of cell sections containing vims particles 
was reduced (92.5%, 87.5%, 85%, 22%, and 0% for cultures treated with OpM, 50pm, 
150pm, 200pm, and 300pM CCX respectively) (column 2 table 9), while the average 
number of vims particles/section were 24.5, 27.1, 9.5, 0.3, and 0 respectively (column 3,
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table 9). Thus, generally fewer virus particles were assembled in each infected cell. The 
data in column 4 (table 9), shows that the percentage number of empty capsids structures 
was unaffected by treatment with up to 150|iM CCX, although the percentage rose from 
around 20% to 82% in cells treated with 200|liM CCX. In the drug-free cultures all of the 
virus particles found in the cytoplasm were enveloped (column 8, table 9). With increasing 
drug concentration, no consistent effect on envelopment of the virus is observed (column 8, 
table 9). The data in column 9 (table 9) shows that percentage of extracellular viruses per 
cell section for the cultures treated with 50p,M, 150pM, 200jxM, and 300pM CCX were 
24.5%, 31.6%, 3.57%, and 2.27%, of the drug-free control respectively. The data in table 9 
column 5 shows that treatment with increasing concentration of CCX did not have any 
significant effect on the percentage of cored particles. Also the data in table 8 columns, 5 
and 6, shows that the number of virus particles exhibiting a DNA core, present in the 
cytoplasm decreased at a faster rate than the number of virus particles present in the 
nucleus, implying that virus release from the nucleus through the nuclear membrane was 
also inhibited by the drug. It is concluded that CCX treatment inhibits the assembly of 
nucleocapsids, and release of the virus particles from the nucleus.
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3.4.4. SDS PAGE investigation of the MI and BHV-1 infected cell proteins labelling
with 35S-methionine and 32P-orthophosphate.
Monolayers of MDBK cells were either MI or infected with BHV-1 at a m.o.i. of 20 
p.f.u./cell. Following the virus absorption period, the monolayers were washed, overlayed 
with methionine-free, or phosphate-free medium (as appropriate) containing increasing 
concentration of drugs, and then labelled with either 35S-methionine (at 3h PI), or 32P - 
orthophosphate ( at 4h PI). After overnight incubation, the cell monolayers were harvested 
in SDS PAGE extraction buffer, and the infected cell proteins examined by SDS PAGE. 
The effect of CCX treatment on the incorporation of 35S-meth into MI and BHV-1 infected 
MDBK cell proteins is shown in Fig 38. Treatment with > 75|iM CCX resulted in a 
decrease of between 70% and 85% in the 35S-methionine incorporation into MI or BHV-1 
infected cells. There was little evidence to suggest that the drug acted selectively against 
BHV-1 and the data suggest that CCX treatment impairs protein synthesis per se.
Figure 39 shows the polypeptide profile of MI, or BHV-1 infected cell extracts from 
cultures treated with OpM, 12.5|iM, 25pM, 50pM, 75pM, lOOpM, 125pM, 150pM, 
200pM, or 300|liM CBX. In the MI cell extracts; bands of 53K, 5 IK, 40K, and 36K, were 
reduced in intensity when treated with CBX concentrations >12.5}iM, while bands of 200K 
and 80K, were reduced in intensity by treatment with CBX concentrations >75pM. In 
addition, bands of, 79K, and 63K, increased in intensity in cultures treated with >25pM 
CBX.
The following virus specific bands were identified in the extracts from drug-free 
infected cells; > 200K, 147K, 141K, 134K, 119K, 90K, 87K, 80K, 74K, 67K, 65K, 60K, 
57K, 49K, 46K, 32K, and 28K. These bands probably correspond to the BHV-1 proteins
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identified by Misra et al., (1981) as VPs; 1/2, 4, 5, 6, 7, 8, 9, 10/11, 12, 13, 14, 15, 16, 20, 
21,22, and 23.
The intensities of all viral bands were progressively reduced with increasing drug 
concentration, but the synthesis of some protein bands were less affected than others (VPs 
4, 5, and 10/11, were detected at 300pM CBX, but VPs 1/2, 6, 7, 8, 12, 13, 14, 16, 20, 21, 
22, and 23 were not detected with > IOOjiM CBX).
Earlier observations, (Dargan, Bandephadhayi, Field and Subak-Sharpe, unpublished 
data) suggested that phosphorylation of the BHV-1 VP8 protein might be impaired in the 
presence of CCX. Figure 40 shows the effect of CCX, tunicamycin, monensin, and H7 on 
the polypeptide profile of uninfected MDBK cells labelled in parallel with 35S-methionine 
and 32P-orthophosphate. H7 is a well-known protein kinase C (PKC) inhibitor (Ito et al., 
1988) included in this experiment as a control. Cellular bands of 180K and 165K were 
reduced in intensity at 300fiM CCX. A novel cellular band appeared at 120K in cultures 
treated with >100pM CCX. Bands of 86K and 67K were more intense in tunicamycin 
treated cells. In addition a 115K novel band was detected in tunicamycin treated cells. As a 
result of treatment with either >50|iM CCX, or tunicamycin treatment, but not with 
monensin or H7 the phosphate labelling of a 156K band was impaired. A novel 
phosphoprotein band of 86K Mwt was detected in cultures treated with > IOOjiM CCX.
Figure 41 shows the parallel 35S-methionine and 32P-orthophosphate labelling of 
BHV-1 infected MDBK cell proteins. The following BHV-1 bands were identified in the 
extracts from drug-free infected cell cultures labelled with 35S methionine; VPs 1/2, 4, 5, 6, 
7, 8, 9, 10/11, 12, 13, 14, 15, 16, 20, 21. The intensities of the following viral bands were
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virtually unaffected by treatment with 300pM CCX; 4, 5, 6, 10/11, 15, 16, 20, 21, while the 
intensities of 1/2, 7, 8, 9, 12, 13, 14, bands were reduced. Two bands of 66K and 55K 
were increased in intensity in infected cultures treated with > 50pM CCX. A novel band 
of 38.5K appears as a result treatment with > 25|iM CCX, this band is not present in 
tunicamycin, monensin, or H7 treated cell extracts. The intensity of the VP8 band was 
unaffected with treatment up to 200jllM CCX, although the intensity of this band was 
greatly reduced when treated with 300pM CCX. Phosphate labelling of VP8, however, was 
increased when treated with 25pM CCX, decreased when treated with >50p,M CCX, and 
was virtually undetectable at 200pM CCX. Phosphate labelling of a protein band at 85K 
was impaired in cultures treated with >100|iM CCX. Treatment with tunicamycin or H7 
seemed to have little effect on the phosphorylation of VP8, but treatment with monensin 
impaired its phosphorylation. Treatment with tunicamycin reduced the intensities of S- 
methionine labelled viral bands VP 1/2 and VP 14, and also resulted in induction of novel 
bands of 92K, and 67K, (the latter corresponds to a MI band). Phosphorylation of VP8 was 
not impaired in the presence of H7 indicating that, VP8 phosphorylation was not mediated 
through the action of protein kinase C. Recent data suggested that VP8 has protein kinase 
C activity and is capable of autophosphoryaltion (V. M., Misra personal communication). 
Whether phosphorylation of VP8 is essential for virus replication is not known, but the fact 
that CCX treatment impaired its phosphorylation under conditions where the protein was 
synthesised is of interest It is also relevant, that the Golgi inhibitor monensin impaired the 
phosphorylation of VP8, but not synthesis of the VP8 protein itself (Fig 41 lanes 9 and 19).
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As CCX also affects the Golgi apparatus, this implicates a Golgi function involved in 
phosphorylation of VP8.
In conclusion the results indicate that CBX treatment reduces protein synthesis per
0
se,but some BHV-1 proteins were mre affected than the others, and that CCX treatment 
impaired the phosphorylation of VP8 at drug concentrations which did not affect the 
synthesis of the VP8 protein.
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FIGURE 39.
Polypeptide profile obtained on a 10% SDS PAGE gel of the 35S-methionine
♦
labelled proteins in the extracts from BHV-1 infected (lanes 1 to 10), and MI (lanes 11 
to 20) of MDBK cells.
Cells were either drug-free (lanes 1 and 11), or treated with 12.5, 25, 50, 75, 100, 
125, 150, 200, or 300|iM CBX ( lanes 2 and 12; 3 and 13; 4 and 14; 5 and 15; 6 and 16; 7 
and 17; 8 and 18; 9 and 19; 10 and 20 respectively).
Identified viral proteins (VPs) (Misra et al., 1981).
The apparent molecular weight of cellular proteins affected by CCX treatment are also 
shown.
• Bands decreasing in intensity with increasing drug concentration, 
o Bands increasing in intensity with increasing drug concentration.
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FIGURE 40.
Polypeptide profiles obtained on a 9% SDS PAGE gel of MI MDBK cell 
extracts from cultures labelled with either 35S-methionine (lanes 1 to 10), or 32P- 
orthophosphate (lanes 11 to 20).
Cells were either drug-free (lanes 1 and 11) or treated with 25, 50, 100, 150, 200, or 
300 |iM CCX (lanes 2 and 12; 3 and 13; 4 and 14; 5 and 15; 6 and 16; 7 and 17
respectively), 2fig/ml tunicamycin (lanes 8 and 18), 5|iM monensin (lanes 9 and 19), or
IjiM H7 (lanes 10 and 20). 
o Bands increasing in intensity with increasing drug concentration.
• Bands decreasing in intensity with increasing drug concentration.
□ Novel bands.

FIGURE 41.
Polypeptide profiles obtained on a 9% SDS PAGE gel of BHV-1 infected 
MDBK cell extracts from cultures labelled with either 35S-methionine (lanes 1 to 10), 
or 32P-phosphate (lanes 11 to 20).
Cells were either drug-free (lanes 1 and 11) or treated with 25, 50, 100, 150, 200, 
300 |iM CCX (lanes 2 and 12; 3 and 13; 4 and 14; 5 and 15; 6 and 16; 7 and 17 
respectively), 2jig/ml tunicamycin (lanes 8 and 18), 5fiM monensin (lanes 9 and 19) and 
lflM H7 (lanes 10 and 20).
Identified viral proteins (VPs) (Misra et al., 1981).
• Bands decreasing in intensity with increasing drug concentration. 
g Novel bands
A Bands unaffected with increasing drug concentration.
O Bands increasing in intensity with increasing drug concentration.
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4.1. CYTOTOXICITY TESTS.
The triterpenoid compounds; CCX , CBX, and GL are lipophilic and affect cell 
membrane functions, it was important therefore, to exclude cell death as a contributing 
factor in the antiviral activity. In order to study the antiviral activity of the drugs, cell lines 
resistant to the drugs had to be identified.
Dargan and Subak-Sharpe (1985), and Galt et al (1990) placed 23 different cell 
lines into one of three classes (resistant, intermediate, or sensitive) based on tolerance to 
48h treatment with up to 300pM CCX. The average cell viabilities obtained for resistant, 
intermediate, and sensitive classes of cell lines (Galt, et al., 1990) are shown in table 10. 
CCX-sensitive cell lines had poor tolerance (12%) to 48h exposure with IOOjliM CCX; cell 
lines belonging to the intermediate class were only ~ 50% viable , when treated with 
lOOjiM CCX for 48h and viability was rapidly reduced at higher drug concentrations; the 
viabilities of cell lines placed in the CCX-resistant class were in general hardly affected by 
treatment with CCX concentrations up to 300pM.
The viabilities of the CrFK and FeA cell lines employed in this study were little 
affected by treatment with up to 200|uM CCX, although treatment with 300|iM CCX 
resulted in a significant (FeA) or sharp (CrFK) loss of viability. Despite the loss of 
viability at 300|iM CCX, the data obtained for the CrFK and FeA cell lines more closely 
approximated that obtained for cell lines classified by Galt et al (1990) as CCX-resistant, 
rather than intermediate or sensitive. It was, therefore, concluded that CrFK and FeA cells 
could be placed within the CCX-resistant group of cell lines.
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The data obtained by Dargan and Subak-Sharpe (1985) and Galt et al (1990) for 
CCX resistant cell lines revealed that, while cell viability remained high the growth rate of 
the culture was reduced. This was also found to be the case for CrFK and FeA cells treated 
with CCX and CBX (Figs; 7A, 7B, 12A, 12B). Galt et al., (1990) have found that most of 
the cell lines that fell into the CCX-resistant class had IC50 concentrations (concentration 
of the drug inhibiting cellular growth by 50%) of > 300jxM after 24h or 48h after drug 
treatment (table 11). The IC50’s obtained for CrFK and FeA cells were >300|iM (24h) and 
150(liM (48h) for both cell lines (table 11). The RI’s obtained for CrFK and FeA cells 
treated with IC50 concentration of CCX at 24h were > 0.68, and > 0.84 respectively and 
0.43 and 0.62 after 48h treatment respectively. Thus the RI’s obtained were greater than 
the average RI values obtained at 24h and 48h with the IC50 concentration of drug for 
sensitive (0.37 and 0.26 respectively) and intermediate (0.29 and 0.26 respectively) cell 
lines. It is, therefore, concluded that the CrFK and FeA cell lines should be placed at the 
lower end of the CCX-resistant cell grouping.
4.2. ANTI-CCX ANTIBODY.
The cel 1-membrane binding properties of triterpenoid compounds suggest several 
possible targets for the drug e.g. plasma membrane, nuclear membrane, mitochondrial 
membrane, Golgi apparatus membrane, and/or various vesicular membranes. In order to 
investigate the intracellular location of CCX molecules, an attempt was made to generate an
antibody against the drug.
As the CCX molecule has a molecular weight of only 668.8 daltons, it was 
considered to be too small to generate an immune response on its own- the molecule falls
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TABLE 10. Average percent cell viability determined at 48h after 
CCX treatment.
CCX - 
tolerance 
class, 48h
300|iM 200|iM 150|iM 100|iM
Sensitive* ND ND 2.6% 12.3%
Intermediate* 1% 16.6% 38.4% 56.4%
Resistant* 82% 82% 88% 90%
CrFK 9% 76.3% 80.2% 88.5%
FeA 58% 84% 95% 97%
ND. not determined.
*Data calculated from Galt et al., (1990).
Table 11. Average CCX IC50* and RI** at IC50 of sensitive and intermediate
cell lines in comparison to FeA and CrFK cells.
Cell line 24h IC50 24h RI at 
IC50
48h IC50 48h RI at 
IC50
Sensitive*** 88.6pM 0.37 48fiM 0.26
Intermediate* 148pM 0.29 118|iM 0.26
Resistant >300pM - >300pM -
CrFK > 300pM 0.68 150 pM 0.43
FeA > 300|iM 0.84 150pM 0.62
* IC50- Defined as the concentration of the drug that inhibits cellular growth by 50% (Galt et 
al., 1990).
** RI-RepIication index is defined as multipliers indicating the increase in total number of cells 
at 24h or 48h relative to the total number of cells at day zero.
*** Data calculated from Galt et al., (1990).
into the class of compounds known as haptens To facilitate the generation of an immune 
response to CCX, the drug was conjugated-via a COONa group to a hydroxyl group on a 
BSA protein molecule.
Despite the apparent detection of a specific anti-CCX antibody by an ELISA test, 
subsequent immunofluorescence experiments to detect CCX failed to exhibit any specific 
reaction (data not shown). In a time-course experiment, in which control and drug-treated 
cells were fixed at various times after drug addition, “CCX-immune sera” gave a punctate 
nuclear fluorescence in both drug-treated and control cells even at time zero, (titrating out 
at 1/400), indicating that the fluorescence observed was non-specific (data not shown). The 
number of fluorescent foci, however appeared to be greater in CCX-treated cells. The pre- 
immune sera gave cytoplasmic and perinuclear fluorescence, (titrating at 1/3200) in drug- 
treated, and untreated cells (data not shown). Again the fluorescence was observed from 
the time of drug-addition suggesting that the fluorescence was non-specific. The pre- 
immune rabbit serum bound non-specifically to CCX-treated MDBK cells, and could not be 
removed by washing. It was possible that this non-specific reaction masked the 
fluorescence that might have come from a specific reaction between CCX and the anti- 
CCX antibody. At the present time, there seems to be no rational explanation for these 
confusing, but consistent observations obtained with different cell lines (4 experiments with 
MDBK cells, and two each with CrFK, and FeA cells).
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4.3. THE EFFECT OF CCX ON THE GOLGI APPARATUS.
Previous studies (Dargan and Subak-Sharpe 1986, and 1986a; Galt et al., 1990), 
have provided some evidence to suggest that the Golgi apparatus might be a target for 
triterpenoid compounds.
The Golgi apparatus consists of a series of flattened, disk-shaped, membrane bound 
compartments arranged in three distinct regions: the cis, medial, and trans Golgi 
compartments. Post-Golgi transport vesicles (the trans-Golgi network) are involved in 
intracellular transport of proteins, following their processing within the Golgi apparatus. 
(Ktistakis, N.,e ta l., 1991).
Individual Golgi compartments have been associated with particular processing 
events, and it is generally accepted that the glycosylases involved in building long sugar 
side-chains on glycoproteins are located in the trans-Golgi compartment
CCX treatment resulted in; a reduction in perinuclear (trans-Golgi; anti-p58 protein) 
fluorescence and the appearance of punctate intranuclear fluorescence (particularly in 
MDBK cells). These observations can be explained either by the disaggregation of the 
trans-Golgi compartment, or even the entire Golgi apparatus, and/or the redistribution of 
p58 protein to the nucleus of the drug-treated cells.
In order to investigate whether the effect of CCX on Na+/K+ ATPase was relevant to 
the effect of the drug on the Golgi apparatus, ouabain (a compound which specifically 
inhibits Na+/K+ ATPase activity by binding to the a  subunit of the molecule) was used in 
the Golgi immunofluorescence experiments. While p58-associated Golgi fluorescence was
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abolished in MDBK cells treated with CCX, the Golgi apparatus was labelled in cells 
treated first with ouabain and lh later with CCX. Thus, CCX-induced up-regulation of the 
Na+/K+ATPase was correlated with the perturbation of the trans-Golgi compartment and 
redistribution of p58 molecules.
It was postulated that, if the trans-Golgi compartment of MDBK cells was normally 
an acidic compartment, and the trans-Golgi membrane contained Na+/K+ ATPase 
molecules, it could be predicted that CCX-induced up-regulation of the Na+/K+ATPase 
activity would result in neutralisation of the acidic environment of the cisternae (Na+ ions 
would be pumped into the cisternae, while H+ ions would be removed). To test this 
hypothesis the acidic compartments of the Golgi apparatus in MDBK CCX-treated cells 
were visualised using the DAMP/anti-DAMP system of Anderson et al. (1989). The results 
(section 3.6) confirmed that the trans-Golgi compartment of MDBK cells was acidic. In the 
presence of CCX, the acidic trans-Golgi compartment of MDBK cells was either 
neutralised, destroyed, or redistributed, in the form of numerous cytoplasmic vesicles. The 
effect of CCX-treatment on the other acidic compartments of the cells; e.g. endocytic 
vesicles, lysosomes (Anderson et al., 1984), and post-Golgi vesicles (Fishkes et al. 1982) 
has not been investigated.
4.4. A MODEL TO EXPLAIN THE EFFECT OF CCX ON GOLGI APPARATUS.
A model which can account for the observed effects of triterpenoid compounds on 
the Golgi apparatus is shown in Figure (42). The model is based on the processing of
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receptors and ligands in early endosomes and the effect of Na+/K+ATPase on this process. 
Figure 42-(A) shows the normal intracellular route of processing of ligands and receptors. 
Receptor molecules are displayed on the plasma membrane (A-l). When a ligand binds to 
the receptor, it is internalised by receptor mediated endocytosis (A-2). After invagination, 
and pinching-off an early endosome is formed (A-3). Endosomes exists as two distinct sub­
population (early, A- 3 and A- 4 and late, A-8) (Schmid, et al., 1988). Early and late 
endosomes are functionally distinct. Early endosomes are CURL compartments 
(compartment of uncoupling of receptor and ligands) (A-4) (Anderson, et al. 1984). Late 
endosomes (A-8), on the other hand, are involved in delivering the ligand to lysosomes (A- 
9) (Schmid, et al., 1988). Endosomes maintain an acidic environment by the action of an 
ATP dependent proton pump located on the membrane of endocytic vesicle (A-3), ( Darrel, 
et al., 1983). Upon acidification of the early endosome, the ligand dissociates from its 
receptors (A-4), a portion of the early endosome membrane containing the receptor then 
buds off, and is transported to the trans-Golgi for recycling to the plasma membrane (A- 
5)(A-6)(A-7). The early endosome then matures into the late endosome form (A-8), and the 
ligand is transported to the lysosome, in which it is degraded (A-9) (Brown, etal. 1983).
Figure 42 B shows the effect of Na+/K+ ATPase on the processing of the ligand and 
the receptor. Two classes of early endosomes, which acidify at different rates have been 
reported (Fuchs et al., 1989). Occasionally Na+/K+ ATPase molecules are included during 
receptor-mediated endocytosis (B-2). Since, the action of the early endosome proton pump 
is under electrogenic control, [i.e. the more positive charge (H+ or Na+) inside the vacuole 
the harder it is to pump in more protons (H+)], those early endosomes which have 
incorporated Na+/K+/ATPase in their membrane, acidify at a slower rate (B-3) (B-3a)
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(Fuchs, et al., 1989). Eventually the pH of the endosome falls sufficiently to allow 
uncoupling of the ligand and receptor (B-4), with subsequent recycling of the receptor and 
Na+/K+ATPase to the plasma membrane via the trans-Golgi system (B-5)(B-6)(B-7) (Fuchs 
et al., 1989). The finding that, Na7K+ ATPase impairs the acidification of some early 
endosomes was further supported by the observation that ouabain treatment resulted in a 
higher proportion of low pH endosomes (Cain, et al., 1989).
Figure 42 C, shows the effect of CCX treatment on the processing of ligand and the 
receptor, when Na+/K+ ATPase is present. Triterpenoid compounds inhibit PKC-activity in 
in vitro assays (Ito et al., 1988). PKC is thought to be responsible for regulation of 
Na+/K+ATPase- activity via phosphorylation of the a-subunit of the pump. 
Phosphorylation inhibits the activity of the pump (Middelton et al., 1993). It can be 
expected, therefore that in CCX-treated cells, those endosomes which have incorporated 
sodium pump molecules accumulate sodium ions rapidly (C-3)(C-3a). The competition 
between the proton pump and the Na+/K+ATPase may seem to be weighted in favour of the 
latter, not only because the proton pump is electrogenic, but also, because the pump accepts 
H+ in place of K+ and consequently removes 3H+ from the endosome, while pumping in 2 
Na+ ions (B-3) and (B-3a). If the pH drop is insufficient for the recycling of receptor or 
Na+/K7ATPase molecules, the sodium pump will remain embedded in the endosomal 
membrane. The large influx of osmotically active Na+ ions into the endosome will result in 
an inflow of H20  into the endosome leading to swelling and formation of a large single- 
compartmented vacuole (C-3a) [such large single-compartmented macro-vacuoles have 
been observed in the cytoplasm of CCX-treated BHK and flow 2002 cells (Dargan and 
Subak-Sharpe, unpublished observations)]. If the proton pump successfully lowers the pH
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of the endosome, it is likely that the Na+/K+ATPase will be recycled with the receptor via 
the trans-cisternae of the Golgi apparatus (C-5). Those Na+/K+ ATPase molecules which 
are transported to the Golgi apparatus might then set up the same Na+/H+ competition with 
Golgi-resident proton pumps (C-5) (Glickman, et al. 1983), leading to neutralisation of the 
acidic environment of the trans-Golgi compartment ( as shown in the Figure 18). An 
increase in Na+ ion concentration in the trans-Golgi cisternae could result in influx of water 
into this compartment (C-10), leading to perturbation of Golgi functions. Large multi- 
compartmented vacuoles in CCX-treated cells (thought to represent disorganised Golgi 
apparatus) have been observed in BHK and Flow 2002 by Dargan and Subak-Sharpe 
(unpublished observations). Influx of water might result in the complete destruction of the 
trans-Golgi compartment, its disintegration into many smaller vesicles, and/or its gross 
disfiguration and swelling into unified multicompartmented vacuoles (C-15) (as shown in 
figure 17).
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The model might also explain the earlier observation G altet (1990) that in 
general fibroblast cell lines are more sensitive to the cytotoxic effect of triterpenoid drugs, 
than are epithelial cell lines. Anderson et a l  (1985) have shown that, in general, fibroblast 
cell lines have an acidic trans Golgi compartment, while that of epithelial cell lines is 
neutral. Both cell lines, however, have an acidic post-Golgi network.
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FIGURE 42A. THF. MOREL EXPLAINING THE EFFECT OF CCX ON
GOLGI APPARATUS.
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4.5. OTHER CELLULAR MECHANISMS WHICH MIGHT BE AFFECTED BY
TREATMENT WITH TRITERPENOID COMPOUNDS.
Although, the model can account for the observed effects of triterpenoid compounds 
on the Golgi apparatus, it is also evident that, there are likely to be additional drug-induced 
effects, which are not directly related to the Golgi apparatus.
Clearly up-regulation of the Na+K+/ATPase will result in a change in ion 
concentration within the cell; the cell operates several systems, (Na+ regulated permeases), 
which are likely to be affected by the effect of CCX on Na+/K+ATPase: These are the 
Ca++/Na+ antiport; H+/Na+ antiport; the amino acid /Na+ symport and the K+/Na+/CL'2. co­
transport system. A K+/H+ antiport has also been identified.
To alleviate the reduction in intracellular Na+ ion concentration, extracellular Na+ 
ions may be exchanged for, either an intracellular Ca++ ions via the Ca++/Na+ antiport (a 
reduction intracellular Ca++ levels might impair the ability of the cell to regulate the 
calmodulin-mediated second messenger system), or an intracellular H+ (raising intracellular 
pH). An increase in the activity of the Na+/K+ATPase will almost certainly involve an 
increase in the activity of the K+/Na+/C L 2 co-transport system, since these two ion 
exchange systems operate together to regulate osmotic pressure and cell volume (Vinge, et 
al., 1982)
CCX treatment induced, both the 90K and 70K families of heat-shock proteins and 
the families of 94K and 78K, glucose-regulated of proteins, in all cell lines tested (Dargan 
and Subak-Sharpe, 1986 and Galt, PhD thesis 1989) (70K protein was also presnt in CrFK
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cells treated with 100|iM CCX; Figure 34A ) . Such cellular stress proteins are thought to be 
responsible for the solubilization of aggregates of unfolded or denatured proteins (Sorger 
and Pelham, 1987; Kozutumi, et al., 1988). CCX treatment might result in protein 
malfolding or denaturation, through a direct interaction between the drug molecules in the 
membrane and proteins present in the lumen of the ER. Alternatively, excessive 
accumulation of proteins in the ER cisternae, due to a blockage in the flow of proteins from 
the ER to the Golgi, then to other intracellular sites (model 42), might result in malfolding 
or denaturation of proteins in the ER or the Golgi apparatus contents. In this regard it is 
interesting to note that grp94 has been located within the Golgi apparatus itself (Welch, et 
a l , 1983).
Stress induces a vigorous activation of the transcription of genes encoding stress 
proteins, and the selective translation of the stress protein mRNA. This is accompanied by 
a reduction in the transcription and translation of other cellular mRNAs (Ashbumer and 
Bonner, 1979; Schlesinger et al., 1982). Therefore it seems possible that induction of the 
stress response by CCX, might contribute to the impaired growth of drug-treated cell 
cultures.
Triterpenoid compounds have been demonstrated to affect the integrity of the 
plasma membrane resulting in leakage of proteins at high drug concentrations (Dargan and 
Subak-Sharpe 1986). GL was found to affect membrane fluidity by decreasing the lipid 
packaging density of cell membranes (Reardon and Audus, 1993). Although, the 
cytotoxicity studies shown here for FeA and CrFK cells have indicated that such effects (if
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induced by the concentrations used here) are non-lethal, the effects are likely to impair cell 
culture growth.
4.6. ANTIVIRAL ACTIVITY AGAINST FELV-A.
Drug-dose response experiments with FeLV-A revealed that, a 100-150 fold 
reduction in infectious virus yield was obtained with CCX, CBX, or GL treatments. With 
all of the drugs, the infectivity of the CR virus yield decreased at a faster rate than that 
remaining cell-associated. This decrease in CR virus infectivity was not entirely due to a 
virucidal effect of the drug, suggesting that the drugs must impair the release of infectious 
virus from the cell surface. This implies that virus maturation can occur while virus 
particles remain attached to the cell surface. The kinetics of the FeLV-A dose-response 
curves obtained were similar for each drug and characterised by a triphasic curve. This 
suggests that the triterpenoid compounds have at least two separate targets. The first is 
sensitive to low drug concentration and provides either an essential function, which is only 
partially impaired by drug treatment or a function which enhances, but is not strictly 
essential for virus replication. The second target is sensitive to high drug concentrations 
and affects functions which appear to be essential for virus replication. At the relatively 
high drug concentrations required to inhibit the second of these targets, the window 
between antiviral activity and cytotoxicity is very narrow.
Comparison of the CCX dose-response curves obtained for FeLV-A with those 
obtained by Galt et a l , (1990), reveals that FeLV-A can be placed within the CCXs-2 class 
along with Bunyaviruses, Adenoviruses, Reoviruses, and Polioviruses. The dose response 
curves for each of these viruses displayed a sharp initial decrease in infectious virus yield at
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low drug concentration, followed by a plateau in the curve. Furthermore, the infectious 
yield reduction (~ 100-150 fold) for each virus was also similar. CCX treatment of FeLV- 
A infected cells did not seem to impair viral protein synthesis, although the protein 
composition of the vims progeny produced in the presence of the drug varied from that of 
the control (gp70 was decreased, while p 15 was unaffected), suggesting some effect at the 
level of vims assembly. Interestingly, the SDS PAGE gels provide no evidence for impaired 
vims glycoprotein processing in CCX-treated FeA cell cultures. Unfortunately, the anti- 
p58 (trans-Golgi specific) antibody failed to work with the FeA cell line and so it was not 
possible to investigate the effect of CCX on Golgi apparatus labelling.
4.6.1. PROPOSED ANTIVIRAL MECHANISM AGAINST FELV-A.
One possible explanation for the antiviral activity against FeLV-A might be that 
FeA cells do not have an acidic trans-Golgi compartment, and therefore, glycoprotein 
processing was not significantly affected. However, it is likely that post-Golgi transport 
vesicles are acidic compartments (Anderson et al., 1985), and it might be that transport of 
glycoproteins which are contained within those post-Golgi vesicles, also recycling 
Na+/K+ATPase molecules is inhibited. Changes in the H+ concentration in such vacuoles 
might inhibit transport of the vacuole and result in a decrease in the amount of gp70 
reaching the plasma membrane. The 100-150 fold reduction in infectious vims yield then 
might be due to a lack of sufficient glycoproteins in the plasma membrane to allow particle 
assembly at normal rates. Presence of CCX molecules within the plasma membrane, or
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incorporated into the virus envelope, might impair particle release, and/or maturation of the 
virions.
4.7. ANTIVIRAL ACTIVITY AGAINST FIV.
Because FIV generally grows to a low titre, it was not possible to perform high MOI 
dose-response curve experiments with this virus, and so antiviral activity was demonstrated 
by plaque reduction assay and determination of ED50 concentration (75pM for CCX and 
101 for CBX). Although, the triterpenoid drugs exhibited virucidal activity against FIV at 
the concentrations used in antiviral experiments, this was of low magnitude (at best 10 fold 
reduction in infectious virus yield after 24h incubation at 37°C).
SDS PAGE analysis of the protein composition of FIV progeny released from cells 
treated with 100pM CCX, showed that the p55 protein was overabundant. While p24 and 
p i7 were present in reduced amounts, suggesting impaired cleavage of p55 into the p24 
and p i7 products. As this cleavage event is thought only to occur after particle assembly; 
during or after, particle release from the cell it seems likely that CCX treatment impairs FIV 
maturation.
The mature form of the FIV surface glycoprotein (gpl20) was detected in extracts 
from drug-free cultures, and cultures treated with 25pM CCX, but not IOOjiM CCX. 
Suggesting either, that the glycosylation process was inhibited by the drug or that the 
precursor protein was not made. The lack of a FIV glycoprotein specific antibody meant 
that immature or partially glycosylated 35S-labelled FIV glycoproteins could not be
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unambiguously identified. With regard to the FIV transmembrane protein gp41; this protein 
was not detected by l4C-glucosamine labelling, but does label with 35S-methionine/cysteine 
and increased in amount in cells treated with IOOjiM CCX. Interestingly, a 35S-meth/cys 
labelled band of about 160K (probably the FIV glycoprotein precursor gpl60) was observed 
to increase in amounts in cells treated with 100|iM CCX. These results are explainable in 
terms of drug induced impairment of either post-Golgi transport of the glycoprotein to the 
plasma membrane, or impairment of the assembly and/or release of progeny virus.
4.7.1. PROPOSED ANTIVIRAL MECHANISM AGAINST FIV.
A model to explain the anti-FIV effect of CCX is explained based upon the effect 
of CCX on the trans-Golgi compartment. Both glycosylation and the passage of 
glycoproteins through the Golgi system is inhibited. The accumulation of the precursor 
glycoprotein gpl60 suggests that cleavage of gpl60 into gpl20 and gp41 is impaired. This 
could be due to slow ER to Golgi transport, resulting in accumulation of gpl60 within the 
ER. As the cleavage of gpl60 into gpl20 and gp41 did not seem to be totally abolished, it 
seems possible that this cleavage event might occur in an earlier (cis or medial) Golgi 
compartment. Impaired transport of virus glycoproteins from trans-Golgi compartment to 
the plasma membrane via the post-Golgi vesicles, would result in reduced expression of 
viral glycoproteins (probably incompletely processed) on the cell surface. This might limit 
the number of virus particles that can be assembled (and also account for the observed 
accumulation of gpl60, gp41, and p55 proteins within CCX-treated cells). It should be 
noted, however, that in general there is a fairly rapid turnover of Golgi apparatus (turnover
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time ~ 20-30 minutes), in uninfected cells and so the drug may not completely abolish 
either glycosylation or post-Golgi transport of virus glycoproteins.
Budding and release of the vims from the plasma membrane may also be impaired; 
whether this is due to the presence of CCX molecules at the site of vims budding, 
incorporation of CCX into the envelope of the virion, or the lack of sugar-residues on the 
glycoproteins is not known. Post-release maturation of the vims particle does seem to be 
impaired, because the cell-free particles produced in the presence of CCX, either process 
p55 into p24 and pl7 at a slower rate, or there is a population of vims particles in which 
p55 processing is completely inhibited. Whether the impaired cleavage of p55 into p24 and 
p 17 resulted from an effect of the drug on the FIV protease activity, or whether CCX dmg 
molecules embedded in the virus envelope directly or indirectly interfere with the protease 
activity is not known.
4.8. ANTIVIRAL ACTIVITY AGAINST BHV-1.
In contrast to the relatively weak antiviral activity of triterpenoid compounds on the 
replication of FeLV-A, the anti BHV-1 activity was very potent (for BHV-1 treatment with 
150|iM CCX, gave 3435 fold reduction in CR infectivity and 200 fold reduction in CA 
infectivity, compared to 155 fold reduction in CR infectivity and 190 fold reduction in CA 
infectivity for FeLV-A).
The magnitude of the anti-BHV-1 activity and the kinetics of the dmg-dose 
response curve obtained in the experiments reported here, confirms the placement of BHV-
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1 in the CCX sensitive class of viruses, described by Galt et al. (1990). Interestingly, BHV- 
1 CR infectivity decreased at a faster rate than CA infectivity, this observation was also 
made for HSV-1 (Dargan and Subak-Sharpe, 1986) and for FeLV-A. Virucidal activity of 
the drugs can account for part of the loss of infectivity of retroviruses (FIV and FeLV-A), 
but in the case of BHV-1, where virucidal activity could only account for ~ 4 fold loss of 
infectivity (at 300|iM CCX), additional factors must be responsible for virtually all of the 
observed loss in infectivity. The data thus implicate, impaired release of BHV-1 progeny 
particles and /or the release of non-infectious progeny virus.
A quantitative electron microscope investigation, in which the numbers of BHV-1 
particles, or virus-related structures, present in cell sections of CCX-treated cultures were 
counted, revealed that with increasing drug concentrations: (1) The percentage of cells 
containing BHV-1 particles decreased. (2) Fewer virus particles were assembled in each 
infected cell. (3) Transport of DNA containing virus particles from the nucleus to the 
cytoplasm was impaired. (4) The percent extracellular virus particles was decreased. Thus, 
the data show that CCX-treatment impaired both virus particle assembly and maturation .
Interestingly, the data also show that treatment with up to 150jnM CCX had little, or 
no effect, on BHV-1 DNA packaging since the percentage of DNA-cored particles 
remained 60%-80% of the total virus particles in the cell. This observation is in accord 
with the findings of Dargan and Subak-Sharpe (1986a) that HSV-1 DNA synthesis was not 
impaired by CCX or CBX treatment.
SDS PAGE analysis of BHV-1 infected cell extracts obtained from cultures grown 
in the presence or absence of triterpenoid compounds, showed an overall decrease in the
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amount of virus proteins synthesised (~ 90% decrease at 300}iM CCX Fig 38), however, 
not all proteins were affected to the same extent (Fig 41). While CCX treatment of MDBK 
cells resulted in a general suppression of protein synthesis per se (to about 10% of the 
control level), the finding that all BHV-1 proteins were not affected equally deserves 
further study. Although the effect of CCX on protein synthesis per se must contribute to 
the reduction in the number of virus particles assembled, it can not by itself account for the 
greater part of the observed anti-BHV-1 activity of the drugs.
CCX treatment specifically impaired the phosphorylation of the BHV-1 VP8 
protein, a tegument protein with protein kinase activity (Carpenter and Misra, 1991). It was 
thought possible that, if VP8 was phosphorylated by PKC, then CCX-induced inhibition of 
PKC activity (Ito et a i, 1988) could explain this observation. Experiments employing the 
PKC inhibitor H7, however, showed that VP8 phosphorylation was not inhibited, 
demonstrating that PKC was not involved in VP8 phosphorylation. More recent data (Misra 
personal communication) has suggested that VP8 is capable of autophosphorylation The 
mechanism by which CCX inhibits autophosphorylation of VP8, is currently under 
investigation by Misra and co-workers. It is not yet known, whether VP8 is an essential 
vims protein or whether its phosphorylation is required for its activity.
4.8.1. PROPOSED ANTIVIRAL MECHANISM AGAINST BHV-1.
Both BHV-1 and HSV-1 are a-herpesviruses. The anti-HSV-1 activity of CCX has 
been studied in detail by Dargan and Subak-Sharpe (1985, 1986, and 1986a). The anti-
187
HSV-1 activity was comprised of 3 components; 1. A virucidal activity; 2. A decrease in 
the number of viral proteins synthesised; 3. An increase in particle/p.f.u. ratio of the 
progeny virus made in the presence of the drug.
The virucidal activity of triterpenoid compounds against BHV-1 could account for 
as much as a 4 fold reduction in BHV-1 infectivity. This is of a similar magnitude of the 
virucidal activity obtained against HSV-1. CCX treatment of uninfected or HSV-1 infected 
BHK or Flow 2002 cells resulted in a decrease in the protein synthesis per se ( > 90% at 
300|nM), and a similar reduction in protein synthesis was found for uninfected or BHV-1 
infected MDBK cells. A reduction of up to 90% in protein synthesis in drug-treated 
infected cells must play a role in decreasing the numbers of virus particles that can be 
assembled. Although, electron microscopy studies showed that, CCX had no effect on the 
envelopment of BHV-1. maturation of the progeny vims particles made in the presence of 
the drugs was impaired. Eleven, of forty, identified BHV-1 proteins labelled with 
glucosamine (Misra et al., 1981). Although the requirement for vims infectivity of addition 
of sugars to these glycoproteins has yet to be studied, it is clear, from immunofluorescence 
experiments that CCX treatment resulted in dismption of the Golgi apparatus of MDBK 
cells. It would seem reasonable to suspect that in the MDBK cell line used, impaired 
glycosylation of BHV-1 glycoproteins would also play a role in the antiviral activity 
against BHV-1. Incorporation of CCX molecules into the various cell membranes might 
also have a role in the antiviral effect. Although, the dmgs did not appear to inhibit the 
envelopment of BHV-1 , the infectious titres decreased in the CR fraction at a faster rate 
than the CA titre, suggesting that the drugs impair the release of the infectious vims 
particles into the growth medium. An alternative explanation is that vims particles
1 8 8
produced and released in the medium in the presence of CCX are less stable than those 
produced under drug-free conditions.
4.9. FINAL CONCLUSIONS
A full and complete comparison of the antiviral effects of triterpenoid compounds 
on the replication of HV and FeLV-A (retroviruses) and the BHV-1 (herpesvirus) was 
hindered, because not all experiments were completed for each virus; in part this was due to 
technical difficulties with particular virus/cell systems, and in part due to a lack of time to 
follow up these studies. Nevertheless, a list of common features can be given; 1. The drugs 
have broad range antiviral activity; 2. Treatment with the drugs resulted in a faster decrease 
in CR than CA infectivity; 3. The faster decrease in CR infectivity was not completely 
explained by the virucidal effect of the drugs; 4. The drugs impaired the release of virus 
particles from the cell.
The following scheme describes current thinking on the mechanism of anti­
retrovirus action of the triterpenoid drugs.
Drug molecules bind to the plasma membrane due to their hydrophobic nature, and 
become embedded in the membrane; with time the drug molecules become distributed 
throughout the cell and are probably membrane bound (Dargan and Subak-Sharpe, 
unpublished observations). The drugs impair PKC activity and so upset those cellular 
processes normally regulated by this ubiquitous enzyme (it is also possible that drug 
molecules also interfere with other cell membrane signalling systems). Impaired PKC
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activity results in an increase in the activity of the Na+/K+ATPase, which when it is present 
within acidic Golgi compartment of the cells (i.e. trans-Golgi or post-Golgi transport 
vesicles) disrupts their function. Inhibition of Golgi function results in incomplete 
processing of virus glycoproteins and/or a failure to efficiently transport these glycoproteins 
to the cell surface where retrovirus assembly takes place. Inefficient assembly results in 
over-accumulation of certain viral proteins in infected cells. The presence of drug 
molecules embedded either in the plasma membrane or in the virus envelope impairs the 
budding process of the virus, and/or post-release cleavage of the FIV p55 GAG protein into 
its cleavage products, p24 and p i7.
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4.10. FUTURE WORK.
This study showed that, the triterpenoid compounds impair the function of the 
Golgi apparatus of CrFK and MDBK cells. It will be important to investigate whether or 
not this finding also applies to other cell lines. The effect of triterpenoid compounds was 
investigated using the trans-Golgi compartment specific anti-p58 antibody in 
immunofluorescence experiments. However, despite repeated attempts this marker failed 
to label Golgi apparatus in the FeA cell line. Additional Golgi markers, such as wheatgerm 
agglutinin could also be employed not only to investigate the effect of the drugs on FeA 
cells, but also to label the cis and medial Golgi compartments. Treatment with CCX 
manifested in an accumulation of single and multi-compartmented vacuoles (thought to 
originate from Golgi apparatus). The origin of these vacuoles could be investigated using 
anti-p58 antibody in immunogold labelling EM studies. Monensin impairs processing and 
movements of proteins through the Golgi apparatus, by neutralising the trans-Golgi portion 
of the organelle (Anderson and Orci, 1988), and a similar mechanism is now proposed to 
account for the effect of CCX on the Golgi apparatus. A study comparing the effects of 
CCX and monensin, using the DAMP anti-DAMP system will be important to investigate 
the modes of action of these two drugs. Drug removal experiments performed in parallel 
with anti-p58 Golgi antibody labelling immunofluorescent experiments would provide 
information concerning the rate of formation of the Golgi apparatus following drug 
removal.
The anti-CCX antibody generated in immunised rabbits, needs further testing and 
characterisation. While the presence of the antibody was detected by an ELISA test, in
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immunofluorescence experiments no specific binding was evident. The titre of the putative 
anti-CCX antibody should be determined.
This study has shown that the triterpenoid compounds have antiviral activity against 
FeLV-A-, BHV-1, and FIV. However, the experiments with FTV were limited by the low 
virus titres attained. If the virus could be concentrated it would be possible to perform 
standard dose-response experiments and so, make a direct comparison between the antiviral 
activities obtained for FIV and FeLV-A. The unambiguous identification of particular FIV 
proteins (particularly the env proteins) has been difficult in the work described here; in the 
future it will be of critical importance to produce either specific or monoclonal antibodies 
directed against these proteins.
Based on the result of Ito et al., (1987), it has been assumed that the triterpenoid 
compounds would not interfere with the reverse transcriptase activity of retrovirus- this 
assumption needs to be confirmed by experiment.
Because, the antiviral activity of the triterpenoid compounds is thought to be 
mediated through interference with cellular functions , more critically required for vims 
than cellular growth, it is considered unlikely that drug resistant viruses will emerge. This 
assumption needs to be confirmed by experiments. Since, ouabain reversed the effect of 
CCX on the Golgi apparatus, it will be important to determine whether ouabain will 
modulate the antiviral activity of the triterpenoid compounds.
Triterpenoid compounds and AZT clearly have different modes of action against 
retroviruses. This fact make it worthwhile to test whether, triterpenoid compounds in 
combination with RT inhibitors could result in synergistic antiviral activity.
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